[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

OA12046A - 3(5)-Amino-pyrazole derivatives, process for theirpreparation and their use as antitumor agents. - Google Patents

3(5)-Amino-pyrazole derivatives, process for theirpreparation and their use as antitumor agents. Download PDF

Info

Publication number
OA12046A
OA12046A OA1200200051A OA1200200051A OA12046A OA 12046 A OA12046 A OA 12046A OA 1200200051 A OA1200200051 A OA 1200200051A OA 1200200051 A OA1200200051 A OA 1200200051A OA 12046 A OA12046 A OA 12046A
Authority
OA
OAPI
Prior art keywords
cyclopropyl
pyrazol
acetamide
phenyl
biphenyl
Prior art date
Application number
OA1200200051A
Inventor
Paolo Pevarello
Paolo Orsini
Gabriella Traquandi
Mario Varasi
Edward L Fritzen
Martha Warpehoski
Betsy PIERCE
Maria Grabriella Brasca
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of OA12046A publication Critical patent/OA12046A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compounds which are 3-amino-pyrazole derivatives represented by formula (I) wherein R is C3-C6 cycloalkyl group optionally substituted by a straight or branched C1-C6 alkyl or arylalkyl group; R1 is a straight or branched C1-C6 alkyl, C2-C4 alkenyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, arylalkyl, arylcarbonyl, aryloxyalkyl or arylalkenyl group, each of which may be optionally further substituted as indicated in the description; or a pharmaceutically acceptable salt thereof. The compounds are useful for the treatment of cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases or neurodegenerative diseases.

Description

1 2046
TITIE.QF THE.,INVENTION
3(5)-AMINO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIRPREPARATION AND THEIR USE AS ANTITUMOR AGENTS
BACKGROUNP OF THEJNVENTIQN
Eisld pf the. Invention:
The présent invention relates to 3(5)-amino-pyrazole dérivatives, to a process for theirpréparation, to pharmaceutical compositions containing them, and to their use as therapeuticagents, particularly in the treatment of cancer and cell proliférative disorders.
Discussion of the Background
Several cytotoxic drugs such as, e.g., fluorouracil (5-FU), doxorubicin and camptothecins,damage DNA or affect cellular metabolic pathways and thus cause, in many cases, an indirectblock of the cell cycle. Therefore, by producing an irréversible damage to both normal andtumor cells, these agents resuit in a significant toxicity and side-effects.
In this respect, compounds capable of functioning as highly spécifie antitumor agents byselectively leading to tumor cell arrest and apoptosis, with comparable efficacy but reducedtoxicity than the currently available drugs, are désirable.
It is well known that progression through the cell cycle is govemed by a sériés of checkpointControls, otherwise referred to as restriction points, which are regulated by a family ofenzymes known as the cyclin-dependent kinases (cdk). In tum, the cdks themselves areregulated at many levels such as, for instance, binding to cyclins.
The coordinated activation and inactivation of different cyclin/cdk complexes is necessary fornormal progression through the cell cycle. Both the critical Gl-S and G2-M transitions arecontrolled by the activation of different cyclin/cdk activities. In Gl, both cyclin D/cdk4 andcyclin E/cdk2 are thought to médiate the onset of S-phase. Progression through S-phaserequîtes the activity of cyclin. A/cdk2 whereas the activation of cyclin A/cdc2 (cdkl) a cyclinB/cdc2 are required for the onset of metaphases. For a general référencé for cyclins andcyclin-dependent kinases see, for instance, Kevin R. Webster et al, in Exp. Opin. Invest.Drugs, 1998, Vol. 7(6), 865-887. SUBSTITUTE SHEET (RULE 26)
DUPLICATA 1 2046 2
Checkpoint Controls are defective in tumor cells due, in part, to disregulation of cdk activity.For example altered expression of cyclin E and cdks has been observed in tumor cells, anddélétion of die cdk inhibitor p27 K1P gene in mice has been shown to resuit in a higherincidence of cancer.
Increasing evidence supports the idea that the cdks are rate-limiting enzymes in cell cycleprogression and, as such, represent molecular targets for therapeutic intervention. Inparticular, the direct inhibition of cdk/cyclin kinase activity should be helpful in restrictingthe unregulated prolifération of a tumor cell.
SUMMARYQFTHE INVENTION
It is an object of the invention to provide compounds which are useful in treating cellproliférative disorders associated with an altered cell dépendent kinase activity. It is anotherobject to provide compounds which hâve cdk/cyclin kinase inhibitory activity.
It is another object of the invention to provide compounds which are useful in therapy asantitumor agents but lack, in terms of both toxicity and side effects, the drawbacks associatedwith currently available antitumor drugs discussed above.
The présent inventons hâve now discovered that 3-amino-pyrazoles are endowed withcdk/cyclin kinase inhibitory activity and are thus useful in therapy as antitumor agents andlack, in terms of both toxicity and side effects, the aforementioned drawbacks associated withcurrently available antitumor drugs.
More specifîcally, the 3-amino-pyrazoles of the invention are useful in the treatment of avariety of cancers including, but not limited to: carcinoma such as bladder, breast, colon,kidney, liver, lung, including small cell lung cancer, esophagus, gall-bladder, ovary, pancréas,stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma;hematopoietic tumors of lymphoid lineage including leukemia, acute lymphocitic leukemia,acute lymphoblastic leukemia, B-cell lyrtiphoma, T-cell-lymphoma, Hodgkin's lymphoma,non-Hodgkin's lymphoma, hairy cell lymphoma and Burkett’s lymphoma; hematopoietictumors of myeloid lineage, including acute and chronic myelogenous leukemias,myelodysplastic syndrome and promyelocytic leukemia; tumors of mesenchymal origin,including fîbrosarcoma and rhabdomyosarcoma; tumors of the central and peripheral nervousSystem, including astrocytoma neuroblastoma, glioma and schwannomas; other tumors, SUBSTITUTE SHEET (RULE 26)
DUPLICATA 1 2046 including melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum,keratoctanthoma, thyroid follicular cancer and Kaposi’s sarcoma.
Due to the key rôle of cdks in the régulation of cellular prolifération, the 3-amino-pyrazole dérivatives are also useful in the treatment of a'variety of cell proliférative disorders such as, for exemple, benign prostate hyperplasia, familial adenomatosis polyposis,neurofibromatosis, psoriasis, vascular smooth cell prolifération associated withatherosclerosis, pulmonary fibrosis, arthritis glomerulonephritis and post-surgical stenosisand restenosis.
The compounds of the invention may be useful in treatment of Alzheimer's disease, assuggested by the fact that cdk5 is involved in the phosphorylation of tau protein (J. Biochem,117,741-749, 1995).
The compounds of this invention, as modulators of apoptosis, may also be useful in thetreatment of cancer, viral infections, prévention of AIDS development in HIV-infectedindividuals, autoimmune diseases and neurodegenerative disorders.
The compounds of this invention may be useful in inhibiting tumor angiogenesis andmetastasis.
The compounds of the invention may also act as inhibitor of other protein kinases, e.g.,protein kinase C, her2, rafl, MEK1, MAP kinase, EGF receptor, PDGF receptor, IGFreceptor, PI3 kinase, weel kinase, Src, Abl, and thus be effective in the treatment of diseasesassociated with other protein kinases.
The compounds of the invention are also useful in the treatment and prévention ofradiotherapy-induced or chemotherapy-induced alopecia.
Accordingly, the présent invention provides a method for treating cell proliférative disordersassociated with an altered cell dépendent kinase activity, by administering to a mammal inneed thereof an effective amount of a 3-amino-pyrazole dérivative represented by formula (I):
wherein SUBSTITÜTE SHEET (RULE 26)
DUPLICATA 1 2046 4 R is a C3-C6 cycloalkyl group optionally substituted by a straight or branched C,-C6alkyl or arylalkyl group; R, is a straight or branched C,-C6 alkyl, C2-C4 alkenyl, cycloalkyl, cycloalkenyl,heterocyclyl, aryl, arylalkyl, arylcarbonyl, aryloxyalkyl or arylalkenyl group, each ofwhich may be optionally further substituted; or a phannacetically acceptable sait therof.
In a preferred embodiment of the method described above, the cell proliférative disorder isselected fiom the group consisting of cancer, Alzheimer’s disease, viral infections, auto-immune diseases and neurodegenerative disorders.
Spécifie types of cancer that may be treated include carcinoma, squamous cell carcinoma,hematopoietic tumors of myeloid or lymphoid lineage, tumors of mesenchymal origin,tumors of the central and peripheral nervous System, melanoma, seminoma, teratocarcinoma,osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer, andKaposi's sarcoma.
In another preferred embodiment of the method described above, the cell proliférativedisorder is selected frora the group consisting of benign prostate hyperplasia, familialadenomatosis polyposis, neuro-fibromatosis, psoriasis, vascular smooth cell proliférationassociated with atherosclerosis, pulmonary fibrosis, arthritis glomerulonephritis and post-surgical stenosis and restenosis.
In addition, the inventive method provides tumor angiogenesis and metastasis inhibition. Theinventive method may also provide cell cycle inhibition or cdk/cyclin dépendent inhibition.
In addition to the above, the method object of the présent invention provides treatment andprévention of radiotherapy-induced or chemotherapy-induced alopecia.
The présent invention also provides a 3-amino-pyrazole dérivative represented by formula (I):
H wherein SUBSTITUTE SHEET (RULE 26)
DUPLICATA 1 2046 5 R is a C3-C6 cycloalkyl group optionally substituted by a straight or branched C,-C6alkyl or arylalkyl group; R, is a straight or branched C,-C6 alkyl, C2-C4 alkenyl, cycloalkyl, cycloalkenyl,heterocyclyl, aryl, arylalkyl, arylcarbonyl, aryloxyalkyl or arylalkenyl group, each ofwhich may be optionally further substituted; or a pharmacetically acceptable sait therof.
The présent invention also includes methods of synthesizing the 3-amino-pyrazole dérivativerepresented by formula (I). A pharmaceutical composition comprising the 3-amino-pyrazoledérivative represented by formula (I) is also included in the présent invention.
The présent invention also includes a compound useful in the synthesis the 3-amino-pyrazoledérivative represented by formula (I), which is represented by formula (V):
wherein R is a C3-C6 cycloalkyl group optionally substituted with a straight or branched C,-C6alkyl group. A more complété appréciation of the invention and many of the attendant advantages thereofwill be readily obtained as the same becomes better understood by reference to the followingdetailed description. Q£TAJLED.DESCRIPW1±Q£..THE INVENTIONSeveral 3-amino-pyrazole dérivatives are known as pesticides, herbicides or even astherapeutic agents. Among them are, as an example, heteroaryl-pyrazoles active as p38kinase inhibitors (WO 98/52941, G.D. Searle and Co.) and other 3-amino-pyrazoles whichinhibit protein kinases ÇWO 96/14843, COR Therapeutics, Inc.).
As will be readily appieciated, the unsubstituted ring nitrogen pyrazoles in the compounds ofthe invention are known to rapidly equilibrate, in solution, as admixtures of both tautomers: SUBSTITÙTE SHEET (RULE 26)
DUPLICATA 1 2046
H
R NH
H m R,
0) (la)
Accordingly, in the présent invention, where only one tautomer is indicated for thecompounds of formula (I), the other, (la), is also within the scope of the présent invention,unless specifically noted otherwise.
As used herein, unless otherwise specified, the tenn C3-C6 cycloalkyl includes cyclopropyl,cyclobutyl, cyclopentyl and cyclohexyl; the term cycloalkyl is also intended to covercycloalkyl groups with, e.g., up to 10 carbon atoms, e.g., an adamantane group.
As used herein, unless otherwise indicated, the tenn cycloalkenyl includes the abovecycloalkyl rings wherein at least one caibon-carbon bond forming the said ring is a doublebond.
As used herein, unless otherwise indicated, the term alkyl includes straight or branched C,-Ç6alkyl groups such as, for instance, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl and the like.
As used herein, unless otherwise indicated, the term C2-C4 alkenyl includes a group selectedfrom vinyl, allyl, 1-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl and the like.
The term aryl includes mono-, bi- or poly- carbocyclic or heterocyclic hydrocarbons withfrom 1 to 4 ring moieties, wherein at least one of the rings is aromatic, either fused or linkedto each other by single bonds. Thus, these groups may hâve 5 to 20 carbon atoms. Preferably6 to 20 carbon atoms.
Examples of aryl groups are, for instance, phenyl, biphenyl, a- or β-naphthyl,dihydronaphthyl, thienyl, benzothienyl, furyl, isobenzofuranyl, dihydrobenzofuranyl,chromenyl, xanthenyl, pyirolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl,isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, isoindolyl, purinyl, quinolyl,isoquinolyl, dihydroquinolinyl, quinoxalinyl, benzodioxolyl, indanyl, indenyl, fluorenyl,bicyclo[4.2.0]octa-l,3,5-trien-yl, dibenzo[b,d]furanyl, chromanyl, chromenyl, triazolyl,tetrazolyl, tetrazol[l,5-b]pyridazinyl, benzodioxinyl and the like. SUBSTITUTE SHEET (RULE 26)
DUPLICATA 1 2046
The tenu heterocycle, hence encompassing heteroaromatic rings also referred to as arylgroupe, includes a 3 to 6 membered saturated or unsaturated carbocycle wherein one or morecarbon atoms are replaced by one or more atoms selected from nitrogen, oxygen and sulphur.Examples of saturated or partly unsaturated heterocycles are, for instance, azetidine, pyran,pyrrolidine, pyrroline, imidazolidine, imidazoline, dihydrofurane, tetrahydrofuran,dihydropyrrole, 1,3-dioxolane, piperidine, piperazine, morpholine and the like.
According to the above indicated substituent meanings and unless otherwise specifîed, any ofthe above R, groups may be optionally substituted in any of the ffee positions by one or moregroups, for instance 1 to 6 groups, independently selected from: halogen, nitro, oxo groups(C=O), cyano, alkyl, perfluorinated alkyl, hydroxyalkyl, aryl, arylalkyl, heterocyclyl,cycloalkyl, hydroxy, alkoxy, perfluorinated alkoxy, aryloxy, heterocyclyloxy,methylenedioxy, alkylcarbonyloxy, aryîcarbonyloxy, carboxy, alkoxycarbonyl,aryloxycarbonyl, cycloalkyloxycarbonyl, amino, ureido, alkylamino, dialkylamino,arylamino, diarylamino, formylamino, alkylcarbonylamino, arylcarbonylamino,heterocyclylcarbonylamino, alkoxycarbonylamino, alkoxyimino, alkylsulfonylamino,arylsulfonylamino, formyl, alkylcarbonyl, arylcarbonyl, cycloalkylcarbonyl,heterocyclylcarbonyl, aminocarbonyl, alkylaminocatbonyl, dialkylaminocarbonyl,alkylsulfonyl, arylsulfonyl, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl,arylthio and alkylthio.
In their tum, whenever appropriate, each of the above possible substituents may be furthersubstituted by one or more of the aforementioned groups. Compounds of formula (I) whereinthe given R, group is substituted by one or more of the aforementioned substituents which, intum, are optionally further substituted as set forth above, are given below.
Just as an example, the compound N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-[2,2-difluoro-3-(3-fluorophenyl)cyclopropyl]acetamide is represented by formula (I) wherein R, is alkyl (e.g.methyl), the alkyl being substituted by cycloalkyl (e.g. cyclopropyl), the cycloalkyl beingfurther substituted by two halogen atoms (e.g. fluorine) and by an aryl group (e.g. phenyl),the aryl group being substituted by a halogen atom (e.g. fluorine).
Among the meanings of the substituents and unless otherwise indicated, the term halogenatom includes, fluorine, chlorine, bromine and iodine; the term perfluorinated alkyl and SUBSTITUTE SHEET (RULE 26)
DUPLICATA 1 2046 8 alkoxy group includes an alkyl or alkoxy group fiirther substituted by more than one fluorineatom such as, for example, trifluoromethyl, triflüoromethoxy and the like.
Likewise, any of the ternis such as, for instance, alkylthio, alkylamino, dialkylamino,alkoxycarbonyl, alkoxycarbonylamino, heterocyclylcarbonyl, heterocyclylcarbonylamino,cycloalkyloxycaibonyl and the like, include groups wherein the alkyl, alkoxy, aryl, cycloalkyland heterocycly moieties are as above defined.
Pharmaceutically acceptable salts of the compounds of formula (I) include the acid additionsalts with inorganic or organic acids, e.g., nitric, hydrochloric, hydrobromic, sulphuric,perchloric, phosphoric, acetic, trifluoroacetic propionic, glycolic, lactic, oxalic, malonic,malic, maleic, tartane, citric, benzoic, cinnamic, mandelic, methanesulphonic, isethionic andsalicylic acid, as well as the salts with inorganic or organic bases, e.g., alkali or alkaline-earthmetals, especially sodium, potassium, calcium or magnésium hydroxides, carbonates orbicarbonates, acyclic or cyclic amines, preferably methylamine, ethylamine, diethylamine,triethylamine or piperidine.
The compounds of formula (I) may hâve asymmetric carbon atoms and may therefore existeither as racemic admixtures or as individual optical isomers.
Accordingly, the use as an antitumor agent of ail possible isomers and their admixtures and ofboth métabolites and the pharmaceutically acceptable bio-precursors (otherwise referred to aspro-drugs) of the compounds of formula (I) are also within the scope ôf the présentinvention..
Preferred compounds of the invention of formula (I) are those wherein R is a cycloalkylgroup and R, is a C,-C4 alkyl, cycloalkyl, aryl, arylalkyl, 5 or 6 membered heterocyclyl orheterocyclylalkyl group, which may be optionally fiirther substituted as described above.
Even more preferred compounds represented by formula (I) are those wherein R is cycloalkyland R, is C,-C4 alkyl, phenyl, phenylalkyl, phenylalkenyl, biphenyl, biphenylalkyl, a- or β-naphthyl, a- or β-naphthylalkyl, pyridyl, thienyl, thienylalkyl, isoxazolyl, isoxazolylalkyl,pyrazolyl, pyrazolylalkyl, furyl, thiazolyl, thiazolylalkyl, pyrrolyl, dihydropyrrolyl, indolyl,indolylalkyl, benzothienyl, benzothienylalkyl, fluorenylalkyl, pyrimidinylalkyl, quinoxalynyland cyclopropyl.
DUPLICATA SUBST1TUTE SHEET (RULE 26) 1 2046 9
Still more preferred, within this class, are the compounds of formula (I) wherein R iscyclopropyl.
Exemples of preferred compounds of the invention, which may be in the form ofpharmaceutically acceptable salts, e.g., a hydrobromide or hydrochloride sait, include thefollowing: 1. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2,2-diphenylacetamide; 2. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(4-nitrophenyl)acetamide; 3. N-(3-cyclopropyl-1 H-pyrazol-5-yl)-4-methoxybenzamide; 4. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(3-methoxyphenyl)acetamide; 5. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-[4-(dimethylamino)phenyl]acetamide; 6. N-(3-cyclopropyl-lH-pyrazol-5-yl)-l-phenylcyclopropancarboxamide; 7. 2-(l,3-benzodioxol-5-yl-N-(3-cyclopropyl-lH-pyrazol-5-yl)acetamide; 8. N-(3-cyclopropyl-lH-pyra2ol-5-yl)-2-(4-methoxyphenyl)acetamide; 9. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-phenylpropanamide; 10. N-(3-cyclopropyl-1 H-pyrazol-5-yl)-2-(3,4-dimethoxyphenyl)acetamide; 11. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(lH-nidol-3-yl)acetamide; 12. N-(3-cyclopropyl-lH-pyrazoI-5-yl)-2-(5-methoxy-lH-indol-3-yl)acetamide; 13. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(l-methyl-lH-indol-3-yl)acetamide; 14.2- (5-chloro-l-benzothiophen-3-yl)-N-(3-cyclopropyl-lH-pyrazol-5-yl)acetamide; 15.2- (l-benzothiophen-3-yl)-N-(3-cyclopropyl-lH-pyrazol-5-yl)acetamide; 16. N-(3-cyclopropyl-1 H-pyrazol-5-yl)-3-cyclopentylpropanamide; 17.2- (4-chlorophenyl)-N-(3-cyclopropyl-lH-pyrazol-5-yl)acetamide; 18. N-(3-cyclopropyl-lH-pyrazol-5-yl)-4-oxo-4-phenylbutanamide; 19. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(2,3-dihydro-lH-inden-5-yl)acetamide; 20. 3-(2-chlorophenoxyl)-N-(3-cyclopropyl-lH-pyrazol-5-yl)propanamide; 21. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-oxo-2-phenylacetamide; 22. N-(3-cyclopropyl-lH-pyrazol-5‘yl)-2-(4-methylphenyl)acetamide; 23.2- [ 1 ,l’-biphenyl]-4-yl-N-(3-cyclopropyl-lH-pyrazol-5-yl)acetamide; 24. N-(3-cyclopropyl-1 H-pyrazol-5-yl)-2-(3-chlorophenyl)acetamide; 25. N-(3-cyclopropyl- lH-pyrazol-5-yl)-2-( 1 -naphtyl)acetamide; SUBSTITUTE SHEET (RULE 26)
DUPLICATA 1 2046 10 26. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(2-fluorophenyl)acetamide; 27. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(2-chlorophenyl)acetamide; 28. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(4-fluorophenyl)acetamide; 29. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(4-trifluoromethyl-phenyl)acetainide; 30. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-methoxy-2-phenylacetamide; 31. N-(3-cyclopropyl-lH-pyrazol-5-yl)-3-oxo-l-indanecarboxamide; 32. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(3-thienyl)acetamide; 33. N-(3-cyclopropyl-1 H-pyrazol-5-yl)bicycIo[4.2.0]octa-1,3»5-triene-7-carboxamide; 34. N-(3-cyclopropyl-1 H-pyrazol-5-yl)-4-phenyl-3-butenamide; 35.4-[(4-chlorophenyl)sulphonyl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)-3-methyl-2-thiophenecarboxamide; 36. 5-[(4-chlorophenyl)sulphonyl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)-3-methyl-2-thiophenecarboxamide; 37. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-4-phenoxybenzamide; 38. 4-bromo-N-(5-cyclopropyl-lH-pyrazol-3-yl)benzamide; 39. N-(5-cyclopropyl-lH-pyrazol-3-yl)-3,5-bis(trifluoromethyl)benzamide; 40. N-(5 -cyclopropyl-1 H-pyrazol-3-yl)-3,3-dimethylbutanamide; 41. N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-iodobenzamide; 42. N-(5 -cyclopropyl-1 H-pyrazol-3-yl)-1 -napthamide; 43. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-3-cyanobenzamide; 44. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-1,3-benzodioxole-5-carboxamide; 45. 3-(2-chlorophenyl)-N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-propenamide; 46. 2,5-dichloro-N-(5-cyclopropyl-lH-pyrazol-3-yl)-3-thiophenecarboxamide; 47. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-(propylsulfanyl)nicotinamide; 48. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2,2,5,7-tetramethyl-l-oxo-4-indanecarboxamide; 49. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-pyridinecarboxamide; 50. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-adamantancarboxamide; 51. N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-methylbenzaniide; 52. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2,3,4,5,6-pentafluorobenzamide; 53. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-phenylacetamide; 54. N-(5-cyclopropyl-1 H-pyrazol-3-yï)-cyclopentancarboxamide; SUBSTITUTE SHEET (RULE 26) 1 2046 11 5 5. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-(2-thienyl)acetamide; 56. N-(5-cyclopropyl-lH-pyrazol-3-yl)-3,5-dichlorobenzamide; 5 7.2-chloro-N-(5-cyclopropyl-1 H-pyrazol-3-yl)-6-methylisonicotinamide; 58. N-(5-cyclopropyl-lH-pyrazol-3-yl)-5-isoxazolecarboxamide; 59.2,4-dichloro-N-(5-cyclopropyl-lH-pyrazol-3-yi)-5-fluorobenzamide; 60. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2,4-difluorobenzamide; 61. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-chlorobenzamide; 62. N-(5-cyclopropyl-1 H-pyrazol-3-yl)"2,4-dichlorobenzamide; 63. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2,6-dichlorobenzamide; 64. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-inethoxybenzamide; 65. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-methylbenzamide; 66. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-3-fluorobenzamide; 67. N-(5-cyclopropyl-lH-pyrazol-3-yl)-3-chlorobenzamide; 68. N-(5-cyclopropyl-lH-pyrazol-3-yl)-3,5-dimethoxybenzamide; 69. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-3-methylbenzamide; 70. N-(5-eyclopropyl-1 H-pyrazol-3-yl)-4-fluorobenzamide; 71. N-(5-cyclopropyl-lH-pyrazol-3-yi>4-trifluoromethylbenzainide; 72. Methyl 4-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-4-oxobutanoate; 73. N-(5-cydlopropyl-lH-pyrazol-3-yl)-cyclopropanecarboxamide; 74. N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-cyanobenzamide; 75. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-napthamide; 1 76. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-thiophenecarboxamide; 77. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-quinoxalinecarboxamide; 78. N-(5-cyclopropyl-lH-pyrazol-3-yl)-3,4-difluorobenzamide; 79. N-(5-cyclopropyl-lH-pyrazol-3-yl)-3,5-difluorobenzamide; 80. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2,5-dimethoxyphenyl)acetamide; 81. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-ethoxybenzamide; 82. N-(5-cyclopropyl-lH-pyrazol-3-yl)-3,4-dimethoxybenzainide; 83. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-phenylbutanainide; 84. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-4-(trifluoromethoxy)benzamide; 85. 3-chloro-N-(5-cyclopropyl-lH-pyrazol-3-yl)-l-benzothiophene-2-carboxamide; SUBSTITUTE SHEET (RULE 26) 1 2 04 6 12 86.2- (4-chlorophenoxy)-N~(5-cyclopropyl- lH-pyrazol-3-yl)nicotinamide; 87.3- chloro-N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-Üiiophenecarboxamide; 88. N-(3-cyclopropyl-lH-pyrazol-5-yl)acetamide; 89. N-(3-cyclopropyl-1 H-pyrazol-5-yl)benzamide; 90. 4-chloro-N-(3-cyclopropyl-1 H-pyrazol-5-yl)benzamide; 91. N-(3-cyclopropyl-lH-pyrazol-5-yl)-l -benzothiophene-2-carboxamide; 92. N-(3-cyclopropyl-lH-pyrazol-5-yl)[l,r-biphenyl]-4-carboxamide; 93. N-(3-cyclopropyl-lH-pyrazol-5-yl)-3-phenylpropanamide; 94. Methyl 4-{[(3-cyclopropyl-lH-pyrazol-5-yl)amino]carbonyl}benzoate; 95.4- {[(3-cyclopropyl-lH-pyrazol-5-yl)amino]carbonyl}benzoic acid; 96. N-(3-cyclopropyl-lH-pyrazol-5-yl)-3-bromobenzamide; 97. N-(3-cyclopropyl-1 H-pyrazol-5-yl)-3,4-dichlorobenzamide; 98. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-bromobenzamide; 99. N-(3-cyclopropyl-lH-pyrazol-5-yl)-3-methoxybenzamide; 100. N-(3-cyclopropyl-lH-pyrazol-5-yl)-3-trifluoromethylbenzamide; 101. 4-butoxy-N-(3-cyclopropyl-lH-pyrazol-5-yl)benzamide; 102. N-(3-cyclopropyl-lH-pyrazol-5-yl)-lH-indole-2-carboxamide; 103. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-[5-(2,6-difluorobenzyl)-2-methoxyphenyl]acetamide; 104. N'-<3-cyclopropyMH-pyrazol-5-yl)therephthalamide. 105. N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-(3,3-dimethylbutanoyl)-lH-pyrrole-2-carboxamide; 106. N-(5-cycloprppyl-lH-pyrazol-3-yl)-4-(cyclopropylcarbonyl)-lH-pyrrole-2-carboxamide; 107. N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-(2-thienylcarbonyl)-lH-pyrrole-2-carboxamide; 108. N-(5-cycIopropyl-l H-pyrazol-3-yl)-4-(2-methylbenzoyl)-1 H-pyrrole-2-carboxamide; 109. 4-( 1 -benzothien-2-ylcarbonyl)-N-(5“Cyclopropyl-1 H-pyrazol-3-yl)-1 H-pyrrole-2-carboxamide; 110. 2-[(4-acetylamino)phenyl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; 111. 4-bromo-N-(5-cyclopentyl-lH-pyrazol-3-yl)benzamide; 112. 4-bromo-N-(5-cycloHexyl-lH-pyrazol-3-yl)benzamide; SUBSTITUTE SHEET (RULE 26)
WKXOASA 1 2046 13 113. N-[5-(2-benzylcyclopropyl)-lH-pyrazol-3-yl]4-bromobenzamide; 114. 4-bromo-N-(5-cyclobutyl-lH-pyrazol-3-yl)benzamide; 115. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2,4-dimethoxybenzamide; 116. N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-(3-methylbenzoyl)-lH-pyrrole-2-carboxamide; 117. N-(5-cyclopropyl- lH-pyrazol-3-yl)-4-(3-methylbutanoyl)-1 H-pyrrole-2-carboxamide; 118. N-(5-cyclopropyHH-pyrazol-3-yl)-4-(3-fluorobenzoyl)-lH-pyrK)le-2-carboxaniide; 119. N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-(2-fluorobenzoyl)-lH-pyrrole-2-carboxainide; 120. 4-(cyclopentylcarbonyl)-N-(5-cyclopropyl-lH-pyrazol-3-yl)-lH-pyrrole-2-carboxamide; 121. N-(5-cyciopropyi-lH-pyrazol-3-yl)-4-pentanoyl-lH-pyrrole-2-carboxamide; 122. 4-(3-chlorobenzoyl)-N-(5-cyclopropyl-lH-pyrazol-3-yl)-lH-pyrrole-2-carboxamide; 123. N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-(phenylacetyl)-lH-pyirole-2-carboxamide; 124. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-4-[(4-fluorophenyl)acetyl]- lH-pyrrole-2-carboxamide; 125. 4-butyryl-N-(5-cyclopropyl- lH-pyrazol-3-yl)-1 H-pyirole-2-carboxamide; 126. N-(5-cyclopropyl- lH-pyrazol-3-yl)-4-(4-fluorobenzoyl)-1 H-pyrrole-2-carboxamide; 127. 2-(4-bromophenyl)-N-(5-cyclopropyl-lH-pyrazol-3-yl)-acetamide; 128. N-(5>cyclopropyl-lH-pyrazol-3-yl)-2-E4-(l-pyrrolidinyl)phenyl3acetainide; 129. (2S)-N-(5-cycIopropyl-lH-pyrazol-3-yl)-2-(2-naphtyl)propanamide; 130. N-(5-cyclopropyl- lH-pyrazol-3-yI)-2-[4'-(hydroxymethyl)[ 1,1 *-biphenyl]-4-yl)acetamide; 131. 3-tert-butyl-N-(5-cyclopropyl-lH-pÿrazol-3-yl)-l-(2-thienylcarbonyl)-lH-pyrazole-5-carboxamide; 132. N-(3-{[(3-cyclopropyl-lH-pyrazol-3-yl)amino]carbonyl}-2-thienyl)-2-thiophenecarboxamide; 133. N-(5-cyclopropyl-lH-pyrazol-3-yl)-5-(methylsulfonyl)-2-thiophenecarboxamide; 134. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-oxo-4-phenyl-3-butenamide; 135. N-5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(3-thienyl)phenyl]acetamide; 136. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4'-fluoro[l ,1 '-biphenyl]-4-yl)acetamidc; 137. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2,4-dimethyI-5-phenyl-1 H-pyrrole-3-carboxamide; SUBSTITÜTE SHEET (RULE 26) 1 2046
, · , I 14 138. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2,5-dimethyl-1 -(2-thienylmethyl)-lH-pyrrole-3-carboxamide; 139. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-methyl-5-phenyl-3-fiiramide; 140. N- {2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}benzamide; 141. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-naphtyl)acetaniide; 142. 5-chloro-N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-thiophenecarboxainide; 143. 4'-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxethyl} [1.1 *-biphenyl]-4-carboxylic acid; 144. 4’-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)ainino]-2-oxethyl}[l,l1-biphenyl]-4-carboxamide; 145. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4’-formyl[ 1,1 '-biphenyl]-4-yl)acetamide; 146. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-{4'-[(dimethylamino]methyl)[l,l,-biphenyl]-4-yl} acetamide; 147. 2-amino-N-(4-{2-[(5-cyclopropyl-lH-pyra2»l-3-yl)amino]-2-oxethyl}phenyl)acetamide; 148. 2-[4-aminomethyl)phenyl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetarnide; 149. 2-[4’-(aniinomethyl)[l,r-biphenyl]-4-yl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; 150. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-{4,-[(methylaniino)methyl][l,r-biphenyl]-4-yl) acetamide; 151. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-[4’-( 1 -pyrrolidinylmethyl)[ 1,1 '-biphenyl]-4-yljacetamide; 152. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-[4'-( 1 -piperidinylmethyl)[ 1,1 '-biphenyl]-4-yljacetamide; 153. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-[4'-(4-raorpholinylmethyl)[ 1, l'-biphenyl]-4-yl]acetamide; 154. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2- {4'-[(4-methyl-1 -piperazinyl)methyl] [ 1, Γ-biphenyl]-4-yl} acetamide; 155. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-[4'-( 1 H-imidazol-2-yl)[ 1,1 ’-biphenyl] -4-yl]acetamide;
DUPLICATA SUBSTITUTE SHEET (RULE 26) 1 2046 15 156. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-{((dimethylamino)carbonyl]aniino}phenyl)acetamide; 157. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-{4-((methylsuIfonyl)amino]phenyl}acetamide; 158. 2-[4-(aminomethyl)phenyl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetaniide; 159. 2-{4-[(acetylamino)methylÎphenyl}-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; 160. 2-[4-(aminosulfonyl)phenyl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; 161. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-[4-(2-oxo-1 -pyrrolidinyl)phenyl]acetamide; 162. N-(3-cyclopropyl-lH-pyrazol-5-yl)-4-(2-methoxyphenoxy)benzamide; 163. 4-(4-chlorophenoxy)-N-(3-cyclopropyl- lH-pyrazol-5-yl)benzamide; 164. 4-(4-chlorophenoxy)-N-(3-cyclopropyl- lH-pyrazol-5-yl)-3-nitrobenzamide; 165. 4-[3,5-bÎs(trifluoromethyl)phenoxy]-N-(3-cyclopropyl-lH--pyrazol-5-yl)benzamide; 166. N-(3-cyclopropyl-lH-pyrazol-5-yl)-4-(4-fluorophenoxy)benzamide; 167. N-(3-cyclopropyl-lH-pyra2»l-5-yl)-4-(4-methylphenoxy)benzamide; 168. 4-(4-cyanophenoxy)-N-(3-cyclopropyl-lH-pyrazol-5-yl)benzamide; 169. N-(3-cyclopropyl-lH-pyrazol-5-yl>-4-(4-hydroxyphenoxy)benzamide; 170. N-(3-cyclopropyl-lH-pyrazol-5-yl)-4-(3-hydroxyphenoxy)benzamide; 171. 2-(1,1 ’-biphenyl]-4-yl-N-(3-cyclopropyl-1 H-pyrazol-5-yl)propanamide; 172. N-(3-cyclopropyl-1 H-pyrazol-5-yl)-2-(4-phenoxyphenyl)acetamide; 173. N-(3-cyclopropyl-lH-pyrazol-5-yl)-3,5-diiodo-4-(4-methoxyphenoxy)benzamide; 174. N-(3-cyclopropyl-lH-pyrazoi-5-yl)-4-[3-(hydroxymethyl)phenyl]-3-butenamide; 175. N-(3-cyclopropyl-lH-pyrazol-5-yl)-4- {3-[(methylamino)methyl]phenyl} -3-butenamide; 176. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(2-phenylcyclopropyl)acetamide; 177. 2-(2-(1,3-benzodioxol-5-yl)cyclopropyl]-N-(3-cyclopropyl- lH-pyrazol-5-yl)acetamide; 178. 2-(3-(1,3-benzodioxol-5-yl)-2,2-difluorocyclopropyl]-N-(3-cyclopropyl-lH-pyrazol- 5-yl)acetamide; 179. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(2,2-difluoro-3-phenylcyclopropyI)acetamide; 180. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(5-inethyl-4-phenyl-3-isoxazolyl)acetainide; 181. N-(3-cyclopropyl- lH-pyrazol-5-yl)-2-(5-methyl-3-phenyl-4-isoxazolyl)acetamide; SUBSTITÛTE SHEET (RULE 26) 1 2046 16 182. 2-(3-(1,3-benzodioxol-5-yl)-5-methyl-4-isoxazolyl]-N-(3-cyclopropyl-lH-pyrazol-5yl)acetamide; 183. 2-(4-(1,3-benzodioxol-5-yl)-5-methyl-3-isoxazolyl]-N-(3-cyclopropyl-1 H-pyrazol-5yl)acetamide; 184. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(3-phenyl-2-oxiranyl)acetainide; 185. N-(3-cyclopropyl- lH-pyrazol-5-yl)-2-(2-(4-fluorophenyl)cyclopropyl]acetamide; 186. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-[2,2-difluoro-3-(3-fluorophenyl)cyclopropyl]acetamide; 187. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(2-oxo-2,3-dihydro-lH-indol-5-yl)acetamide; 188. 2-[4-(acetylamino)phenyl]-N-(3-cyclopropyl-lH-pyrazol-5-yl)acetamide; 189. N-(4-{2-[(3-cyclopropyl-lH-pyrazol-5-yl)amino]-2-oxoethyl}phenyl)-l-pyrrolidinecarboxamide; 190. N-(4- {2-[(3-cyclopropyl- lH-pyrazol-5-yl)amino]-2-oxoethyl} phenyl)-1 -piperidinecarboxamide; 191. N-(4- {2-[(3-cyclopropyl-l H-pyrazol-5-yl)amino]-2-oxoethyl} phenyl)-4-morpholinecarboxamide; 192. N-(4- {2-[(3-cyclopropyl-1 H-pyrazol-5-yl)amino]-2-oxoethyl}phenyl)-4-methyl-1 -piperazinecarboxamide; 193. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(2-pyridinyl)acetamide; 194. N-(3-cyclopropyl-1 H-pyrazol-5-yl)-2-(3-pyridinyl)acetamide; 195. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(4-pyridinyl)acetamide; 196. N-(3-cyclopropyl-1 H-pyrazol-5-yl)-5-(3-nitrophenyl)-2-furamide; 197. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(2,5-dioxo-4-imidazolidinyl)acetamide; 198. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(9-oxo-9H-fluoren-2-yl)acetamide; 199. N-(5-cydopropyl-1 H-pyrazol-3-yl)-2-(4’-ethyl[ 1,1 ’-biphenyl]-4-yl)acetamide; 200. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-(4'-propyl[ 1,1 '-biphenyl]-4-yl)acetamide; 201. N-(5-cydopropyl-lH-pyrazol-3-yl)-2-(9H-fluoren-2-yl)acetainide; 202. N-(5-cyclopropyl-lH-pyrazol-3-yI)-2-(9-methyl-9H-fluoren-2-yl)acetamide; 203. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-hydroxydibenzo[b,d]furan-3-yl)acetamide; 204. N-(5-cycIopropyl-1 H-pyrazol-3-yl)-2-(4'-hydroxy[ 1,1 '-biphenyI]-4-yl)acetamide; 205. 2-(4’-cyano[ 1,1 '-biphenyl]-4-yl)-N-(5-cyclopropyl- lH-pyrazol-3-yl)acetamide; SUBSTITUTE SHEET (RULE 26) 1 2046 17 206. 2-(4'-bromo[ 1,1 '-biphenyl]-4-yl)-N-(5 -cyclopropyl-1 H-pyrazol-3 -yl)acetamide; 207. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(4'-propoxy[ 1,1 '-biphenyl]-4-y l)acetamide; 208. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(4'-butoxy[ 1,1 '-biphenyl]-4-yl)acetamide; 209. N-(5-cyclopropyl- lH-pyra2»l-3-yl)-2-(4'-pentoxy[ 1,1 '-biphenyl]-4-yl)acetamide; 210. 4'- {2-[(5-cyclopropyl-1 H-pyrazol-3-yl)amino]-2-oxoethyl} [ 1,1 '-biphenyl]-4-ylacetate; 211. 2-(4'-tert-butyl[l,l'-biphenyl]-4-yl)-N-(5-cyclopropyl-lH-pyrazoI-3-yl)acetamide; 212. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3',4'-dicbloro[l,r-biphenyl]-4-yl)acetamide; 213. N-(5-cyclopropyl-l H-pyrazol-3-yl)-2-(3'-hydroxy[ 1,1 ’-biphenyl]-4-yl)acetamide; 214. 2-(3'-bromo[ 1,1 ’-biphenyl]-4-yl)-N-(5-cyclopropyl-1 H-pyrazol-3-yl)acetamide; 215. 2-{3’-anuno[ 1,1 '-biphenyl]-4-yl)-N-(5-cyclopropyl- lH-pyrazol-3-yl)acetamide; 216. 2-(4'-amino[ 1,1 ’-biphenyl]-4-yl)-N-(5-cycIopropyl-1 H-pyrazol-3-yl)acetamide; 217. N-(5-cyclopropyl-l H-pyrazol-3-yl>2-(3-hydroxy-2-naphthyl)acetamide; 218. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3,5-dihydroxy-2-naphthyl)acetaniide; 219. 2-(3-amino-2-naphthyl)-N-(5-cyclopropyl- lH-pyrazol-3-yl)acetamide; 220. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(6-hydroxy-2-naphthyl)acetamide; 221. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(2-hydroxy-1 -naphthyl)acetamide; 222. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(6-hydroxy-l-naphthyl)acetamide; 223. 3-amino-N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-[(2-furylmethyl)sulfonyl)-2-thiophenecarboxamide; 224. 3-amino-4-[(4-chlorophenyl)sulfonyl]-N-(5-cycIopropyl-1 H-pyrazol-3-yl)-2-thiophenecarboxamide; 225. 3-amino-N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-(phenylsulfonyl)-2-thiophenecarboxamide; 226. 3-chloro-N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-(methylsulfonyl)-2-thiophenecarboxamide; 227. 3-amino-N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-(isopropyIsulfonyl)-2-thiophenecarboxamide; 228. 3-amino-N-(5-cyclopropyl-lH-pyraz»l-3-yl)-4-(propylsulfonyl)-2-thiophenecarboxamide; SUBSTITUTE SHEET (RULE 26) 1 2046 18 229. 3-chloro-N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-(isopropylsulfonyl)-2-thiophenecarboxamide; 230. N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-(isopropylsulfonyl)-2-thiophenecarboxamide; 231. 4- {2-[(5-cyclopropyl- lH-pyrazol-3-yl)amino]-2-oxoethyl) benzamide; 232. 4'-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino3-2-oxoethyl}-N-[2-(l-pyrrolidinyl)ethyl][ 1,1 '-biphenyl]-4-carboxamide; 233. 4'- {2-[(5-cyclopropyl- lH-pyrazol-3-yl)amino]-2-oxoethyl} -N-[2-( 1 -pyrrolidinyl)propy 1] [1,1 ’-bipheny l]-4-carboxamide; 234. 4'- {2-[(5-cyclopropyl-1 H-pyrazol-3-yl)ammo]-2-oxoethyl} -N-[2-( 1 -piperidinyl)ethyl] [1,1 '-biphenyl]-4-carboxamide; 235. 4’-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}-N-[2-(l-piperidinyl)propyl][ 1,1 ’-biphenyl]-4-caiboxamide; 236. 4’-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoetbyl}-N-[2-(4-morpholinyl)ethyl] [ 1, r-biphenyl]-4-carboxamide; 237. 4’-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}-N-[2-(4-morpholinyl)propyl] [ 1, r-biphenyl]-4-carboxamide; 238. 4'-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}-N-[2-(4-methyl-l-piperazinyl)ethyl] [1,1 '-biphenyl]-4-carboxamide; 239. 4'- {2-[(5-cyclopropyl- lH-pyrazol-3-yl)amino]-2-oxoethyl} -N-[2-(4-methyl-1 -piperazinyl)propyl] [1,1 '-biphenyl]-4-carboxamide; 240. N-(3-cyclopropyl-l H-pyrazol-5-yl)-4-(3,4-dimethyIbenzoyl)- lH-pyrrole-2-carboxamide; 241. N-(3-cyclopropyl- lH-pyrazol-5-yl)-4-(4-fluorobenzoyl)-1 H-pyrrole-2-carboxamide; 242. N-(3-cyclopropyl-lH-pyrazol-5-yl)-4-(4-methylbenzoyl)-lH-pyirole-2-carboxamide; 243. 4-(4-chlorobenzoyl)-N-(3-cyclopropyl-lH-pyrazol-5-yl)-lH-pyiTole-2-carboxamide; 244. 4-(cyclohexylcarbonyl)-N-(3-cyclopropyl-lH-pyrazol-5-yl)-lH-pyrrole-2-carboxamide; 245. methyl5-(5-{[(3-cyclopropyl-lH-pyrazol-5-yl)amino]carbonyl}-lH-pyrrol-3-yl)-5-oxopentanoate 246. 4-acetyl-N-(3-cyclopropyl-lH-pyrazol-5-yl)-lH-pyrrole-2-carboxamide; SUBSTITUTE SHEET (RULE 26) WLIOÀÆà 1 2.046 ( 19 247. N-(3-cyclopropyl-lH-pyrazol-5-yl)-4-(2,6-dimethoxybenzoyl)-lH-pyrrole-2-carboxamide; 248. N-(3-cyclopropyl-lH-pyrazol-5-yl)-lH-pyrrole-2-carboxamide; 249. N-(3-cyclobutyl-lH-pyrazol-5-yl>lH-pyrrole-2-carboxamide 250. N-(3-cycIopropyl- lH-pyrazol-5-yl)-1 -methyl-1 H-pyrrole-2-carboxamide; 251. 4-bromo-N-(3-cyclopropyl-lH-pyrazol-5-yl)-lH-pyrrole-2-carboxamide; 252. N-(3-cyclopropyl-lH-pyrazol-5-yl)-l-inethyl-4-(3-methylbenzoyl)-lH-pyrrole-2-carboxamide; 253. N-(3-cyclopropy 1-1 H-pyrazol-5-yl)-2-quinoxalinecarboxamide; 254. (lR,2R)-N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-phenylcyclopropanecarboxamide; 255. N-(3-cyclopropyl-lH-pyra2ol-5-yl)-2-phenylcyclopropanecatboxamide; 256. 3-chloro-N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-thiophenecarboxamide; 257. 4-benzoyl-N-(3-cyclopropyl-lH-pyrazol-5-yl)benzamide; 258. (2S)-N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(6-methoxy-2-naphthyl)propanamide; 259. N-(3-cyclopropyl-lH-pyrazol-5-yl)-4-morpholinocarboxainide; 260. (2S)-N-(3-Gyclopropyl-lH-pyra2»l-5-yl)-3,3,3-trifluoro-2-methoxy-2-phenylpropanamide; 261. (2S)-N-(3-cyclopropyl-1 H-pyrazol-5-yl)-2-methoxy-2-phenylethanamide; 262. 2-[5-(benzyloxy)-lH-indol-3-yl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; 263. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(5-meihoxy-2-niethyl-lH-indol-3-yl)acetamide; 264. (2S)-N-(3-cyclopropyHH-pyrazol-5-yl)-2,5-dihydro-lH-pyiTole-2-carboxanùde; 265. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(2,5-difluorophenyl)acetamide; 266. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(5-hydroxy-lH-indole-3-yl)acetamide; 267. 2-[l-(4-chlorobenzoyl)-5-methoxy-2-methyl-lH-indol-3-yl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; 268. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3-inethylphenyl)acetamide; 269. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3-hydroxyphenyl)acetamide; 270. (2S)-2-ainino-N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-phenylethanainide; 271. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-nitrophenyl)propanamide·, 272. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(4-hydroxy-3-methoxyphenyl)acetamide; 273. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[3,5-bis(trifluoromethyl)pheny]lacetamide;
SUBSTITUTE SHEET (RULE 26)DUPLICATA 1 2046
"H 20 274. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-chloro-6-fluorophenyl)acetamide; 275. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-hydroxy-2-(4-hydroxy-3-methoxyphenyl)acetamide; 276. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2- {4-[(2S)-2-aminopropanoyloxymethyljphenyl} acetamide; 277. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-bromomethylphenyl)acetamide; 278. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-methylsulphonylphenyl)acetamide; 279. (2R)-N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-methoxy-2-phenylethanamide; 280. N-(5-cyclopropyl-lH-pyrazoi-3-yl)-2-(2-methylphenyl)acetamide; 281. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[2-(foimylamino)-l ,3-thiazol-4-yl]-2-(methoxyimino)ethanamide; 282. 2-[5-(chloroacetyl)-2-thienyl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; 283. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-oxo-2-(2-thienyl)acetamide; 284. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-methyl-lH-indol-3-yl)acetamide; 285. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3,5-dimethoxyphenyl)acetamide; 286. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3,4-difluorophenyl)acetamide; 287. N-(5-cyclopropyI-lH-pyrazol-3-yl)-2-(3,4-dichIorophenyl)acetamide; 288. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3-bromophenyl)acetamide; 289. 2-cyclohexyl-N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-phenylacetamide; 290. (lR)-2-[(3-cyclopropyl-lH-pyrazol-5-yl)amino]-2-oxo-l-phenylethylacetate; 291. 2-chloro-N-(5-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}-l,3-thiazol-2-yl)acetamide; 292. 9H-fluoren-9-yI (2S)-2-{[(3-cyclopropyl-lH-pyrazol-5-yl)amino]carbonyl}-2,5-dihydro-1 H-pyrrole-1 -carboxylate; 293. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-hydroxy-2-diphenyl)acetamide; 294. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-methylsulfanylphenyl)acetamide; 295. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-bromophenyl)acetamide; 296. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2,6-dihydroxy-4-pyrimidinyl)acetamide; 297. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-hydroxy-3-nitrophenyl)acetamide; 298. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3-chloro-4-hydroxyphenyl)acetamide; 299. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(7-methoxy-2-oxo-2H-chromen-4-yl)acetamide; SUBSTITJjg^gEJJRULE 26) 1 2046 21 300. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-acetylamino-2-phenyl)acetamide; 301. N-(5-cyclopropyl-lH-pyrazol-3-yI)-2-(l-methylimidazol-4-yl)acetamide; 302. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3-nitrophenyl)acetamide; 303. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(2-bromo-2-phenyl)acetamide, 304. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-benzyloxy-3-methoxyphenyl)acetamide; 305. (2S)-N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-hydroxy-2-phenylethanamide; 306. l-(4-chlorophenyl)-N-(5-cyclopropyl-lH-pyrazol-3-yl)cyclopentanecarboxamide; 307. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3-trifluoromethylphenyl)acetamide; 308. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(lH-indol-3-yl)-2-oxoacetamide; 309. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2,4-dichlorophenyl)acetamide; 310. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3,4-dihydroxyphenyl)acetamide; 311. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(3,5-di-tert-butyl-4-hydroxyphenyl)acetamide; 312. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3>5-difluorophenyl)acetamide; 313. N-(5-cyclopropyl-lH-pyrazol-3-yl>2-benzyloxycarbonyl-2-phenylacetamide; 314. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3-methyl-l-benzothien-2-yl)acetamide; 315. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-butoxyphenyl)acetaniide; 316. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-thienyl)acetamide; 317. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(3-fluorophenyl)acetamide; 318. 5-cydohexyl l-(4-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}benzyl) 2-aminopentanedioate; 319. N-(5-cyelopropyl-1 H-pyrazol-3-yl)-2-(4-isobutylphenyl)propanamide; 320. N-(5-cyclopropyl-1 H-pytazoI-3-yl)-2-(7-hydroxy-2-oxo-2H-chromen-4-yl)acetamide; 321. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(4-hydroxyphenyl)acetamide; 322. 2-cyclopenlyl-N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-phenylacetainide; 323. (lS)-2-[(3-cyclopropyl-lH-pyrazol-5-yl)amino]-2-oxo-l-phenylethylacetate; 324. N-(3-cyclopropyl- lH-pyrazol-5-yl)-2-fluoro-2-phenylacetamide·, 325. N-(5-cycîopropyl-lH-pyrazol-3-yl)-2-(2-furyl)-2-oxoacetainide; 326. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(5-bromo-lH-indol-3-yl)acetamide; 327. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-trifluoromethylphenyl)acetamide; 328. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-methoxyphenyl)acetamide; 329. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-(3,4,5-trimethoxyphenyl)acetamide; SUBSTITÜTE SHEET (RULE 26)
BHWàAM 1 2046 22 330. N-(5-cyclopropyl-lH-pyrazol-3-yI)-2-(2,5-dioxo-2,5-dihydro-3-furanyl)acetamide; 331. 2-chloro-2,2-bis(2-chlorophenyl)-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; 332. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-hydroxy-2-(3-hydroxy-4-methoxyphenyl)acetamide; 333. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(pentafluorophenyl)acetamide; 334. N-(3-cyclopropyl-lH-pyrazol-5-yl)-3-methyl-2-phenylpentanamide; 335. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2"nitrophenyI)acetamide; 336. N-(5-cyclopropyl-lH-pyrazol-3-yl)-l-phenylcyclopentane-l-carboxamide; 337. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-trifluoromethoxyphenyl)acetamide; 338. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-ethoxyphenyl)acetamide; 339. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-fluorophenyl)acetamide; 340. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(2-nitro-4-trifluoromethylphenyl)acetamide; 341. 2-(5-bromo-3-pyridinyl)-N-(5-cyclopropyl-1 H-pyrazol-3-yl)acetamide; 342. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2,6-dichlorophenyl)acetamide; 343. N-(5-cyclopropyl-lH-pyrazol-3-yl)- 2-oxo-2H-pyran-5-carboxamide; 344. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2,4-dinitrophenyl)acetamide; 345. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2,4-difluorophenylacetamide; 346. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(3-bromo-4-methoxyphenyl)acetamide; 347. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-3-hydroxy-2-phenylpropanamide; 348. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3-fluoro-4-hydroxyphenyl)acetamide; 349. 2- {2-[(chloroacetyl)amino]-1,3-thiazol-5-yl} -N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(methoxyimino)ethananiide; 350. N-(5-cyclopropyl-lH-pyrazol-3-yl)-l-phenylcyclopropanecarboxamide; 351. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2,6-difluorophenyl)acetamide; 352. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2,5-dihydroxyphenyl)acetamide; 353. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2,4,6-trimethylphenyl)acetanHde; 354. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-[2,5-bis(trifluoromethyl)phenyl]acetamide; 355. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[2-(2,4-difluorophenyl)-l,3-thiazol-4-yl]acetamide; 356. N-(5-cyclopropyl-l H-pyrazol-3-yl)-2-(5-methoxy-3-hydroxy-2-propylphenyl)acetamide; SUBSTITUTE SHEET (RULE 26) 1 2046 23 357. N-(3-cyclopropyl-lH-pyrazoI-5-yl)-2-(2-fluoro[l,r-biphenyl]-4-yl)propanamide; 358. (2R)-N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(2-fluoro[l,l'-biphenyl]-4-yl)propanamide;; 359. 2- {4-[(aminocarbonyl)amino]phenyl} -N-(5-cyclopropyl-1 H-pyrazol-3-yl)acetamide; 360. 2-{4-[(2-amino-2-oxoethyl)ainino]phenyl}-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; 361. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(5-methyl-2-phenyl-l,3-thiazol-4-yl)acetainide; 362. 4-bromo-N-(4-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}-l,3-thiazol-2-yl)benzamide 363. 2-[2-(4-chlorophenyl)-4-hydroxy-l,3-thiazoI-5-yl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; 364. N-(4- {2-[(5^cyclopropyl- lH-pyrazol-3-yl)amino]-2-oxoethyl} -1,3-thiazol-2-yl)-2-(2-pyridinylsulfanyl)acetamide; 365. N-(4-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}-l,3-thiazol-2-yl)-2-(isopropylsulfanyl)acetamide; 366. 2-(5-{[(4-chlorophenyl)sulfanyl]acetyl}-2-thienyl)-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; 367. 2-(5-chloro-3-methyl-l-benzothien-2-yl)-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetarhide; 368. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-iodophenyl)acetamide; 369. N-(5-cyclopropyHH-pyrazol-3-yl)-9H-xanthene-9-carboxamide; 370. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-phenyl-l,3-thiazol-4-yl)acetamide; 371. 2-[2-(4-chlorophenyl)-5-methyl-l,3-thiazol-4-yl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; 372. N-(4-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}-l,3-thiazol-2-yl)benzamide; 373. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(6-methoxy-2-naphthyl)acrylaniide; 374. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-(2-hydroxyphenyl)acetamide; 375. N-(5-cyclopiopyl-lH-pyrazol-3-yl)-2,3-di(2-thienyl)-2-propenaniide; 376. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[2-(2-pyrazinyl)-l,3-thiazol-4-yl]acetajnide; 377. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-{2,5-dibromo-3-thienyl)acetamide; SUBSTITÙTE SHEET (RULE 26) BOmCAlÀ 1 2046 24 378. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3-methylsulfonylaminophenyl)acetainide; 379. N-(5-cyclopropyl-lH-pyra2»l-3-yl)-2-(4-methylsulfonylaminophenyl)acetamide; 3 80. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2- {4-[2-(4-methyl-l - piperazinyl)ethoxy]phenyl} acetamide; 381. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2- {4-[2-(l-pyrrolidinyl)ethoxy]phenyl} acetamide; 382. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-{4-(2-amino-2-oxoethoxy)phenyl}acetamide; 383. N-(5-cyclopropyl-lH-pyrazol-3-yl)- 2-{4-[2-oxo-2-(l-pyrrolidinyl)ethoxy]phenyl}acetamide; 384. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-[3-(2-amino-2-oxoethoxy)phenyl]acetamide; 385. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-phenoxyacetamide; 386. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2,4-dichlorophenoxy)acetamide; 387. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-phenoxy-2-methylpropanamide; 388. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-chIorophenoxy)propanamide; 389. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-nitrophenoxy)acetamide; 390. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(5-isopropyl-2-methyl-lH-indol-3-yl)acetamide; 391. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3-methoxyphenyl)acetamide; 392. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-methyl-2-(2-methyl-2,3-dihydro- 1-benzofuran- 5-yl)propanamide; 393. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[2-(4-methoxyphenyl)-4-oxo-4H-cliromen-6-yl]acetamide; 394. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(6.-chloro-2,3-dihydro-lH-inden-3-yl)butanamide; 395. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-[4-(l -oxo-1,3-dihydro-2H-isoindol-2-yl)phenyl]hexanamide; 396. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-phenyl-3-(4-pyridinyl)propenamide; 397. 2-[l,r-biphenyl]-4-yl-N-(5-cyclopropyl-lH-pyrazol-3-yl)butanamide; 398. N-(5-cyciopropyl-lH-pyrazol-3-yl)-2-[4-(l,3-dihydro-2H-isoindol-2-yl)phenyl]propanamide; 399. N-(5-cyclopropyHH-pyrazol-3-yl)-2-[4-(l-oxo-l,3-dihydro-2H-isoindol-2-yl)phenyl]butanamide;
SUBSTITUTE SHEET (RULE 26)DUPLICATA 1 2046 25 400. N-(5-cyclopropyl-lH-pyrazol-3-yl)-(2S)-2-[4-(l-oxo-l,3-dihydro-2H-isoindol-2-yl)phenyl]propanamide; 401. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(5-amino-4-phenyl-lH-l,2,3-triazol-l-yl)phenyl]acetaxnide; 402. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(l-oxo-l,3-dihydro-2H-isoindol-2-yl)phenyl]pentanamide; 403. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-benzyloxyphenyl)acetamide; 404. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2- {4-[(3,3-diethyl-4-oxo-2-azetidinyl)oxy]phenyl) acetamide; 405. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(5,6-diniethyl-lH-benzimidazol-l-yl)acetamide; 406. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-pyridylsulfanyl)acetamide; 407. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(lH-tetrazol-l-yl)acetamide; 408. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(tetrazolo[l ,5-b]pyridazin-6-ylsulfanyl)acetamide; 409. 2-[l,l'-biphenyl]-4-yl-N-(5-cyclopropyî-lH-pyrazol-3-yl)-2-hydroxyacetamide; 410. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-cyclohexene-1 -carboxamide; 411. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-oxo-2H-pyran-4-carboxamide; 412. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-3-bromo-2,2-diphenylpropanamide; 413. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-4,4-bis(4-inethylphenyl)-3-butenamide; 414. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-hydroxy-5-isopropyl-2-methylphenyl)acetamide; 415. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-(4-nitrophenyl)-2-butenamide; 416. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3,4-dihydro-l-naphthyl)butanamide; 417. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2,3,6-trifluorophenyl)acetamide; 418. N-(3-cyclopropyl-lH-pyrazol-5-yl)-l,4-benzodioxine-2-carboxamide; 419. N-(3-cyclopropyl-lH-pyrazol-5-yl)-3-phenyl-l,4-ben2odioxine-2-carboxamide; 420. N-(3-cyclopropyl- lH-pyrazol-5-yl)-4-oxo-4H-chromene-2-carboxamide; 421. N-(3-cyclopropyl-1 H-pyrazol-5-yl)-2-oxo-1,2-dihydro-4-quinolinecarboxamide; 422. 2-anilino-N-(3-cyclopropyl-lH-pyra2»l-5-yl)acetamide; 423. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4’-fluoro[ 1,1 ’-biphenyl]-4-yl)acetamide 424. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2’-fluoro[l,l'-biphenyl]-4-yl)acetamide SUBSTITÛTE SHEET (RULE 26) 1 2046 26 425. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-(3 ’-fluoro[ 1,1 ’-biphenyl]-4-yl)acetamide 426. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(3 ’-methoxy [ 1,1 ’-biphenyl]-4-yl)acetamide 427. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-(pentafluoro[ 1,1 ’-biphenyl]-4-yl)acetamide 428. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(4’-(trifluoromethoxy)[ 1,1 ’-biphenyl]-4-yl)acetamide 429. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4’-carboxy[l,l'-biphenyl]-4-yl)acetamide 430. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-(3 ’-formyl-4’-methoxy[ 1,1 '-biphenyl]-4-yl)acetamide 431. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4’-fluoro-3’-methyl[l,r-biphenyl]-4-yl)acetamide 432. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2’,5’-dichloro[l,r-biphenyl]-4-yl)acetamide 433. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(3 ’-acetyl[ 1,1 '-biphenyl]-4-yl)acetamide 434. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4’-formyl[l,r-biphenyl]-4-yl)acetamide 435. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2’,5 ’ difluoro[ 1,1 '-biphenyl]-4-yl)acetamide 436. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2’,5’-dimethyl[l,r-biphenyl]-4-yl)acetamide 437. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-(2’,6-difluoro[ 1,1 '-biphenyl]-4-yl)acetamide 438. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-(4’-methoxy[ 1,1 '-biphenyl]-4-yl)acetamide 439. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2’,6-dimethyl[l,r-biphenyl]-4-yl)acetamide 440. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(5 ’-fluoro-2 ’-methoxy[ 1,1 '-biphenyl]-4-yl)acetamide 441. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(2 ’,5 ’-dimethoxy[ 1,1 ’-biphenyl]-4-yl)acetamide 442. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2’,6-dimethoxy[l,r-biphenyl]-4-yl)acetaniide 443. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-(4’-acetyl-[ 1,1 '-biphenyl]-4-yl)acetamide 444. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4*-ethoxy-[l,r-biphenyl]-4-yl)acetamide 445. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-((4’-methylthio)-[l,r-biphenyl]-4-yl)acetamide 446. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3’-chloro-4’-fluoro-[l,r-biphenyl]-4-yl)acetamide 447. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2’-acetyl-[l,r-biphenyl]-4-yl)acetaniide 448. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(4‘-ethyl-[ 1,1 '-biphenyl]-4-yl)acetamide 449. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-(3 ’-ethoxy-[ 1,1 ’-biphenyl]-4-yl)acetamide SUBSTITUTE SHEET (RULE 26)
MHUIMEA 1 2046 27 450. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3’,4’-dimethoxy-[l,r-biphenyl]-4-yl)acetamide 451. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2’-ethoxy-[l,r-biphenyl]-4-yl)acetamide 452. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(3 ’,5 ’-difluoro-[ 1,1 '-biphenyl]-4-yl)acetamide 453. N-(5-eyclopropyl-lH-pyrazol-3-yl)-2-(2’,4’-dirnethoxy-[l,l'-biphenyl]-4-yl)acetamide 454. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-(2 ’,3 ’-dimethyl-[ 1,1 '-biphenyl]-4-yl)acetamide 455. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-(3 ’-(trifluoromethoxy)[ 1, l’-biphenyl]-4-yl)acetamide 456. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3’,4’-difluoro-[l,r-biphenyl]-4-yl)acetamide 457. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-(4’-tert-butyl-[ 1,1 ,-biphenyl]-4-yl)acetamide 458. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-(3 ’-aeetamido[ 1,1 ’-biphenyl]-4-yl)acetamide 459. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4’-trifluoromethyl-[l,r-biphenyl]-4-yl)acetamide 460. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3’-(hydroxymethyl)[l,r-biphenyl]-4-yl)acetamide 461. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3’-mtro-[l,r-biphenyl]-4-yl)acetamide 462. N-(5-cyciopropyl-lH-pyrazol-3-yl)-2-(4’-(hydroxymethyl)[l,r-biphenyl]-4-yl)acetamide 463. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2’-cbloro-[l,r-biphenyl3-4-yl)acetamide 464. 2-(4-(1,3-benzodioxol-5-yl)phenyl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; 465. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-[4-( 1 -naphthyl)phenyl]acetamide; 466. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-(2-naphthyl)phenyl]acetamide; 467. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(2-furyl)phenyl]acetainide; 468. 2-[4-(5-acetyl-2-thienyl)phenyl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; 469. 2-[4-(5-chloro-2-thienyl)phenyl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; 470. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(5-inethyl-2-thienyl)phenyl]acetamide; 471. 2-[4-(l-benzofiïran-2-yl)phenylJ-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; 472. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-[4-(2-thienyl)phenyl]acetamide; 473. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-[3'-( {(5-(dimethylamino)-1 -naphthyl]sulfonyl} amino)[l, 1 ’-biphenyl]-4-yl]acetamide; SUBSTITUTE SHEET (RULE 26) 12046 1 28 474. 2-(4-(1-benzothien-2-yl)phenyl]-N-(5-cyclopropyl-1 H-pyrazol-3-yl)acetamide; 475. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(3-formyl-2-thienyl)phenyl]acetamide; 476. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(3-formyl-2-thienyl)phenyl]acetamide; 477. 5-(4- {2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}phenyl)-2-furoic acid; 478. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(3-methyl-lH-pyrazol-4-yl)phenyl]acetamide; 479. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(3,5-dimethyl-lH-pyrazol-4-yl)phenyl]acetamide; 480. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(3-furyl)phenyl]acetamide; 481. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(5-formyl-3-thienyl)phenyl]acetamide; 482. [5-(4- {2-[(5-cyclopropyl-1 H-pyrazol-3-yl)amino]-2-oxoethyl} phenyl)-1 H-indol-3-yl]acetic acid; 483. 5-(4-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}phenyl)tryptophan; 484. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(2-pyridinyl)phenyl]acetamide; 485. l-acetyl-5-(4-{2-((5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}phenyl)-lH-indol-3-yl acetate; 486. 2-[4-(2-amino-4-hydroxy-6-methyl-5-pyrimidinyl)phenyl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; 487. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-[4-(5-pyriinidmyl)phenyl]acetamide; 488. N-(5-cycIopropyl-lH-pyrazol-3-yl)-2-[4-(2-pyridinyl)phenyl]acetamide; 489. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(5-nitro-2-pyridinyl)phenyl]acetamide; 490. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(6-amino-3-pyridinyl)phenyl]acetamide; 491. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-[4-(3-pyridinyl)phenyl]acetamide; 492. N-(5-cyclopropyl-lH-pyra2»l-3-yl)-2-[4-(3-quinolinyl)phenyl]acetainide; 493. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(4-isoquinolmyl)phenyl]acetaniide; 494. 5-(4-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}phenyl)nicotinicacid; 495. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(2-amino-5-pyriraidinyl)phenyl]acetamide; 496. N-(5-cyclopropyl-lH-pyrazolr3-yl)-2-[4-(4-pyridinyl)phenyl]acetamide; 497. N-(5-cyclopropyl-lH-pyrazol-3-yl)“2-[4-(5-acetyl-2-thienyl)phenyl]acetamide; 498. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-(9H-purin-6-yl)phenyl]acetamide; 499. 2-[4-(l-benzothien-3-yl)phenyl]-N-(5-cyclopropyI-lH-pyrazol-3-yl)acetamide; SUBSTITUTE SHEET (RULE 26)
WmGAXÀ 1 2046 29 500. 5-(4-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}phenyl)-lH-indol-3-ylacetate; 501. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(2,4-dimethoxy-5-pyrimidinyl)phenyl]acetamide; 502. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(2-chloro-3-thienyl)phenyl]acetamide; 503. N-(5-cyclopropyl-lH-pyrazol-3-yI)-2-[4-(6-methyl-2-pyridinyl)phenyl]acetainide; 504. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(lH-imidazol-5-yl)phenyl]acetamide; 505. 2-[4-(6-amino-5-nitro-3-pyridinyl)phenyl]-N-(5-cycIopropyl-lH-pyrazol-3-yl)acetamide; 506. N-(5-cyclopropyl-lH-pyrazoI-3-yl)-2-[4-(2,3,5,6-tetrafluoro-4-pyridinyl)phenyl]acetamide; 507. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(4-methyl-2-pyridinyl)phenyl]acetamide; 508. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(lH-pyrazol-4-yl)phenyl]acetaniide; 509. 5-(4-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}phenyl)-2-thiopheneacid; 510. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(6-methoxy-2-pyridinyl)phenyl]acetamide; 511. 6-(4-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}phenyl)-2-pyridinecarboxylic acid; 512. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(2,4-dichloro-5-pyrimidinyl)phenyl]acetamide; 513. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(4-methyl-3-thicnyl)phenyl]acetamide; 514. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-[4-(5-fonnyI-2-ftHyl)phenyl]acetamide; 515. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(6-nitro-3-pyridinyl)phenyl]acetamide; 516. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-[4-(8-quinolinyl)phenyl]acetamide; 517. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(5-niethyl-2-pyridinyl)phenyl)acetamide; 518. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(3-methyl-2-pyridinyl)phenylJacetamide; 519. N-(5-cyclopropyHH-pyrazol-3-yl)-2-[4-(lH-indol-7-yl)phenyi]acetamide; 520. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(6-methoxy-3-pyridinyl)phenyl]acetamide; 521. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(2-amino-9H-purin-6-yl)phenyl]acetamide; 522. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(2-methyi-lH-indol-5-yl)phenyl]acetaTnide; 523. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(6-fluoro-3-pyridinyl)phenyl]acetamide.
SUBSTITÜTE SHEET (RULE 26)DUPLICATA 1 2046 30 524. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-[4'-(ethylsulfanyl)[ 1,1 '-biphenylJ-4-yl]acetamide; 525. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(3',4'-dimethyl[ 1,1 '-biphenyl]-4-yl)acetamide; 526. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4’-hydroxy[l,r-biphenyl]-4-yl)acetamide; 527. (2E)-3-(4'- {2-[(5-cyclopropyl-1 H-pyrazol-3-yl)amino]-2-oxoethyl} [1,1 ’-biphenyl]-3 -yl)-2-propenoic acid; 528. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-[3’-(trifluoromethyl)[ 1 ,l'-biphenyl]-4-yljacetamide; 529. N-(5-cyclopropyl-l H-pyrazol-3-yl)-2-(4’-methyl[ 1,1 ’-biphenyl]-4-yl)acetamide; 530. N-(5-cyclopropyl-lH-pyraz»l-3-yl)-2-[2’-(methylsulfanyl)[l,r-biphenyl]-4-yl]acetamide; 531. 4'-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}[l,r-biphenyl]-2-carboxylic acid; 532. 3-(4'-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}[l,r-biphenyl]-4-yl)propanoic acid; 533. 2-[4’-(benzyloxy)[ 1,1 '-biphenyl]-4-yl]-N-(5-cyclopropyl- lH-pyrazol-3-yl)acetamide; 534. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2',3'-dichloro[l,r-biphenyl]-4-yl)acetamide; 535. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3'-isopropyl[l,r-biphenyl]-4-yl)acetamide; 536. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(3-formyl-2-furyl)phenyl]acetamide; 537. (2E)-3-(4'-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}[l,r-biphenyl]-4-yl)-2-propenoic acid; 538. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2- {4'-[(E)-2-nitroethenyl][l, 1 '-biphenyl]-4-yl}acetamide; 539. 2-(4'-cMoro[l,r-biphenyl]"4-yl)-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetainide; 540. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3’-methyl[l,r-biphenyl]-4-yI)acetamide; 541. 2-(4'-phenyl[ 1,1 ’-biphenyl]-4-yl)-N-(5-cyclopropyl- lH-pyrazol-3-yl)acetamide; 542. N-(5-cyclopropyHH-pyrazol-3-yl)-2-(4'-phenoxy[l,l'-biphenyl]-4-yl)acetamide; 543. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-(2'-fonnyl[ 1,1 '-biphenyl]-4-yl)acetamide; 544. 2-(3’-chloro[l, 1 ’-biphenyl]-4-yl)-N-(5-cyclopropyl-1 H-pyrazol-3-yl)acetamide; 545. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3'-formyl[l,r-biphenyl]-4-yl)acetamide; SUBSTITUTE SHEET (RULE 26) 1 2046 31 546. tert-butyl 2-(4- {2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}phenyl)- 1H-pyrrole-1 -carboxylate; 547. 2-(3'-cyano[ 1,1 '-biphenyl]-4-yl)-N-(5-cyclopropyl- lH-pyrazol-3-yl)acetamide; 548. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-dibenzo[b,d]furan-4-ylphenyl)acetamide.
The compounds of formula (I), and the salts thereof, may be obtained, for example, by aprocess comprising: (a) reacting a compound represented by formula (II): R-COORj (Π) where R is as defined above and R^ is an alkyl group, with acetonitrile in the presence of abasic agent, to obtain a compound represented by formula (III): R-CO-CH2-CN (ΙΠ) where R is as defined above; (b) reacting a compound represented by formula (ΠΙ) with hydrazine hydrate toobtain a compound represented by formula (IV):
H (IV) where R is as defined above; (c) oxidizing a compound represented by formula (IV) to obtain a compound represented by formula (V): NO, (V) where R is as defined above; (d) reacting a compound represented by formula (V) with tert-butoxycarbonylanhydride (Boc2O) to obtain a compound represented by formula (VI): SUBSTITUTE SHEET (RULE 26) 1 2046
where R is as defined above; (e) reducing a compound represented by formula (VI) to obtain a compoundrepresented by formula (VII):
where R is as defined above; (f) reacting a compound represented by formula (VII) with a compound representedby formula (VIII): R.-COX (Vm) where X is hydroxy or a suitable leaving group and R, is as defined above, to obtain acompound represented by formula (IX):
RI Λ (IX)
where R and R, are as defined above; and (g) hydrolyzing a compound represented by formula (IX) in an acidic medium to obtain a compound of formula (I), where R and R, are as defined above; SUBSTITUTE SHEET (RULE 26) 1 2046 • <1 33 and, if desired, converting a 3-amino-pyrazole dérivative represented by formula (I) intoanother dérivative represented by formula (I), and/or into a sait thereof.
Altematively, the compounds represented by formula (I) and pharmaceutically acceptablesalts thereof may be obtained by a process comprising: (a) reacting a compound represented by formula (TV):
with a compound represented by formula (VIII): R.-COX (VIII) where R and R, are as defîned above and X is hydroxy or a suitable leaving group, preferablychlorine or bromine, to obtain a compound represented by formula (X):
where R and R, are as defîned above; and (b) selectively hydrolyzing a compound of formula (X) in a basic medium, to obtain a compound represented by formula (I).
Altematively, the compounds represented by formula (I) and pharmaceutically acceptablesalts thereof may be obtained by reacting a compound represented by formula (IV):
with a compound represented by formula (XI): R,-COCC13 (XI) where R and R, are as defîned above. SUBSTITUTE SHEET (RULE 26) 1 2 046 34
Altematively, the compound of formula (I) and pharmaceutically acceptable salts thereof maybe obtained by reacting a compound of formula (I) wherein R, is a 4-halogeno-phenylacetylgroup, or a polymer supported form of it (Ib)
wherein X is a halogen atom such as bromine or iodine, with a compound of formula (ΧΠ) (X»)
OH
I .B, R3 oh where R3 is an aryl group, under well known Suzuki conditions, to obtain a compound offormula (I) wherein R3 is aryl, or a polymer supported form of it (Ib)
and, in the case of a polymer supported compound (Ib), hydrolizing it by acidic treatment toobtain the above compound of formula (I).
Altematively, the compounds of formula (I) and pharmaceutically acceptable salts thereofmay be obtained by a process comprising: a) reacting a compound of formula (I) wherein R, is a 4-halgeno-phenylacetylgroup, or a polymer supported form of it (Ib) with a pinacol ester of a diboron compound,under Miyaura’s conditions, to obtain a compound of formula (ΧΠΙ) or a polymer supportedform of it (Xlllb)
SUBSTITUTE SHEET (RULE 26)DUPLICATA 1 2046 35
b) reacting a compound of formula (ΧΠΙ) or a polymer supported form of it(XlIIb) with a compound of formula (XIV) R3X (XIV) where R3 is aryl and X is bromine or iodine, to obtain a compound of formula (I) wherein R3is aryl or a polymer supported form of it (Ib) (Ib) (I) c) and, in the case of a polymer supported compound (Ib), hydrolizing it byacidic treatnient to obtain the above compound of formula (I).
As will be readily appreciated, if the compounds of formula (I), prepared according to anyone of the processes described above, are obtained as an admixture of isomers, theirséparation into the single isomers of formula (I), according to conventional techniques, iswithin the scope of the présent invention.
Likewise, the conversion into the free compounds (I) of the corresponding salts thereof,according to well-known procedures, is still within the scope of the invention.
The reaction of a compound of formula (II) to produce a compound of formula (III) may becarried out with acetonitrile and a base such as sodium hydride in a suitable solvent such asdiethylether, tetrahydrofuran, dioxane at a température ranging from room température to120°C. SUBSTI1
RULE 26) 1 2046 36
The reaction between a compound of formula (ΙΠ) to produce a compound of formula (IV) iscarried out with hydrazine hydrate, in a solvant such as methanol or éthanol at a températureranging from room température to 80°C.
The reaction of a compound of formula (IV) to produce a compound of formula (V) is carriedout with oxone® (potassium peroxymonosulfate) or another oxidizing agent such ashydrogen peroxide in a suitable solvent such as a mixture of water-acetone at a températureranging from 0°C to room température.
The reaction of a compound of compound of formula (V) to produce a compound of formula (VI) is carried out with tert-butoxycarbonyl anhydride in a suitable solvent such as mixturesof methylene chloride-water at room température.
The reaction of a compound of formula (VI) to produce a compound of formula (VH) may becarried out directly with hydrogen in the presence of a catalyst such as palladium on charcoal,in a suitable solvent such as methanol or éthanol at room température.
The reaction between a compound of formula (VII) and a compound of formula (VM) whereX is a hydroxy group can be carried out in the presence of a coupling agent such as forinstance, carbodiimide, i.e., 1,3-dicyclohexylcarbodiimide, 1,3-diisopropylcarbodiimide, or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, in a suitable solvent such as, for example,dichloromethane, chloroform, tetrahydrofuran, diethyl ether, 1,4-dioxane, acetonitrile,toluene, or Ν,Ν-dimethylformamide at a température ranging from about -10 C to reflux for asuitable time, i.e., from about 30 min. to about 96 hours. The reaction between a compoundof formula (VII) and a compound of formula (VIII) may be also carried out by using apolymer supported coupling agent such as polystyrène supported dicyclohexylcarbodiimidein a suitable solvent such as methylene chloride, chloroform, dioxane, acetonitrile, Ν,Ν-dimethylformamide, tetrahydrofuran at room température for a time ranging from 12 to 96hours.
The reaction between a compound of formula (VH) and a compound of formula (VIH) can bealso carried out, for example, by a mixed anhydride method, using an alkyl chloroformatesuch as ethyl, iso-butyl, or iso-propyl chloroformate, in the presence of a tertiary base, suchas triethylamine, Ν,Ν-diisopropylethylamine or pyridine, in a suitable solvent such as, forinstance, toluene, dichloromethane, chloroform, tetrahydrofuran, acetonitrile, diethyl ether, SUBSTITUTE SHEET (RULE 26) 1 2 046 37 1,4-dioxane, or Ν,Ν-dimethylformamide, at a température ranging from about -30°C to roomtempérature.
The reaction of a compound of formula (IX) to produce a compound of formula (I) can becarried out with an acid, such as trifluoroacetic acid, hydrochloric acid, formic acid, in asuitable solvent such as methylene chloride at a température ranging from 10°C to roomtempérature.
The reaction between a compound of formula (IV) with a compound of formula (VIII)wherein X is a suitable leaving group can be carried out in the presence of a tertiary base,such as triethylamine, N-methylmorpholine, Ν,Ν-diisopropylethylamine or pyridine, in asuitable solvent such as toluene, dichloromethane, chloroform, diethylether, tetrahydrofuran,acetonitrile, dioxane or Ν,Ν-dimethylformamide, at a température ranging from about 10 C toreflux, The reaction between a compound of formula (IV) and a compound of formula (VIU)can be also carried out the presence of a polymer supported tertiary base such as polystyrènesupported N-methylmorpholine in a suitable solvent, for instance toluene, dichloromethane,chlorofom, diethylether, tetrahydrofuran, acetonitrile, dioxane or Ν,Ν-dimethylformamide, atroom température.
The reaction of a compound of formula (X) to produce a compound of formula (I) can becarried out with a base such as sodium hydroxide, potassium hydroxide, sodium carbonate orpotassium carbonate in a suitable solvent such as mixture of methanol or éthanol and water atroom température. The reaction of a compound of formula (X) to produce compound offormula (I) can be also carried out by using a polystyrène supported trisamine as a basicagent.
The reaction between a compound of formula (TV) with a compound of formula (XI) to obtaina compound of formula (I) can be carried out in the presence of a base such as triethylamine,Ν,Ν-diisopropylethylamine, Ν-methyhnorpholine in a suitable solvent such as acetonitrile,dioxane, tetrahydrofurane, dimethylformamide at a température ranging from roomtemoerature to reflux. SUBSTITUTE SHEET (RULE 26) 1 2 046 38
The reaction between a compound of formula (ï) wherein R, is 4-halogeno-phenylacetyl and acompound of formula (ΧΠ) to obtain a compound of formula (I) wherein R, is 4-aryl-phenylacetyl can be carried out in the presence of a base such as CsF, NajCOj, K2CO3 and acatalyst such as Pd(PPh3)4, PdCl2(PPh3)2, Pd(OAc)2/PPh3 in a suitable mixture of solvent suchas dimethoxyethane and methanol, dioxane, tetrahydrofurane, dimethoxyethane, at atempérature ranging from room température to reflux.
The reaction between a compound of formula (I) wherein R, is 4-halogeno-phenylacetyl witha pinacol ester of a diboron compound to obtain a compound of formula (ΧΠΙ) can be carriedout in the presence of a base such as potassium acetate, triethylamine and a catalyst such asPdCl2(diphenylphosphinoferrocene), PdCl2(PPh3)2 in a suitable solvent such asdimethylformamide, dioxane, dimethylsolfoxide, dimethoxyethane, acetonitrile a températureranging from room température to reflux.
The reaction between a compound of formula (XIII) and a compound of formula (XIV) canbe carried out in the presence of a suitable catalyst such as Pd(PPh3)4, PdCl2(PPh3)2 andK3PO4, K2CO3, NajCOj in a suitable solvent such as dimethylformamide, dioxane,tetrahydrofurane, dimethoxyethane.
The compounds of formula (I) and the intermediates for preparing them as polymer supportedforms, can be easily prepared according to conventional techniques known in the art; see, forexample, Tetrahedron Letters 38 (15), 2629-2632 (1997).
Likewise, the conversion of these polymer supported forms into the free compounds is carriedout according to conventional procedures by acid hydrolysis.
Also, the optional conversion of a compound of formula (I) into another compound offormula (I) can be carried according to known methods. The optional salification of acompound of formula (I) 6r the conversion of a sait into the free compound as well as theséparation of a mixture of isomers into the single isomers may be carried out by conventionalmethods. SUBSTITUTE SHEET (RULE 26) 1 2046 39
The compounds of formula (Π), (VUI) wherein X is hydroxy or a leaving group as definedabove, (XI), (ΧΠ) and (XIV) are known or can be obtained according to conventionaltechniques.
When preparing the compounds of formula (I), optional functional groups within both thestarting matériels or the intermediates thereof, which could give rise to unwanted sidereactions, are preferably protected according conventional techniques. Likewise, theconversion of these protected compounds into the free deprotected compounds may be carriedout according to well-known procedures. ffcaniiacûlQgy
The compounds of formula (I) are active as cdk/cyclin ihibitors as they gave positive résultewhen test according to the following procedure.
The inhibiting activity of putative cdk/cyclin inhibitors and the potency of selectedcompounds was determined through a method of assay based on the use of the MultiScreen-PH 96 well plate (Millipore), in which phosphocellulose fîlter paper was placed at each wellbottom allowing binding of positive charged substrate after a washing/filtration step.
When a radioactivity labelled phosphate moiety was transferred by the ser/threo kinase to thefilter-bound histone, light emitted was measured in a scintillation counter.
The inhibition assay of cdk2/Cyclin A activity performed according to the followingprotocol:
Kinase reaction: 1.5 ·Μ histone H1 substrate, 25 ·Μ ATP (0.5 uCi P33g-ATP), 100 ng CyclinA/cdk2 complex, 10 ·Μ inhibitor in a final volume of 100 ·1 buffer (TRIS HCl 10 mM pH7.5, MgC12 10 mM, 7.5 mM DTT) were added to each well of a 96 U bottom well plate.After 10 min at 37 C incubation, reaction was stopped by 20 ·1 EDTA 120 mM.
Capture: 100 ·1 were transferred from each well MultiScreen plate, to allow substratebinding phosphocellulose fîlter. Plates were then washed 3 times with 150 *l/well PBSCa++/Mg++ free and filtered by MultiScreen filtration System..
SUBSTITUTE SHEET (RULE 26)DUPLICATA 12 046 '1 40 Détections: filters were allowed to dry at 37°C, then 100 Ί/well scintillant were added and33P labelled histone H1 was detected by radioactivity counting in the Top-Count instrument.
Results: data were analyzed and expressed as % inhibition referred to total activity ofenzyme (=100%).
Ail compounds showing inhibition > 50 % were further analyzed in order to study and definethe kinetic-profîle of the inhibitor via Ki calculation.
The protocol used was the same described above, except for ATP and substrateconcentrations. Either the concentrate of ATP and histone H1 substrate were varied: 4, 8,12,24, 48 ·Μ for ATP (containing proportionally diluted P33g-ATP) and 0.4, 0.8, 1.2, 2.4, 4.8•M for histone were used in absence and presence of two different, properly chosen inhibitorconcentrations.
Experimental data were analyzed by the computer program "SigmaPlot" for Kidétermination, using a random bireactant System équation:
Vmax (A) (B)
aKAKB 1+ (A) + (B) + (A) (B)
KA KB aKAKB where A=ATP and B=histone Hl.
In addition, the inhibiting activity of putative cdk/cyclin inhibitors and the potency ofselected compounds was determined using a method of assay based on the use of a SPA(Scintillation Proximity Assay) 96 well plate assay. The assay is based on the ability ofstreptavidin-coated SPA beads to capture a biotinylated peptide derived from aphosphorylation site of histone.
When a radioactivity labelled phosphate moiety was transferred by the ser/threo kinase to thebiotinylated histone peptide, light emitted was measured in scintillation counter.
The inhibition assay of cdk5/p25 activity was performed according to the following protocol;Kinase reaction: 1.0 ·Μ biotinylated histone peptide substrate, 0.25 uCi P33g-ATP, 4 nMcdk2/p25 complex, 0-100 ·Μ] inhibitor in a final volume of 100 ·1 buffer (Hepes 20 mM pH SUBSTITlJj^jJgJ^gULE 26) 1 2046 41 7.5, MgC12 15 mM, 1 mM DTT) were added to each well of a 96 U bottom well plate. After20 min at 37 C incubation, the reaction was stopped by the addition of 500 ug SPA beads inphosphate-buffered saline containing 0.1% Triton X-100, 50 Μ ATP and 5 mM EDTA. Thebeads were allowed to settle, and the radioactivity incorporated in the 33P-labelled peptidewas detected in a Top Count scintillation counter.
Results: Data were analyzed and expressed as % Inhibition using the formula: 100x(l - (Unknown - Bkgd)/(Enz. Control - Bkgd)) IC50 values were calculated using a variation of the four parameter logistics équation: Y = 100/[l + 10 ~{(LogEC50 - X)*Slope}]
Where X =4og(uM) and Y = % Inhibition.
The compounds of formula (I) are therefore useful to restrict the unregulated prolifération oftumor cells, hence in therapy in the treatment of various tumors such as, for instance,carcinomas, e.g., mammary carcinoma, carcinoma, bladder carcinoma, colon carcinoma,ovary endométrial tumors, sarcomas, e.g., soft tissue and bone sarcomas, and thehematological malignancies such as, e.g., leukemias.
In addition, the compounds of formula (I) are also useful in the treatment of other cellproliférative disorders such as psoriasis, vascular smooth cell prolifération associted withatherosclerosis and post-surgical stenosis a restenosis, and in the treatment of Alzheimer'sdisease.
The compounds of the présent invention can be administered either as single agents or,altematively, in combination with known anticancer treatments such as radiation therapy orchemotherapy regimen in combination with cytostatic or cytotoxic agents, antibiotic-typeagents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents,interferon-type agents, cyclooxygenase inhibitors (e.g. COX-2 inhibitors),metallomatrixprotease inhibitors, telomerase inhibitors, tyrosine kinase inhibitors, anti-growth factor receptor agents, anti-HER agents, anti-EGFR agents, anti-angiogenesis agents, SUBSTITÜTE SHEET (RULE 26) 1 2046 42 famesyl transferase inhibitors, ras-raf signal transduction pathway inhibitors, cell cycleinhibitors, other cdks inhibitors, tubulin binding agents, topoisomerase I inhibitors,topoisomerase Q inhibitors, and the like.
As an example, the compounds of the invention can be administered in combination with oneor more chemotherapeutic agents such as, for instance, taxane, taxane dérivatives,encapsulated taxanes, CPT-11, camptothecin dérivatives, anthracycline giycosides, e.g.,doxorubicin, idarubicin, epirubicin, etoposide, navelbine, Vinblastine, carboplatin, cisplatin,estramustine, celecoxib, Sugen SU-5416, Sugen SU-6668, Herceptin, and the like, optionallywithin liposomal formulations thereof.
If formulated as a fixed dose, such combination products employ the compounds of thisinvention within the dosage range described below and the other pharmaceutically activeagent within the approved dosage range.
Compounds of formula (I) may be used sequentially with known anticancer agents when acombination formulation is inappropriate.
The compounds of formula (I) of the présent invention, suitable for administration to amammal, e.g., to humans, can be administered by the usual routes and the dosage, leveldépends upon the âge, weight, conditions of patient and the administration route.
For example, a suitable dosage adopted for oral administration of a compound of formula (I)may range from about 10 to about 500 mg per dose, from 1 to 5 times daily. The compoundsof the invention can be administered in a variety of dosage forms, e.g., orally, in the formtablets, capsules, sugar or film coated tablets, liquid solutions or suspensions; rectally in theform suppositories; parenterally, e.g., intramuscularly, or intravenous and/or intrathecaland/or intraspinal injection or infusion. *
The présent invention also includes pharmaceutical compositions comprising a compound offormula (I) or a pharmaceutically acceptable sait thereof in association with apharmaceutically acceptable excipient, which may be a carrier or a diluent.
The pharmaceutical compositions containing the compounds of the invention are usuallyprepared following convention methods and are administered in a pharmaceutically suitableform. SUBSTITUTE SHEET (RULE 26) WUOÀÏâ 12046 43
For example, the solid oral forms may contain, together with the active compound, diluents,e.g., lactose, dextrose saccharose, sucrose, cellulose, corn starch or potato starch; lubricants,e.g., silica, talc, stearic acid, magnésium or calcium stéarate, and/or polyethylene glycols;binding agents, e.g., starches, arabic gum, gelatin methylcellulose, carboxymethylcellulose orpolyvinyl pyrrolidone; disintegrating agents, e.g., a starch, alginic acid, alginates or sodiumstarch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents such as lecithin,polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactivesubstances used in pharmaceutical formulations. These pharmaceutical préparations may bemanufactured in known manner, for example, by means of mixing, granulating, tabletting,sugar-coating, or film-coating processes.
The liquid dispersions for oral administration may be, e.g, syrups, émulsions andsuspensions.
The syrups may contain as carrier, for example, saccharose or saccharose with glycérineand/or mannitol and sorbitol.
The suspensions and the émulsions may contain as carrier, for example, a naturel gum,. agar,sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.
The suspension or solutions for intramuscular injections may contain, together with the activecompound, a pharmaceutically acceptable carrier, e.g., stérile water, olive oil, ethyl oleate,glycols, e.g., propylene glycol, and, if desired, a suitable amount of lidocaine hydrochloride.The solutions for intravenous injections or infusions may contain as a carrier, for example,stérile water or preferably they may be in the form of stérile, aqueous isotonie saline solutionsor they may contain as a carrier propylene glycol,
The suppositories may contain together with the active compound a pharmaceuticallyacceptable carrier, e.g., cocoa butter, polyethylene glycol, a polyoxyethylene sorbitan fattyacid ester surfactant or lecithin.
EXAMEEES
Having generally described this invention, a further understanding can be obtained byreference to certain spécifie examples which are provided herein for purposes of illustrationonly and are not intended to be limiting unless otherwise specified.
SUBSTITUTE SHEET (RULE 26)WPUCMLiM WO 01/12189 1 2046 PCT/US00/06699 44
Example 1 N-(5-çyçloproyl:lH-pyraz9l-3-yl)-2t2-diphepylaçetamide
To a solution of 45.6 mg (0.215 mmol) of diphenylacetic acid in 3 ml of dichloromethane at0°C 41.2 mg (0.215 mmol) of N-(3-dimethylaminopropyl) - Ν' - ethylcarbodiimidehydrochloride were added. After 1 hour at the same température under stirring 40 mg (0.179mmol) of tert-butyl-3-anMno-5-cyclopropyl-lH-pyrazole-l-carboxylate were added. Themixture was maintained at room température for 16 hours, then was diluted withdichloromethane and washed with a saturated solution of sodium hydrogenocarbonate. Theorganic layer was dried over anhydrous sodium sulfate evaporated to diyness, to give, aftercolumn chromatography (hexane-ethylacetate) 60 mg (80% yield) of N-(5-cyclopropyl-l-terbutoxycarbonyl-pyrazol-3-yl)-2,2-diphenyl acetamide. This intermediate was submitted tohydrolysis with 15 ml of trifluoroacetic acid 10 % v/v in dichloromethane for an hour. Thesolvent was then evaporated under vacuum, the residue redissolved with dichloromethane andwashed with a saturated solution sodium hydrogen carbonate. The organic layer was driedover anhydrous sodium sulfate and evaporated to give 42 mg (92% yield) of the titlecompound. 1H-NMR (400 MHz, DMSO-d6) ppm: 0.62 (m, 2H, cyclopropyl CHH + CHH); 0.88 (m, 2H,cyclopropyl CHH + CHH); 1.81 (dddd, 1H, J=5.2, 5.2, 8.4, 8.4, cyclopropyl CH); 5.17 (s,1H, CHPh2); 6.17 (s, 1H, pyrazole CH); 7.30 (m, 10H, phenyl CH); 10.6 (s, 1H, amidic NH);12.04 (s, 1H, pyrazole NH).
ESI (+) MS: m/z 318 (100, MH+).m.p. 218-220 °C
Analogously the following products were prepared starting from the correspondingcarboxylic acid: N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-methyl-5-phenyl-3-furamide; 1H-NMR (400 MHz, DMSO-d6) ppm 7.6-7.3 (m, 5H, Ph), 6.24 (s, 1H, CH-pyrazole), 2.6 (s,3H, CH3); 1.83 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 308 (100, MH+); N-(5-cyclopropyl-l H-pyrazol-3-yl)-2,5-dimethyl-1 -(2-thienylmethyl)-1 H-pyrrole-3-carboxamide;
SUBSTITUTE SHEET (RULE 26)DUPLICATA WO 01/12189 Ί 2 OA6 PCT/USOO/06699 45 1H-NMR (400 MHz, DMSO-d6) ppm 7.41 (dd, J=5-1.2 Hz, 5H, SCH), 6.48 (s, 1H, CH-pyrrole), 6.09 (s, 1H, CH-pyrazole); 1.83 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 341 (100, MH+); N-(5-cyclopropyl-lH-pyrazol-3-yl)-5-(metiiylsulfonyl)-2-thiophenecarboxamide; 1H-NMR (400 MHz, DMSO-d6) ppm 7.41 (dd, J=5-1.2 Hz, 5H, SCH), 6.48 (s, 1H, CH-pyrrole), 6.09 (s, 1H, CH-pyrazole); 1.83 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 312 (100, MH+);N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-oxo-4-phenyl-3-butenamide; 1H-NMR (400 MHz, DMSO-d6) ppm 7.8 (m, 3H, CH-o-Ph + CH-4), 6.48 (s, 4H, CH-m,p-Ph + CH-3), 6.25 (s, 1H, CH-pyrazole); 1.85 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 282 (100, MH+); 2-amino-N-(4- {2-[(N-(5-cyclopropyl- lH-pyrazol-3-yl)-amino]-2-oxoethyl}phenyl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.36 (s,lH, NHCO), 7.20 (d, >8.5 Hz, 2H, CH-o-Ph), 6.09 (s, 1H, CH-pyrazole); 3.49 (s, 2H, COCH2NH2), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 314 (100, MH+); 2-[4-(aminomethyl)phenyl]-N-(3-cyclopropyl-lH-pyrazol-5-yl)acetamide 1H-NMR (400 MHz, DMSO-d6) ppm 10.36 (s, 1H, NHCO), 7,47 (d, >8.5 Hz, 4H, Ph), 6.08(s, 1H, CH-pyrazole); 3.48 (s, 2H, COCH2), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 271 (100, MH+); N-(3-cyclopropyl-lH-pyrazol-5-yl>2-[4-(2-oxo-l-pyrrolidinyl)phenyl]acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.37 (s, 1H, NHCO), 7.55 (dd, J=9.2-2.5 Hz, 2H, m-Ph), 6.09 (s, 1H, CH-pyrazole); 3.52 (s, 2H, COCH2), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 325 (100, MH+); 4- {2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}benzamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.45 (s, 1H, NHCO), 7.77 (dd, >6.5-1.8 Hz, 2H, m-Ph), 6.09 (s, 1H, CH-pyrazole); 3.61 (s, 2H, COCH2), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 285 (100, MH+); 2-[4-(acetylamino)phenyl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 7.46 (d, >8.5 Hz, 2H, m-Ph), 6.09 (s, 1H, CH-pyrazole); 3.48 (s, 2H, COCH2), 1.81 (m, 1H, cyclopropyl-CH); SUBST1TUTE SHEET (RULE 26) WIPUCAÎÀ 1 2046 WO 01/12189 PCT/US00/06699 46 ESI (+) MS: m/z 299 (100, MH+); N-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl)benzamide; 1H-NMR (400 MHz, DMSO-d6) ppm 7.9-7.4 (m, 5H, Ph), 6.12 (s, 1H, CH-pyrazole); 3.99(d, J-6 Hz, 2H, COCH2), 1.80 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 285 (100, MH+);N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-naphthyl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 6.10 (s, 1H, CH-pyrazole); 3.73 (s, 2H, COCH2), 1.80(m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 292 (100, MH+); 5-chloro-N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-thiophenecarboxamide; 1H-NMR (400 MHz, DMSO-d6) ppm 7.91 (d, J=4 Hz, 1H, CHCC1), 6.20 (s, 1H, CH-pyrazole); 1.85 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 268 (100, MH+); N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(l-pyrrolidmyl)phenyl]acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 6.44 (d, J=6.5 Hz, 2H, CH-m-Ph), 6.07 (s, 1H, CH-pyrazole); 3.37 (s, 2H, COCH2), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 311 (100, MH+); (2S)-N-(5-cyclopropyi-lH-pyrazol-3-yl)-2-(6-methoxy-2-naphthyl)propanamide1H-NMR (400 MHz, DMSO-d6) ppm 6.11 (s, 1H, CH-pyrazole); 3.89 (q, J=6 Hz, 1H,COCH), 3.83 (s, 3H, OCH3), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 336 (100, MH+);N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(3-methoxyphenyl)acetamidem.p. 118-120 °C; N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(4-nitrophenyl)acetamide m.p. 183-185 °C; 2-[5-(benzyloxy)-lH-indol-3-yl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(5-methoxy-2-methyl-lH-indol-3-yl)acetamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(5-hydroxy-lH-indole-3-yl)acetamide; 2-[ 1 -(4-chlorobenzoyl)-5-methoxy-2-methyl-l H-indol-3-yl]-N-(5-cyclopropyl- lH-pyrazol-3-yl)acetamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3-hydroxyphenyl)acetamide; SUBSTITUTE SHEET (RULE 26) 1 2046 WO 01/12189 PCT/US00/06699 47 N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-hydroxy-3-methoxyphenyl)acetamide; N-(5-cyclopropyMH-pyrazol-3-yl)-2-hydroxy-2-(4-hydroxy-3-methoxyphenyI)acetamÎde; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-bromomethylphenyl)acetamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[2-(formylamino)-lJ3-thiazol-4-yl]-2- (methoxyimino)ethanamide; 2-[5-(chloroacetyl)-2-thienyl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetaniide; N-(5-cyclopropyl-lH-pyrazol-3-yI)-2-(2-meÛiyl-lH-indol-3-yl)acetamide; 2-chloro-N-(5-{2-[(5-cyclopropyl-lH-pyra2»l-3-yl)amino]-2-oxoethyl}-l,3-thiazol-2- yl)acetamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-hydroxy-2-diphenyl)acetamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2,6-dihydroxy-4-pyrimidinyl)acetamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3-chloro-4-hydroxyphenyl)acetamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(7-methoxy-2-oxo-2H-chromen-4-yl)acetamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-acetylamino-2-phenyl)acetamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(l-methylimidazol-4-yl)acetamide; N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(2-bromo-2-phenyl)acetamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-benzyloxy-3-methoxyphenyl)acetamide; (2S)-N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-hydroxy-2-phenylethanamide; 1- (4-chlorophenyl)-N-(5-cyclopropyHH-pyrazol-3-yl)cyclopentanecarboxainide;N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(lH-indol-3-yl)-2-oxoacetamide;N-(5-cyclopropyl-lH-pyrazol-3-yî)-2-(3,4-dihydroxyphenyl)acetamide;N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-benzyloxycarbonyl-2-phenylacetamide;N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3-methyH-benzothien-2-yl)acetamide;N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(2-thienyl)acetamide; 5-cyclohexyl-1 -(4- {2-[(5-cyclopropyl- lH-pyrazol-3-yl)amino]-2-oxoethyl} benzyl)2-aminopentanedioate; N-(5-cycIopropyl-lH-pyrazol-3-yl)-2-(4-isobutylphenyl)propanainide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(7-hydroxy-2-oxo-2H-chromen-4-yl)acetamide;N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(4-hydroxyphenyl)acetamide; 2- cyclopentyl-N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-phenylacetamide; N-(5-cyclopropyl-lH-pyrazoI-3-yl)-2-(2>fiuyl)-2-oxoacetamide; SUBSTITÙTE SHEET (RULE 26)
WUCAÎA 1 2046 WO 01/12189 PCT/USOO/06699 48 N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(5-broïno-lH-indol-3-yl)acetamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2,5-dioxo-2,5-dihydro-3-fiiranyl)acetamide; 2-chloro-2,2-bis(2-chlorophenyl)-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-hydroxy-2-(3-hydroxy-4-methoxyphenyl)acetamide; 2-(5-bromo-3-pyridinyl)-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-oxo-2H-pyran-5-carboxamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2,4-dinitrophenyl)acetamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3-bromo-4-methoxyphenyl)acetamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-3-hydroxy-2-phenylpropanainide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3-fluoro-4-hydroxyphenyl)acetamide; 2- {2-[(chloroacetyl)amino]-1,3-thiazol-5-yl} -N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(methoxyimino)ethanamide; N-(5-cyclopropyl-1 H-pyrazol-3-yl)-1 -phenylcyclopropanecarboxamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2,5-dihydroxyphenyl)acetamide; N-(5-cyclopropyl-1 H-pyrazol>3-yl)-2-[2-(2,4-difluorophenyl)-1,3-thiazol-4-yl]acetamide;N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(5-methoxy-3-hydroxy-2-propylphenyl)acetamide;(2R)-N-(3-cyclopropyl-1 H-pyrazol-5-yl)-2-(2-fluoro[ 1,1 ’-biphenyl]-4-yl)propanamide;; 2-{4-[(aminocarbonyl)amino]phenyl}-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; 2-{4-[(2-amino-2-oxoethyl)amino]phenyl}-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide;N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-(5-methyl-2-phenyl-1,3-thiazol-4-yl)acetamide;4-bromo-N-(4-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}-l,3-thiazol-2-yl)benzamide . ..-a” 2-[2-(4-chlorophenyl)-4-hydroxy-l,3-thiazol-5-yl]-N-(5-cycIopropyl-lH-pyrazol-3- yl)acetamide; N-(4-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}-l,3-thiazol-2-yl)-2-(2- pyridinylsulfanyl)acetamide; N-(4- {2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl} -1,3-thiazol-2-yl)-2-(isopropylsulfanyl)acetamide; 2-(5-{[(4-chlorophenyl)sulfanyl]acetyl}-2-thienyl)-N-(5-cyclopropyl-lH-pyrazol-3- yl)acetamide; 2-(5-chloro-3-methyl-1 -benzothien-2-yl)-N-(5-cyclopropyl-l H-pyrazol-3-yl)acetamide; SUBSTITUTE SHEET (RULE 26) 1 2046 PCT/US00/06699 WO 01/12189 49 N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-iodophenyl)acetamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-9H-xanthene-9-carboxamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-phenyl-l,3-thiazol-4-yl)acetamide; 2-[2-(4-chlorophenyl)-5-methyl-l,3-thiazol-4-yl]-N-(5-cyclopropyl-lH-pyrazol-3- yl)acetamide; N-(4- {2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl} -1,3-thiazol-2-yl)benzamide;N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(6-methoxy-2-naphthyl)acrylamide; N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(2-hydroxyphenyl)acetaniide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2>3-di(2-thienyl)-2-propenamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[2-(2-pyrazinyl)-l,3-thiazol-4-yl]acetamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2,5-dibromo-3-thienyl)acetamide; N-(5-cyclopropyMH-pyrazol-3-yl)-2-(4-methylsulfonylaminophenyl)acetamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2- {4-[2-(4-methyl-1 - piperazinyl)ethoxy]phenyl} acetamide; N-(5-cyclopropyl-lH-pyrazol-3-yî)-2-{4-[2-(l-pyrrolidinyl)ethoxy]phenyl}acetamide;N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-{4-(2-amino-2-oxoethoxy)phenyl}acetamide;N-(5-cycIopropyl-1 H-pyrazol-3-yl)-2-phenoxy-2-methylpropanamide;N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-chlorophenoxy)propanamide;N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-nitrophenoxy)acetaraide; N-(5-cyclopropyl-lH-pyraz»l-3-yl)-2-(5-Îsopropyl-2-methyl-lH-indol-3-yl)acetainide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3-methoxyphenyl)acetamide; N-(5-cyelopropyl-lH-pyrazol-3-yl)-2-methyl-2-(2-methyl-2,3-dihydro-l-benzofuran-5- yl)propanamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[2-(4-metlioxyphenyl)-4-oxo-4H-chromen-6- yljacetamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(6-chloro-2,3-dihydro-lH-inden-3-yl)butanamide;N-(5-cyclopropyl-l H-pyrazol-3-yl)-2-[4-(l -oxo-1,3-dihydto-2H-isoindol-2-yl)phenyl]hexanamide; N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-phenyl-3-(4-pyridinyl)propenamide; 2-[ 1,1 '-biphenyl]-4-yl-N-(5-cyclopropyl-1 H-pyrazol-3-yl)butanamide; N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-[4-( 1,3-dihydro-2H-isoindol-2-yl)phenyl]propanamide;
SUBSTITUTE SHEET (RULE 26)DUPLICATA 1 2046 PCT/US00/06699 WO 01/12189 50 N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-[4-( 1 -oxo-1,3-dihydro-2H-isoindol-2-yl)phenyl]butanamide; * N-(5-cyclopropyl-lH-pyrazol-3-yl)-(2S)-2-[4-(l-oxo-l,3-dihydro-2H-isomdol-2-yl)phenyl]propanamide; N-(5-cycIopropyl-lH-pyrazol-3-yl)-2-[4-(5-amino-4-phenyl-lH-l,2,3-triazol-l- yl)phenyl]acetamide; N-(5-cyclopropyl-lH-pyra2»l-3-yl)-2-[4-(l-oxo-l,3-dihydro-2H-isoindol-2- yl)phenyl]pentanamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-benzyloxyphenyl)acetamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-{4-[(3,3-diethyl-4-oxo-2- azetidinyl)oxy]phenyl} acetamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(5,6-dimethyl-lH-benzimidazol-l-yl)acetamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-pyridyIsulfanyl)acetamide; N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-( 1 H-tetrazol-1 -yl)acetamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(tetrazolo[l,5-b]pyridazin-6-ylsulfanyl)acetamide; 2-[ 1,1 ’-biphenyl]-4-yl-N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-hydroxyacetamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-cyclohexene-l-carboxamide; N-(5-cyclopropyl-lH-pyra2»l-3-yl)-2-oxo-2H-pyran-4-carboxamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-3-bromo-2,2-diphenylpropanamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-4,4-bis(4-methylphenyl)-3-butenamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4‘hydroxy-5-isopropyl-2-methylphenyl)acetamide; N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(4-nitrophenyl)-2-butenamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3,4-dihydro-l-naphthyl)butanamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-l,4-benzodioxine-2-carboxamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-3-phenyl-l,4-benzodioxine-2-carboxamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-4-oxo!-4H-chromene-2-carboxamide; N-(3-cyclopropyl-lH-pyra2Xîl-5-yl)-2-oxo-l,2-dihydro-4-quinolinecarboxamide; 2-anilino-N-(3-cyclopropyl-lH-pyrazol-5-yl)acetamide.
Example 2 SUBSTITUTE SHEET (RULE 26)
WUOA'fA 1 2046 WO 01/12189 PCT/US00/06699 51 2-(1.3-benzodioxol-5-vD-N-(3-cvcloDroovl-lH-pvrazol-5-vD-acetamide
To a solution of 96.8 mg (0.537 mmol) of 2-(l,3-benzodioxol-5-yl)-acetic acid in 3 ml ofdichloromethane 360 mg (0.720 mmol) of polystyrène supported dicyclohexylcarbodiimide(loading = 2 mmol/g) and 40 mg (0.179 mmol) of tert-butyl-3- amino-5-cyclopropyl-lH-pyrazole-l-carboxylate were added. The mixture was maintained under stirring at roomtempérature for 96 hours and after that time filtered, washed several times withdichloromethane and evaporated to dryness. The residue was re-dissolved with 3 ml oftrifluoroacetic acid 10 % V/V in dichloromethane and maintained at room température for anhour. The solvent was then evaporated, the residue re-dissolved in dichloromethane andwashed with a saturated solution of sodium hydrogenocarbonate. The organic layer wasevaporated to dryness to give, after trituration with diethylether, 32 mg (63% yield) of thetitle compound.
ESI (+) MS: m/z 286 (100, MH+).m.p. 174-176 °C
Analogously, the following products were prepared: N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3,5-difluorophenyl)acetamide 1H-NMR (400 MHz, DMSO-d6) ppm 10.48 (s, 1H, NHCO), 7.1-6.9 (m, 3H, Ph), 6.09 (s,1H, CH-pyrazole), 3.61 (s, 2H, COCH2), 1.82 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 278 (100, MH+); N-(5-cyclopropyI-lH-pyrazol-3-yl)-2-(2,4-difluorophenyl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.46 (s, 1H, NHCO), 7.4-7.0 (m, 3H, Ph), 6.07 (s,1H, CH-pyrazole), 3.62 (s, 2H, COCH2), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 278 (100, MH+); N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(2-chloro-6-fluorophenyl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.55 (s, 1H, NHCO), 7.3-7.1 (m, 3H, Ph), 6.05 (s,1H, CH-pyrazole), 3.80 (s, 2H, COCHE), 1.82 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 294 (100, MH+); N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-methylsulphonylphenyl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.54 (s, 1H, NHCO), 7.54 (dd, >6.5-2 Hz, 2H, CH-o-Ph), 6.08 (s, 1H, CH-pyrazole), 3.70 (s, 2H, COCHE), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 320 (100, MH+); SUBST1TUTE SHEET (RÜLE 26) mraoACà 1 2046
I WO 01/12189 PCT/US00/06699 52 N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[3,5-bis(trifluoromethyl)pheny]lacetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.56 (s, 1H, NHCO), 6.08 (s, 1H, CH-pyrazole), 3.83(s, 2H, COCH2), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 378 (100, MH+); N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(2,5-difluorophenyl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.48 (s, 1H, NHCO), 7.2-7.0 (m, 3H, Ph), 6.08 (s,1H, CH-pyrazole), 3.65 (s, 2H, COCH2), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 278 (100, MH+); N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-nitro-4-trifluoromethylphenyl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.56 (s, 1H, NHCO), 7.78 (d, J=8 Hz, 1H, CH-o-Ph),6.01 (s, 1H, CH-pyrazole), 4.14 (s, 2H, COCH2), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 355 (100, MH+); N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2,6-difluorophenyl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.52 (s, 1H, NHCO), 7.4-7.0 (m, 3H, Ph), 6.06 (s,1H, CH-pyrazole), 3.68 (s, 2H, COCH2), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 278 (100, MH+);N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-fluorophenyl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.45 (s, 1H, NHCO), 7.3-7.1 (m, 4H, Ph), 6.08 (s,1H, CH-pyrazole), 3.64 (s, 2H, COCH2), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 260 (100, MH+); N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-trifluoromethylphenyl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.45 (s, 1H, NHCO), 7.6-7.4 (m, 4H, Ph), 6.06 (s,1H, CH-pyrazole), 3.83 (s, 2H, COCH2), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 310 (100, MH+);N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3-fluorophenyl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.46 (s, 1H, NHCO), 7.3-7.0 (m, 4H, Ph), 6.08 (s,1H, CH-pyrazole), 3.58 (s, 2H, COCH2), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 260 (100, MH+);N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3-bromophenyl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.46 (s, 1H, NHCO), 7.5-7.2 (m, 4H, Ph), 6.08 (s,1H, CH-pyrazole), 3.56 (s, 2H, COCH2), 1.81 (m, 1H, cyclopropyl-CH); SUBSTITUTE SHEET (RULE 26) WPUCAÎÀ 1 2 04 6 WO 01/12189 PCT/US00/06699 53 ESI (+) MS: m/z 320 (100, MH+); N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3,4-dichlorophenyl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.49 (s, 1H, NHCO), 6.08 (s, 1H, CH-pyrazole), 3.59(s, 2H, COCH2), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 310 (100, MH+); N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3-trifluoromethylphenyl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.51 (s, 1H, NHCO), 6.08 (s, 1H, CH-pyrazole), 3.68(s, 2H, COCH2), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 310 (100, MH+); N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2,6-dichlorophenyl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.54 (s, 1H, NHCO), 7.5-7.3 (m, 3H, Ph), 6.04 (s,1H, CH-pyrazole), 3.96 (s, 2H, COCH2), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 310 (100, MH+); N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3,4-difluorophenyl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.43 (s, 1H, NHCO), 6.08 (s, 1H, CH-pyrazole), 3.57(s, 2H, COCH2), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 278 (100, MH+); N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3,5-dimethoxyphenyl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.35 (s, 1H, NHCO), 6.45 (d, J=2.4 Hz, 2H, CH-o-Ph), 6.08 (s, 1H, CH-pyrazole), 3.78 (s, 2H, COCH2), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 302 (100, MH+);N-(5-cyclopropyl-lH-pyrazoI-3-yl)-2-(3-methylphenyl)acetamide; 1H-NMR (400 MHz, DMSO-Ù6) ppm 10.38 (s, 1H, NHCO), 7.2-7.0 (m, 4H, Ph), 6.08 (s,1H, CH-pyrazole), 3.50 (s, 2H, COCH2), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 256 (100, MH+);N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-methylphenyl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.37 (s, 1H, NHCO), 7.2-7.0 (m, 4H, Ph), 6.08 (s,1H, CH-pyrazole), 3.59 (s, 2H, COCH2), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 256 (100, MH+); N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-hydroxy-3-nitrophenyl)acetamide; SUBSTITUTE SHEET (RULE 26)SUPLXÛAÎÀ 1 2046 WO 01/12189 PCT/USOO/06699 54 1H-NMR (400 MHz, DMSO-d6) ppm 10.45 (s, 1H, NHCO), 6.08 (s, 1H, CH-pyrazole), 3.54(s, 2H, COCH2), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 303 (100, MH+);N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-ethoxyphenyl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.35 (s, 1H, NHCO), 6.07 (s, 1H, CH-pyrazole), 3.96(q, >7 Hz, 2H, OCH2), 3.45 (s, 2H, COCH2), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 286 (100, MH+); N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(2,4,6-trimethylphenyl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.31 (s, 1H, NHCO), 6.78 (s, 2H, Ph), 6.05 (s, 1H,CH-pyrazole), 3.60 (s, 2H, COCH2), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 284 (100, MH+); N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(4-trifluoromethoxyphenyl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.48 (s, 1H, NHCO), 7.4-7.2 (m, 4H, Ph), 6.08 (s,1H, CH-pyrazole), 3.60 (s, 2H, COCH2), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 326 (100, MH+);N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-nitrophenyl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.47 (s, 1H, NHCO), 8.0-7.5 (m, 4H, Ph), 6.01 (s,1H, CH-pyrazole), 4.03 (s, 2H, COCH2), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 287 (100, MH+); N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3,4,5-trimethoxyphenyl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.36 (s, 1H, NHCO), 6.60 (s, 2H, Ph), 6.08 (s, 1H,CH-pyrazole), 3.60 (s, 2H, COCH2), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 332 (100, MH+); N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(2-methoxyphenyl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.22 (s, 1H, NHCO), 7.2-6.8 (m, 4H, Ph), 6.07 (s,1H, CH-pyrazole), 3.54 (s, 2H, COCH2), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 272 (100, MH+); N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(4-butoxyphenyl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.35 (s, 1H, NHCO), 7.17 (dd, J=7-2 Hz, 2H, CH-o-Ph), 6.07 (s, 1H, CH-pyrazole), 3.45 (s, 2H, COCH2), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 314 (100, MH+); SUBSTITÜTE SHEET (RULE 26)
DUPLICATA 1 2046 WO 01/12189 PCT/US00/06699 55 N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(pentafluorophenyl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.63 (s, 1H, NHCO), 6.07 (s, 1H, CH-pyrazole), 3.80(s, 2H, COCH2), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 332 (100, MH+); N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-methylsulfanylphenyl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.40 (s, IH, NHCO), 7.20 (m, 4H, Ph), 6.07 (s, 1H,CH-pyrazole), 3.50 (s, 2H, COCH2), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 288 (100, MH+);N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-bromophenyl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.44 (s, 1H, NHCO), 7.6-7.2 (m, 4H, Ph), 6.08 (s,1H, CH-pyrazole), 3.76 (s, 2H, COCH2), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 320 (100, MH+); N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[2,5-bis(trifluoromethyl)pheny]lacetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.55 (s, 1H, NHCO), 8.0-7.8 (m, 3H, Ph), 6.05 (s,1H, CH-pyrazole), 3.98 (s, 2H, COCH2), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 378 (100, MH+);N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3-nitrophenyl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.56 (s, 1H, NHCO), 6.09 (s, 1H, CH-pyrazole), 3.74(s, 2H, COCH2), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 287 (100, MH+); N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2,4-dichlorophenyl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.48 (s, 1H, NHCO), 7.6-7.4 (m, 3H, Ph), 6.07 (s,1H, CH-pyrazole), 3.75 (s, 2H, COCH2), 1.82 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 310 (100, MH+); N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3,5-di-îert-butyl-4-hydroxyphenyl)aCetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.33 (s, 1H, NHCO), 7.04 (s, 2H, Ph), 6.08 (s, 1H,CH-pyrazole), 3.40 (s, 2H, COCH2), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 370 (100, MH+); N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2,3,6-trifluorophenyl)acetamide 1H-NMR (400 MHz, DMSO-d6) ppm 10.58 (s, 1H, NHCO), 7.4-7.1 (m, 2H, Ph), 6.06 (s,1H, CH-pyrazole), 3.74 (s, 2H, COCH2), 1.81 (m, 1H, cyclopropyl-CH); SUBSTITUTE SHEET (RULE 26) mm WO 01/12189 1 2046 PCT/USOO/06699 56 ESI (+) MS: m/z 296 (100, MH+); N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3-methylsulfonylaminophenyl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.39 (s, 1H, NHCO), 6.08 (s, 1H, CH-pyrazole), 3.58(s, 2H, COCH2), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 350 (100, MH+);N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-fluorophenyl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.43 (s, 1H, NHCO), 7.4-7.0 (m, 4H, Ph), 6.08 (s,1H, CH-pyrazole), 3.55 (s, 2H, COCH2), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 260 (100, MH+); N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(2,3-dihydro-lH-inden-5-yl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.35 (s, 1H, NHCO), 7.2-7.0 (m, 3H, Ph), 6.07 (s,1H, CH-pyrazole), 3.48 (s, 2H, COCH2), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 282 (100, MH+); N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[3-(2-amino-2-oxoethoxy)phenyl]acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.41 (s, 1H, NHCO), 6.08 (s, 1H, CH-pyrazole), 4.37(s, 2H, COCH2O), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 315 (100, MH+); N-(5-cyclopropyl-1 H-pyrazol-3-yl)- 2- {4-[2-oxo-2-( 1 -pyrrolidinyl)ethoxy]phenyl} acetamide;1H-NMR (400 MHz, DMSO-d6) ppm 10.37 (s, 1H, NHCO), 6.07 (s, 1H, CH-pyrazole), 4.64(s, 2H, COCH2O), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 369 (100, MH+); N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(2-fluoro[l,r-biphenyl]-4-yl)propanamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.45 (s, 1H, NHCO), 6.11 (s, 1H, CH-pyrazole), 3.82(q, J=7 Hz, 1H, NHCOCH), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 350 (100, MH+);N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-oxo-2-(2-thienyl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.85 (s, 1H, NHCO), 6.25 (s, ÎH, CH-pyrazole), 1.81(m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 262 (100, MH+);N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-nitrophenyl)propanamide; SUBSTITUTE SHEET (RULE 26) WLicm 1 2046 WO 01/12189 PCT/US00/06699 57 1H-NMR (400 MHz, DMSO-d6) ppm 10.51 (s, 1H, NHCO), 6.11 (s, 1H, CH-pyrazole), 3.98(q, J=7 Hz, 1H, NHCOCH), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 301 (100, MH+); 2-cyclohexyl-N-(3-cyclopropyl-1 H-pyrazol-5-yl)-2-phenylacetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.36 (s, 1H, NHCO), 7.4-7.1 (m, 5H, Ph), 6.09 (s,1H, CH-pyrazole), 3.15 (m, 1H, NHCOCH), 1.80 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 324 (100, MH+); (2R)-N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-methoxy-2-phenyIethanamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.23 (s, 1H, NHCO), 7.4-7.2 (m, 5H, Ph), 6.08 (s,1H, CH-pyrazole), 4.83 (s, 1H, NHCOCHPh), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 272 (100, MH+); (2S)-2-amino-N-(3-cyclopropyl-1 H-pyrazol-5-yl)-2-phenyIethanamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.95 (s, 1H, NHCO), 7.5-7.4 (m, 5H, Ph), 6.15 (s,1H, CH-pyrazole), 4.99 (m, 1H, NHCOCH), 1.82 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 257 (100, MH+); (2S)-N-(3-cyclopropyl-1 H-pyrazol-5-yl)-2,5-dihydro-1 H-pyrrole-2-carboxamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.18 (s, 1H, NHCO), 6.14 (s, 1H, CH-pyrazole), 4.1- 3.9 (m, 1H, NHCOCH), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 219 (100, MH+); N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2,4-dichlorophenoxy)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.37 (s, 1H, NHCO), 6.12 (s, 1H, CH-pyrazole), 4.80(s, 2H, NHCOCH2), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 226 (100, MH+);N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-phenoxyacetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.30 (s, 1H, NHCO), 7.26 (m, 2H, CH-m-Ph), 6.13(s, 1H, CH-pyrazole), 4.64 (s, 2H, NHCOCH2), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 258 (100, MH+); (2S)-N-(3-cyclopropyl-1 H-pyrazol-5-yl)-2-methoxy-2-phenylethanamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.23 (s, 1H, NHCO), 7.4-7.2 (m, 5H, Ph), 6.08 (s,1H, CH-pyrazole), 4.83 (s, 1H, NHCOCHPh), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 272 (100, MH+); SUBSTITUTE SHEET (RULE 26)
PttPXiCAÎEÀ WO 01/12189 1 2046 PCT/US00/06699 58 (2S)-N-(3-cyclopropyl-lH-pyrazol-5-yl)-3,3,3-trifluoro-2-methoxy-2-phenylpropanamide;1H-NMR (400 MHz, DMSO-d6) ppm 10.30 (s, 1H, NHCO), 7.5-7.4 (m, 5H, Ph), 6.14 (s,1H, CH-pyrazole), 1.83 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 340 (100, MH+); N-(5-cyclopropyl-lH-pyrazol-3-yl)-l-phenylcyclopentane-l-carboxamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.32 (s, 1H, NHCO), 6.09 (s, 1H, CH-pyrazole), 3.20(m, 1H, cyclopentyl-CH), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 310 (100, MH+); 9H-fluoren-9-yl (2S)-2- {[(3-cycIopropyl-l H-pyrazol-5-yl)amino]carbonyl) -2,5-dihydro-1H-pyrrole-1 -carboxylate; 1H-NMR (400 MHz, DMSO-d6, syn/anti isomers) ppm 10.67/10.45 (2s, 1H, NHCO),6.20/6.05 (2s, 1H, CH-pyrazole), 4.4-4.0 (m, 3H, COOCH2CH); ESI (+) MS: m/z 441 (100, MH+); (lR)-2-[(3-cyclopropyl-lH-pyrazol-5-yl)amino]-2-oxo-l-phenylethyl acetate; 1H-NMR (400 MHz, DMSO-d6) ppm 10.67 (s, 1H, NHCO), 7.5-7.3 (m, 5H, Ph), 6.08 (s,1H, CH-pyrazole), 5.94 (s, 1H, COCHPh); ESI (+) MS: m/z 300 (100, MH+); N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-{4-[(2S)-2- aminopropanoyloxymethyl]phenyl}acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.44 (s, 1H, NHCO), 7.30 (m, 4H, Ph), 6.07 (s, 1H,CH-pyrazole), 3.59 (s, 2H, COCH2), 1.80 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 343 (100, MH+); ( 1 S)-2-[(3-cyclopropyl-1 H-pyrazol-5-yl)amino]-2-oxo-1 -phenylethyl acetate; ' ï 1H-NMR (400 MHz, DMSO-d6) ppm 10.67 (s, 1H, NHCO), 7.5-7.3 (m, 5H, Ph), 6.08 (s,1H, CH-pyrazole), 5.94 (s, 1H, COCHPh); 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 300 (100, MH+); N-(3-cyclopropyl-1 H-pyrazol-5-yl)-2-fluoro-2-phenylacetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.67 (s, 1H, NHCO), 7.3-7.4 (m, 5H, Ph), 6.10 (s,1H, CH-pyrazole), 5.95 (d, J=47.5,1H, CHF), 1.82 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 260 (100, MH+);N-(3-cyclopropyl-lH-pyrazol-5-yl)-3-methyl-2-phenylpentanamide; SUBSTITÜTE SHEET (RULE 26) wxaoAn WO 01/12189 1 2046 PCT/US00/06699 59 1H-NMR (400 MHz, DMSO-d6) ppm 7.4-7.1 (m, 5H, Ph), 6.09 (s, 1H, CH-pyrazole), 3.75(d, J=10.0,1H, COCH), 1.82 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 298 (100, MH+); N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(3,4-dimethoxyphenyl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 6.9-6.7 (m, 3H, Ph), 6.07 (s, 1H, CH-pyrazole), 3.50(s, 2H, COCH2), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 302 (100, MH+); 2-(4-chloropheoyl)-N-(3-cyclopropyl-lH-pyrazol-5-yl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 7.4-7.3 (m, 4H, Ph), 6.09 (s, 1H, CH-pyrazole), 3.56(s, 2H, COCH2), 1.82 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 276 (100, MH+);N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(l-naphthyl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 6.07 (s, 1H, CH-pyrazole), 4.07 (s, 2H, COCH2), 1.80(m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 292 (100, MH+); N-(3-cyclopropyl-1 H-pyrazol-5-yl)-2-(5-methoxy-1 H-indol-3-yI)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 7.17 (s, 1H, CCHNH), 6.10 (s, 1H, CH-pyrazole), 3.60(s, 2H, COCH2), 1.80 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 311 (100, MH+); N-(3-cyclopropyl-lH-pyrazol-5-yl>2-(l-methyl-lH-indol-3-yl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 7.19 (s, 1H, CCHNCH3), 6.09 (s, 1H, CH-pyrazole),3.64 (s, 2H, COCH2), 1.80 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 295 (100, MH+); 2-(5-chloro-1 -benzothiophen-3-yl)-N-(3-cyclopropyl- lH-pyrazol-5-yl)acetamide; 1H-NMR (400 MHz, î)MSO-d6) ppm 7.66 (s, 1H, CCHS), 6.08 (s, 1H, CH-pyrazole), 3.85(s, 2H, COCH2), 1.82 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 332 (100, MH+); 2(1 -benzothiophen-3-yl)-N-(3-cyclopropyI-1 H-pyrazol-5-yl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 7.54 (s, 1H, CCHS), 6.10 (s, 1H, CH-pyrazole), 3.85(s, 2H, COCH2), 1.82 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 298 (100, MH+); SUBSTITÛTE SHEET (RULE 26)
DUPLICATA 1 2046 WO 01/12189 PCT/US00/06699 60 N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(4-methylphenyl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 7.2-7.1 (m, 4H, Ph), 6.08 (s, 1H, CH-pyrazole), 2.25(s, 3H, CH3), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 256 (100, MH+); N-(3-cyclopropyl-1 H-pyrazol-5-yl)-2-oxo-2-phenylacetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 7.94 (d, J=7.5 Hz, 2H, o-Ph), 7.74 (t, J=7.5 Hz, 1H, p-Ph), 6.27 (s, 1H, CH-pyrazole), 1.89 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 256 (100, MH+);N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-methoxy-2-phenylacetamide; 1H-NMR (400 MHz, DMSO-d6) 7.4-7.2 (m, 5H, Ph), 6.05 (s, 1H, CH-pyrazole), 4.80 (s, 1H,COCH), 1.82 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 272 (100, MH+);N-(3-cyclopropyl-lH-pyrazol-5-yl)-3-cyclopentylpropanamide; 1H-NMR (400 MHz, DMSO-d6) 6.07 (s, 1H, CH-pyrazole), 2.15 (t, J=8 Hz, 2H, COCH2), 1.82 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 248 (100, MH+); N-(3-cyclopropyl-1 H-pyrazol-5-yl)-4-oxo-4-phenylbutanamide; 1H-NMR (400 MHz, DMSO-d6) 7.85 (d, J=8 Hz, 2H, CH-o-Ph), 6.05 (s, 1H, CH-pyrazole), 1.82 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 284 (100, MH+);N-(3-cyclopropyl-lH-pyrazol-5-yI)-4-phenyl-3-butenamide; 1H-NMR (400 MHz, DMSO-d6) 6.49 (d, J=15.8 Hz, 1H, CHPh), 6.15 (s, 1H, CH-pyrazole), 3.2 (d, J=7.7 Hz, 2H, COCH2), 1.83 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 268 (100, MH+); N-(3-cyclopropyl-1 H-pyrazol-5-yl)-2-phenylpropanamide; 1H-NMR (400 MHz, DMSO-d6) 7.4-7.2 (m, 5H, Ph), 6.08 (s, 1H, CH-pyrazole), 3.79 (s, 1H,COCH), 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 256 (100, MH+); N-(3-cyclopropyl-1 H-pyrazol-5-yl)-2-[4-(dimethylamino)phenyl]acetamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-l-phenylcyclopropancarboxamide; N-(3-cyclopropyl-1 H-pyrazol-5-yl)-2-(4-methoxyphenyl)acetamide; SUBSTITUTE SHEET (RULE 26) WO 01/12189 1 2046 PCT/ÜS00/06699 61 N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(lH-indol-3-yl)acetamide; 3-(2-chlorophenoxy)-N-(3-cycIopropyl-lH-pyrazol-5-yl)propanamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(3-chlorophenyl)acetamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(2-fluorophenyl)acetamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(2-chlorophenyl)acetamide; N-(3-cyclopropÿl-lH-pyrazol-5-yI)-2-(4-tri£luorotnethyl-phenyl)acetainide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-3-oxo-l-indanecarboxamide; N-(3-cyclopropyl-1 H-pyrazol-5-yl)-2-(3-thienyl)acetamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)bicyclo[4.2.0]octa-l,3,5-triene-7-carboxamide;
Ail compounds were characterized by mass spectrometry (MS). LC-MS confirmed that ineach case the principle component had a molecular ion corresponding to the expectedproduct. The compounds showed an HPLC area % ranging from 78 to 100. HPLC analysis:
Solvent A: H20/CH3CN=90/10 + 0.1% TFASolvent B: H20/CH3CN=10/90 + 0.075% TFA
Time (min) %A %B 0 0 100 6.5 0 100 7 100 0 10 100 0
Rate: 1.5ml/minDétection: UV254nmTempérature: room température '
Colurnn: Supelco™, Discovery RP Amide Cl6,5*m, (50x4.6)mm î
Example 3 3-Cycloprcjpyl-3.-ox{>-prop.anenitrik SUBSTITÜTE SHEET (RULE 26) 1 2046 WO 01/12189 PCT/US00/06699 62 4.5 g (0.15 mol) of sodium hydride 80% were suspended in 200 ml of dioxane, 7.5 ml ofacetonitrile (0.15 mol) were dropped and, after 20 minutes, a solution of ethylcyclopropancarboxylate (0.125 mol) in 100 ml of the same solvent was added. The mixturewas maintained at reflux for 3 hours, under stirring, then 400 ml of water were added and theunreacted starting material extracted with methylene chloride. The aqueous layer wasacidified with diluted hydrochloric acid and extracted with the same solvent. The organiclayer was dried over anhydrous sodium sulfate and evaporated to dryness to give a residuethat, after column chromatography (cyclohexane-ethylacetate), afforded 7.8 g (57% yield) ofthe title compound. 1H-NMR (400 MHz, CDC13) ppm: 1.20 (m, 2H, cyclopropyl CHH + CHH); 1.21 (m, 2H,CHH + CHN; 2.12 (dddd, 1H, J=7.6,7.6,4.5,4.5, cyclopropyl CH); 3.59 (s, 2H, COCH2). EI-MS: m/z 69 (85, M-C3H5-); m/z 39 (100, C3H5+).
Example 4 3-Cvclopropvl-5-amino-lH-pvrazole 5 g (0.046 mol) of 3-cyclopropyl-3-oxo-propanenitrile were dissolved in 200 ml of éthanoland 2.26 ml (0.046 mol) of hydrazine hydrate were added. The solution was maintained atreflux for 5 hours and then the solvent evaporated under vacuum. The residue was re-dissolved with methylene chloride and washed several times with brine. The organic- layerwas dried over anhydrous sodium sulfate and the solvent evaporated to give 4.53 g (80%yield) of the title compound. 1H-NMR (400 MHz, DMSO-d6) ppm: 0.54 (m, 2H, pyrazoie CHH + CHH); 0,76 (m, 2H,CHH + CHH); 1.68 (dddd, 1H, J=4.9,4.9, 8.3, 8.3, pyrazoie CH); 5.02 (s, 1H, pyrazoie CH); 6-7 (b, 3H, NH + NH2). ESI (+) MS: m/z 124 (100, MH+).
Analogously the following compounds wére prepared: 3-Cyclobutyl-5-amino-lH-pyrazole 1H-NMR (DMSO-d6) ppm 11.10 (br. s, IH), 5.23 (s, 1H), 4.43 (br. s, 2H), 3.31 (m, 1H),2.18 (ni, 2H), 2.04 (m, 2H), 1.80 (m, 2H); MS (FAB) m/z 138 (MH+, 100). 3-(2-benzylcyclopropyl)-lH-pyrazol-5-aminehydrochloride SUBSTITUTE SHEET (RULE 26) WO 01/12189 1 2046 PCT/US00/06699 63 1H-NMR (DMSO-d6) pm 7.23 (complex, 5H), 5.48 (s, 1H), 2.67 (m, 2H), 1.85 (m, 1H), 1.48(m, 1H), 1.06 (m, 2H); MS (F AB) m/z 214 (MH+, 100). 3-Cyclopentyl-5-amino-lH-pyrazole 1H-NMR (DMSO-d6) ppm 11.15 (s, 1H), 5. 17 (s, 1H), 4.41 (br. s, 2H), 2.49 (m, 1H), 2.20(complex, 4H), 1.80 (complex, 2H), 1.39 (complex, 2H).
Example 5 l-Cyclapropyl-S-nitrorlH-ftyrazole
To a solution of 2.7 g of sodium hydrate in 454 ml of water 7.1 g (0.058 mol) of 3-cyclopropyl-5-amino-lH-pyrazole and 46.5 g of sodium hydrogenocarbonate were added at0°C. After 10 minutes a solution of 337 ml of acetone in 221 ml of water and a solution of130 g (0.21 mol) of oxone in 580 ml of water were contemporaneously dropped undervigorous stirring. After 4 hours at the same température the reaction is quenched with asaturated solution of sodium sulfite and extracted with ethylacetate. The organic layer wasdried over anhydrous sodium sulfate and evaporated to dryness to give 4.6 g (52% yield) ofthe title compound. 1H-NMR (400 MHz, CDC13) ppm: 0.79 (m, 2H, cyclopropyl CHH + CHH); 1.10 (m,2H, cyclopropyl CHH + CHH); 2.01 (dddd, 1H, >5.1, 5.1, 8.2, 8.2, cyclopropyl CH); 6.51(s, 1H, pyrazole CH). EI-MS: m/z 153 (100, M+); 136 (60, M-OH).
Example 6
Terizhttiyl-J-nitro-S-cyclQpropyi-lH-pyrazflle-l-.carhoxylate 4.9 g (0.032 mol) of 3-cyclopropyl-5-nitro-lH-pyrazole were dissolved in 200 ml ofmethylene chloride and 200 ml of a saturated solution of sodium hydrogenocarbonate wereadded. 35 g (0.16 mol) of tertbutoxycarbonyl anhydride were then added under stirring atroom température. After 24 hours the layers were separated and the organic one dried oversodium sulfate and evaporated under vacuum. The residue was chromatographed on a silicagel coîumn (cyclohexane-ethyl acetate) to give 7.7 g (95% yield) of the title compound. SUBSTITUTE SHEET (RULE 26) nauem 1 2046 PCT/ÜS00/06699 WO 01/12189 64 1H-NMR (400 MHz, CDC13) ppm: 0.78 (m, 2H, cyclopropyl CHH + CHH); 1.13 (m, 2H,CHH + CHH); 1.68 (s, 9H, (CH3)3-); 2.48 (dddd, 1H, >5.3, 5.3, 8.5, 8.5, cyclopropyl CH); 6.49 (s, 1H, pyrazole CH). ESI (+) MS: m/z 276 (100, MNa+); 220 [60, (MNa-C4H8)+J.
Example 7
Tert-butylT3-ami)(io-5-çyçlQpropyl-lH-pyrazolc-l-carboxylatc l. 2 g (4.74 mmol) of tert-butyl-3-nitro-5-cyclopropyl-lH-pyrazole-l-carboxylate weredissolved in 20 ml of éthanol and hydrogenated in presence of 200 mg of palladium oncharcoal (10%) at 50 psi and room température to give, after filtration on celite andévaporation of the solvent, 0.96 g (95% yield) of the title compound. 1H-NMR (400 MHz, CDC13) ppm: 0.64 (m, 2H, cyclopropyl CHH + CHH); 0.97 (m, 2Hcyclopropyl CHH + CHH); 1.63 (s, 9H, (CH3)3); 2.34 (dddd, 1H, >5.2, 5.2, 8.4, 8.4,cyclopropyl CH); 3.82 (s b, 2H, NH2); 5.39 (s, 1H, pyrazole CH). ESI (+) MS: m/z 246 (20, MNa+); 168 [100, (MH-C4H8)+]; 124 [90, [MH-C5H8O2)+].
Example 8 N-(3-cvclopropvl-lH-pvrazol-5-vDbenzamide
To a solution of 0.37 g (3 mmol) of 3-cyclopropyl-5-amino-lH-pyrazole in 15 ml ofdichloromethane 0.8 ml (7.3 mmol) of N-methylmorpholine and 0.8 ml (6.9 mmol) ofbenzoyl chloride were successively added at room température. After 16 hours under stirringthe mixture was concentrated and the residue was dissolved in 15 ml of methanol. 3.5 ml ofsodium hydrate 2.5 M were added dropwise and 10 ml of tetrahydrofuran were finally addedin order to obtain a homogéneous solution. After 15 minutes the mixture was concentratedand poured into water. The precipitate was filtered and dried in vacuum to afford 585 mg(86% yield) the title compound. m. p. 234°C; 1H NMR (DMSO-d6) ppm 12. Γ (s, 1H), 10.65 (s, 1H), 7.97 (app.d, 2H), 7.7 (m, 3H), 6.31(s, 1H), 1.89 (m, 1H), 0.93 (m, 2H), 0.69 (m, 2H); SUBSTITUTE SHEET (RULE 26) mioin 1 2046 PCT/US00/06699 WO 01/12189 65 MS (El) m/z (rel. intensity) 227 (M+, 22), 226 (11), 199 (23), 106 (13), 105 (95), 78(11), 77 (99), 66 (9), 65 (14), 51 (29).
Analogously, the following products were prepared starting from the correspondingcarboxylic acid: N-(3-cyclopropyl-lH-pyrazol-5-yl)-4-chlorobenzamide m.p. 186-187’C; 1H NMR (DMSO-d6) ppm 12.2 (s, 1H), 10.8 (s, 1H), 7.97 (app.d, 2H), 7.53 (app.d, 2H),6.28 (s, 1H), 1.87 (m, 1H), 0.91 (m, 2H), 0.67 (m, 2H); MS (El) m/z (rel. intensity) 261 (M+, 27), 235 (8), 233 (36), 141 (66), 139 (99), 113(31),111(78),65(10). N-(3-cyclopropyl-lH-pyrazol-5-yl)-4-methoxybenzamide;
m.p. 175-176 °C 1H-NMR (DMSO-d6) ppm 12.11 (s, 1H), 10.51 (s, 1H), 7.97 (d, J=8.8 Hz, 2H), 7.00 (d,J=8.8 Hz, 2H), 6.26 (s, 1H), 3.80 (s, 3H), 1.86 (m, 1H), 0.91 (m, 2H), 0.67 (m, 2H);
MS (El) m/z (rel. intensity) 257 (M+, 32), 257 (32), 229 (14), 135 (99), 107 (19), 92(38), 77 (58), 74 (15), 73 (18), 65 (17), 64 (18).N-(3-cyclopropyl-lH-pyrazol-5-yl)-4-butoxybenzamide;m.p. 192 °C 1H-NMR (DMSO-d6) ppm 12.11 (s, 1H), 10.48 (s, 1H), 7.95 (d, J=8.8 Hz, 2H), 6.98 (d,J=8.7 Hz, 2H), 6.26 (s, 1H), 4.01 (t, J=6.5 Hz, 2H), 1.86 (m, 1H), 1.69 (m, 2H), 1.43 (m, 2H),0.92 (m,5H), 0.66 (m,2H); MS (El) m/z (rel. intensity) 299 (M+, 58), 299 (58), 271 (25), 177 (92), 121 (99), 93(66), 92 (16), 67 (16), 65 (62), 63 (17). N-(5-cyclopropyl-lH-pyrazol-3-yl)[l, 1 '-biphenyl]-4-carboxamide;m.p. 253-254°C; 1H NMR (DMSO-d6) ppm 12.15 (s, 1H), 10.7 (s, 1H), 8.05 (d, J = 8 Hz, 2H), 7.76 (d, J = 8Hz, 2H), 7.72 (d, J = 7 Hz, 2H), 7.48 (t, J = 7 Hz, 2H), 7.39 (t, J - 7 Hz, 1H), 6.31 (br s, 1H),1.88 (m, 1H), 0.91 (m, 2H), 0.68 (m, 2H) ; MS (FAB) m/z (rel. intensity) 304 (MH+, 83), 152 (34), 151 (47), 128 (36), 107 (50),95 (38), 89 (32), 78 (27), 77 (99), 39 (35). N-(3-cyclopropyl-lH-pyrazol-5-yl)phenylacetamide
SUBSTITUTE SHEET (RULE 26)DIPLICATA WO 01/12189 1 2046 PCT/USO0/O6699 66 m.p. 208°C; 1H NMR (DMSO-d6) ppm 12.05 (s, 1H), 10.5 (s, 1H), 7.28 (app.d, 4H), 7.21 (m, 1H), 6.10(s, 1H), 3.54 (s, 2H) 1.80 (m, 1H), 0.86 (m, 2H), 0.59 (m, 2H); MS (El) m/z (rel. intensity) 241 (M+, 64), 123 (99), 118 (10), 96 (16), 95 (9), 91 (99),80 (35), 73 (14), 66 (10), 65 (48). N-(3-cyclopropyl-lH-pyrazol-5-yl)-3-phenylpropanamidem.p. 152-160°C, 1H NMR (DMSO-d6) ppm 12.00 (br s, 1H), 10.25 (s, 1H), 7.21 (m, 5H), 6.12 (s, 1H), 2.83 (t,J = 8 Hz, 2H), 2.53 (t, J - 8 Hz, 2H) 1.82 (m, 1H), 0.87 (m, 2H), 0.61 (m, 2H); MS (FAB) m/z (rel. intensity) 256 (MH+, 99), 255 (18), 219 (15), 167 (9), 150 (9),135 (10), 107 (26), 105 (23), 93 (9), 89 (28).N-(3-cyclopropyl-lH-pyrazol-5-yl)-3-trifluoromethylbenzamide;m.p. 193-194 °C; 1H-NMR (DMS0-d6) ppm 12.25 (s, 1H), 11.00 (s, 1), 8.32 (s, 1H), 8.26 (d, J=7.9 Hz, 1H), 7.90 (d, 1H), 7.71 (t, 1H), 6.31 (s, 1H), 1.88 (m, 1H), 0.92 (m, 2H), 0.62 (m, 2H); MS (El) m/z (rel. intensity) 295 (M+, 15), 295 (15), 267 (21), 266 (10), 173 (99), 145(99), 126 (13), 95 (18), 75 (15), 66 (19), 65 (18).N-(3-cyclopropyl-lH-pyrazol-5-yl)-l-benzothiophene-2-carboxamidem.p. 238-239°C; 1H NMR (DMS0-d6) ppm 12.2 (s, 1H), 11.1 (s, 1H), 8.39 (s, 1H), 8.01 (app.d, 1H), 7.91(app.d, 1H), 7.44 (m, 2H), 6.28 (s, 1H), 1.88 (m, 1H), 0.91 (m, 2H), 0.67 (m, 2H); MS (El) m/z (rel. intensity) 283 (M+, 78), 255 (18), 162 (23), 161 (99), 133 (75), 89(93), 73 (18), 65 (14), 63 (11). 4-[(4-chlorophenyl)sulphonyl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)-3-methyl-2- thiophenecarboxamide 1H-NMR (DMSO-d6) ppm 10.81 (s, 1H), 8.67 (s, 1H), 7.93-7.91 (d, >7 Hz, 2H), 7.74-7-71(d, J=9 Hz, 2H), 6.16 (s, 1H), 2.32 (s, 3H), 1.87 (m, 1H), 0.91 (m, J- 2.8 Hz, 2H), 0.67 (m,J=2.5 Hz, 2H);
MS (FAB) m/z (rel. intensity) 422 (MH+, 100).N‘-(3-cyclopropyl-lH-pyrazol-5-yl)therephthalamide;m.p. 262-263 °C SUBSTI BèKS8ïSïRULE 26) 1 2046 PCT/US00/06699 WO 01/12189 67 1H-NMR (DMSO-d6) ppm 12.2 (s, 1H), 10.85 (s, 1H), 8.09 (s, 1H), 8.01 (d, J=8.0 Hz, 2H), 7.92 (d, >8.0 Hz, 2H) 7.50 (s, 1H), 6.28 (s, 1H), 1.87 (m, 1H), 0.91 (m, 2H), 067 (m, 2H); MS (El) m/z (rel. intensity) 270 (M+, 10), 148 (99), 128 (72), 103 (25), 73 (87), 71(42),60(25), 59(58), 58(50).
N-(3-cyclopropyHH-pyrazol-5-yl)acetamide;m.p. 167-171 °C 1H-NMR (DMSO-d6) ppm 12.0 (s, 1H), 10.2 (s, 1H), 6.13 (s, 1H), 1.95 (s, 3H), 1,84 (m,1H), 0.89 (m, 2H), 0.64 (m, 2H); MS (El) m/z (rel. intensity) 165 (M+, 47), 123 (99), 122 (33), 97 (15), 96 (31), 81 (19), 80 (72), 67 (17), 66 (28), 65 (40).
Methyl 4- {[(3-cycIopropyl-IH-pyrazol-5-yl)amino]carbonyl}benzoate; m.p. 173-174 °C; 1H-NMR (DMSO-d6) ppm 12.2 (s, 1H), 10.9 (s, 1H), 8.06 (d, >8.0 Hz, 2H), 8.01 (d, >8.0Hz, 2H), 6.30 (s, 1H), 3.87 (s, 3H), 1.88 (m, 1H), 0.91 (m, 2H), 0.67 (m, 2H); MS (El) m/z (rel. intensity) 285 (M+, 9), 256 (13), 163 (99), 136 (21), 135 (22), 119(14), 104 (14), 103 (28), 77 (26), 75 (18).N-(3-cyclopropyl-lH-pyrazol-5-yl)-3-bromobenzamide;m.p. 158-159 °C; 1H-NMR (DMSO-d6) ppm 12.20 (s, 1H), 10.75 (s, 1H), 8.14 (s, 1H), 7.96 (d, >7.9 Hz, 1H),7.72 (d, 1H), 7.43 (t, >7.9 Hz, 1H), 6.28 (s, 1H), 1.87 (m, 1H), 0.92 (m, 2H), 0.67 (m, 2H); MS (El) m/z (rel. intensity) 305 (M+, 16), 185 (99), 183 (99), 157 (45), 155 (50), 77(39), 76 (53), 75 (22), 66 (31), 65 (17), 51 (24).N-(3-cyclopropyl-lH-pyrazol-5-yl)-3-methoxybenzamide;m.p. 149°C; 1H-NMR (DMSO-d6) ppm 12.15 (s, 1H), 10.65 (s, 1H), 7.55 (d, 2H), 7.39-7.36 (t, >8.0 Hz,1H), 7.10 (app. D. 1H), 6.29 (s, 1H), 3.80(s, 3H), 1.87 (m, 1H), 0.92 (m, 2H), 0.67 (m, 2H),; MS (FAB) m/z (rel. intensity) 258 (MH+, 100). 4-bromo-N-(5-cyclobutyl-lH-pyrazol-3-yl)benzamide;m.p. 192-194 °C; MS (El) m/z (rel. intensity) 319 (M+, 5), 263 (59), 185 (96), 183 (99), 157 (76), 155(82), 76 (83), 73 (74), 53 (56). SUBST1TUTE SHEET (RULE 26) WO 01/12189 PCT/USOO/06699 68 2-[(4-acetylamino)phenyl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; 4-bromo-N-(5-cyclohexyl-lH-pyrazol-3-yl)benzaniide; 4- bromo-N-(5-cyclopentyl-1 H-pyrazol-3-yl)benzamide; N-[5-(2-benzylcyclopropyl)-lH-pyrazol-3-yl]4-bromobenzamide; N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2,4-dimethoxybenzaraide; 5- [(4-chlorophenyl)sulphonyl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)-3-methyI-2-thiophenecarboxamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2,3,4,5,6-pentafluorobenzamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-cyclopentancarboxamide; N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(2-1hienyl)acetamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-3,5-dichlorobenzaxnide; 2-chloro-N-(5-cyclopropyl-lH-pyrazol-3-yl)-6-methylisonicotinamide; N-(5-cyclopropyl-1 H-pyrazol-3-yl)-5-isoxazolecarboxamide; 2,4-dichloro-N-(5-cyclopropyl-lH-pyrazol-3-yl)-5-fluorobenzamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2,4-difluorobenzamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-3,4-dimethoxybenzamide; 4- {[(3-cyclopropyl-lH-pyrazol-5-yl)amino]carbonyl}benzoic acid; 2- (4-bromophenyl)-N-(5-cyclopropyl-lH-pyrazol-3-yl)-acetamide; (2S)-N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-naphtyl)propanamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4l-(hydroxymethyl)[l,l'-biphenyl]-4-yl)acetamide; 3- tert-butyl-N-(5-cyclopropyl-lH-pyrazol-3-yl)-l-(2-thienylcarbonyl)-lH-pyrazole-5-carboxamide; N-(3-{[(3-cyclopropyl-lH-pyrazol-3-yl)amino]carbonyl}-2-thienyl)-2- thiophenecarboxamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(41-fluoro[l,l‘-biphenyl]-4-yl)acetamide;N-(5-cyclopropyl-lH-pyrazol-3-yl)-2,4-dimethyl-5-phenyl-lH-pyrrole-3-carboxamide;N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2- {4‘-[(dimethylamino]methyl)[ 1,1' -biphenyl]-4-yljacetamide; 2-[4'-(aminomethyl)[l,r-biphenyl]-4-yl}7N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-{4'-[(methylamino)methyl][l,r-biphenyl]-4- yljacetamide; SUBSTITÙTE SHEET (RULE 26)
Mamaia WO 01/12189 1 2046 PCT/US00/06699 69 N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-[4'-(l-pyrrolidinylmethyl)[ 1,1 ’-biphenyl]-4-yl]acetamide; N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-[4'-( 1 -piperidinylmethyl)[ l, 1 '-biphenyl]-4-yl]acetamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4’-(4-moipholinylmethyl)[l, î'-biphenyl]-4-yl]acetamide; N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2- {4'-[(4-methyl-l -piperazinyl)methyl] [1,1 '-biphenyl]-4-yl) acetamide; N-(5-cyclopropyl-lH-pyrazol-3-yI)-2-[4'-(lH-iinidazol-2-yl)[l,l’-biphenyl]-4-yl]acetamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4- {[(dimethylamino)carbonyl]amino}phenyl)acetamide; N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2- {4-[(methylsulfonyl)ammo]phenyl} acetamide; 2-[4-(aminomethyI)phenyl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; 2-{4-[(acetylamino)methyl]phenyl}-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; 2-[4-(aminosulfonyl)phenyl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-4-(2-methoxyphenoxy)benzamide; 4-(4-chlorophenoxy)-N-(3-cyclopropyl-1 H-pyrazol-5-yl)benzamide; 4-(4-chlorophenoxy)-N-(3-cyclopropyl-lH-pyrazol-5-yl)-3-nitrobenzamide; 4-[3,5-bis(trifluoromethyl)phenoxy]-N-(3-cyclopropyl-lH-pyrazol-5-yl)benzamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-4-(4-fluorophenoxy)benzamide; N-(3-cyclopropyl-1 H-pyrazol-5-yl)-4-(4-methylphenoxy)benzamide; 4-(4-cyanophenoxy)-N-(3-cyclopropyl-lH-pyrazol-5-yl)benzamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-4-(4-hydroxyphenoxy)benzamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-4-(3-hydroxyphenoxy)benzaniide; 2-[l,r-biphenyl]-4-yl-N-(3-cyclopropyl-lH-pyrazol-5-yl)propanamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(4-phenoxyphenyl)acetamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-3,5-diiodo-4-(4-methoxyphenoxy)benzamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-4-[3-(hydroxymethyl)phenyl]-3-butenamide; N-(3-cycloprppyl-l H-pyrazol-5-yl)-4- {3-[(methylamino)methyl]phenyl} -3-butenamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(2-phenylcyclopropyl)acetamide; 2-(2-(1,3-benzodioxol-5-yl)cyclopropyl]-N-(3-cyclopropyl-lH-pyrazol-5-yl)acetamide; SUBSTITUTE SHEET (RULE 26) •Wtom 1 2046 PCT/US0O/O6699 WO 01/12189 70 2-(3-(1,3-benzodioxol-5-yl)-2,2-difluorocyclopropyl]-N-(3-cyclopropyl-lH-pyrazol-5-yl)acetamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(2,2-difluoro-3-phenylcyclopropyl)acetamide;N-(3-cyclopropyl-lH-pyrazol-5-yî)-2-(5-methyl-4-phenyl-3-isoxazolyl)acetamide;N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(5-methyl-3-phenyl-4-isoxazolyl)acetamide; 2-(3-(1,3-benzodioxol-5-yl)-5-methyl-4-isoxazolyl]-N-(3-cyclopropyl-lH-pyrazol-5-yl)acetamide; 2-(4-(1,3-benzodioxol-5-yl)-5-methyl-3-isoxazolyl]-N-(3-cyclopropyl-lH-pyrazol-5-yl)acetamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3-phenyl-2-oxiranyl)acetamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-[2-(4-fluorophenyl)cyclopropyl]acetamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(2,2-difluoro-3-(3- fluorophenyl)cyclopropyl]acetamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(2-oxo-2,3-dihydro-lH-indol-5-yl)acetamide;N-(4- {2-[(3-cyclopropyl-1 H-pyrazol-5-yl)amino]-2-oxoethyl} phenyl)-1 -pyrrolidinecarboxamide; N-(4- {2-[(3-cyclopropyl-1 H-pyrazol-5-yl)amino]-2-oxoethyl}phenyl)-1 -piperidinecarboxamide; N-(4-{2-[(3-cyclopropyl-lH-pyrazx>l-5-yl)amino]-2-oxoethyl}phenyl)-4- morpholinecarboxamide; N-(4- {2-[(3-cyclopropyl- lH-pyrazol-5-yl)amino]-2-oxoethyl}phenyl)-4-methyl-l -piperazinecarboxamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(2-pyridinyl)acetamide; N-(3-cyclopropyl-1 H-pyrazol-5-yl)-2-(3-pyridinyl)acetamide; N-(3-cyclopropyl-1 H-pyrazol-5-yl)-2-(4-pyridinyl)acetaniide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-5-(3-nitrophenyl)-2-furamide; N-(3-cyclopropyl-lH-pyra2ol-5-yl)-2-(2,5-dioxo-4-iniidazolidinyl)acetamide;N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(9-oxo-9H-fluoren-2-yl)acetamide;N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-(4*-ethyl[ 1,1 '-biphenyl]-4-yl)acetamide;N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-(4'-propyl[ 1,1 ’-biphenyl]-4-yl)acetamide;N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(9H-fluoren-2-yl)acetamide; SUBSTITUTE SHEET (RULE 26)
Mraram 1 2046 PCT/US00/06699 WO 01/12189 71 N-(5-cyclopropyl-lH-pyrazoI-3-yI)-2-(9-methyI-9H-fluoren-2-yl)acetamide;N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-hydroxydibenzo[b,d]furan-3-yl)acetamide;N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(4'-hydroxy[ 1,1 '-biphenyl j-4-yl)acetamide; 2-(4'-cyano[ 1,1 ’-biphenyl]-4-yl)-N-(5-cyclopropyl- lH-pyrazol-3-yl)acetamide; 2-(4'-bromo[l,r-biphenyl]-4-yl)-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide;N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4'-propoxy[l,r-biphenyl]-4-yl)acetamide;N-(5-cyclopropyl-l H-pyrazol-3-yl)-2-(4’-butoxy[ 1,1 ’-biphenyl]-4-yl)acetamide;N-(5-cyclopropyHH-pyrazol-3-yl)-2-(4'-pentoxy[l,r-biphenyl]-4-yl)acetamide; 4’- {2-[(5-cyclopropyl- lH-pyrazol-3-yl)amino]-2-oxoethyi) [1,1 ’-biphenyl3-4-yl acetate; 2-(4'-tert-butyi[ 1,1 '-biphenyl]-4-yl)-N-{5-cyclopropyl- lH-pyrazol-3-yl)acetamide;N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3',4'-dichloro[l,l’-biphenyl]-4-yl)acetamide;N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3'-hydroxy[ 1,1 *-biphenyl]-4-yl)acetamide; 2-(3'-bromo[l, 1 -biphenyl]-4-yl)-N-(5-cyclopropyl-1 H-pyrazol-3-yl)acetamide; 2-(3'-amino[l,r-biphenyl]-4-yl)-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; 2-(4’-amino[ 1,1 '-biphenyl]-4-yl)-N“(5-cyclopropyl-1 H-pyrazol-3-yl)acetamide;N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(3-hydroxy-2-naphthyl)acetamide;N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3,5-dihydroxy-2-naphthyl)acetamide; 2- (3-amino-2-naphthyl)-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; N-(5-cyclopropyl-lH-pyrazoI-3-yl>2-(6-hydroxy-2-naphthyl)acetamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-hydroxy-l-naphthyl)acetamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(6-hydroxy-l-naphthyl)acetamide; 3- amino-N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-[(2-furylmethyl)sulfonyl]-2- thiophenecarboxamide; 3-amino-4-[(4-chlorophenyl)sulfonyl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)-2- thiophenecarboxamide; « 3-amino-N-(5-cyclopropyl-lH-pyrazol-3-yI)-4-(phenylsulfonyl)-2-thiophenecarboxarnide; 3-chloro-N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-(methylsulfonyl)-2-thiophenecarboxamide; 3-amino-N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-(isopropylsulfonyl)-2-thiophenecarboxamide; 3-amino-N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-(propylsulfonyl)-2-thiophenecarboxainide; 3-chloro-N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-(isopropylsulfonyl)-2-thiophenecarboxamide; N-(5-cyclopropyl-lH-pyrazol-3-yI)-4-(isopropylsulfonyl)-2-thiophenecarboxamide;
SUBST1TUTE SHEET (RULE 26)DUPLICATA WO 01/12189 1 2046 PCT/USOO/06699 72 4'-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}-N-[2-(l-pyrroIidinyl)ethyl][l,l'- biphenyl]-4-carboxamide; 4'- {2-[(5-cyclopropyl- lH-pyrazol-3-yl)amino)-2-oxoethyl) -N-[2-( 1 -pyrrolidinyl)propyl][ 1, Γ-biphenyl]-4-carboxamide; 4'- {2-[(5-cyclopropyl- lH-pyrazol-3-yl)amino]-2-oxoethyl) -N-[2-( 1 -piperidinyl)ethyl] [ 1, Γ-biphenyl)-4-carboxamide; 4'- {2-[(5-cyclopropyl-1 H-pyrazol-3-yl)amino]-2-oxoethyl} -N-[2-( 1 -piperidinyl)propyl][ 1,1'-biphenyl]-4-carboxamide; 4'-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}-N-[2-(4-morpholinyl)ethyl][l,r- biphenyl]-4-carboxamide; 4’-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino)-2-oxoethyl}-N-[2-(4- morpholiny l)propyl] [1,1 ’-bipheny l]-4-carboxamide; 4'- {2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl) -N-[2-(4-methyl-l - piperazinyl)ethyl] [1,1 ’-biphenyl]-4-carboxamide; 4'- {2-[(5-cyclopropyl-1 H-pyrazol-3-yl)amino]-2-oxoethyl) -N-[2-(4-methyl-1 - piperazinyl)propyl] [1,1 '-biphenyl]-4-carboxamide;
Example 9 N-(3-cvclopropvl-IH-pvrazol-5-vn-4-bromobenzamide 122 mg (loading 1.91 mmol/g, 0.233 mmol) of polystyrène supported-N-methylmoipholinewere suspended in 4 ml of chloromethane and then treated with 25.6 mg (0.117 mmol) of 4-bromobenzoyl chloride followed by 4.8 mg (0.039 mmol) of 3-cyclopropyl-5-amino-pyrazole. After 48 hours under stirring at room température the resin was separated byfiltration and washed with 2 ml of dichloromethane. The fîltrate was evaporated to dryness,the residue re-dissolved in 4 ml of dichloromethane and 100 mg of polystyrène supportedtrisamine were added. After 48 hours or stirring at room température the resin was filtered,washed with 2 ml of dichloromethane and concentrated to give, after triturating withdiethylether, 9.3 mg (78% yield) of the title compound.
m.p. 190-192 °C 1H-NMR (DMSO-d6) ppm 7.91 (d, J=8.5 Hz, 2H), 7.68 (d, 2H), 6.29 (s, 1H), 1.88 (m, 1H),0.90 (m, 2H), 0.67 (m, 2H); SUBSTITÜTE SHEET (RULE 26) imam 1 2046 PCT/US00/06699 WO 01/12189 73 MS (El) m/z (rel. intensity) 305 (M+, 27), 185 (99), 183 (68), 157 (44), 155 (49), 77(38), 76(41),66(42),51(29).
Analogously the following compounds were prepared:N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-chlorobenzamide;m.p. 155-156 °C; 1H-NMR (DMSO-d6) ppm 12.15 (s, 1H), 10.75 (s, 1H), 7.47-7.37 (m, 4H), 6.25 (s, 1H), 1.87(m, 1H), 0.92 (m, 2H), 0.67 (m, 2H); MS (El) m/z (rel. intensity) 261 (M+, 6), 226 (22), 141 (23), 139 (99), 113 (19), 111 (58), 75(42), 67 (17), 65 (38), 52 (16), 51 (24).N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-bromobenzamide;m.p. 158-159 °C; 1H-NMR (DMSO-d6) ppm 12.15 (s, 1H), 10.75 (s, 1H), 7.65 (d, J=7.7 Hz, 1H), 7.41 (app. d.,1H), 7.35 (m, 2H), 6.26 (s, 1H), 1.86 (s, 1H), 0.92 (m, 2H), 0.68 (m, 2H); MS (FAB) m/z (rel. intensity) 306 (MH+, 99), 613 (10), 384 (15), 382 (15), 308 (97),307 (26), 306 (99), 305 (13), 226 (10), 185 (15), 183 (16).N-(3-cyclopropyl-lH-pyrazol-5-yl)-3,4-dichlorobenzamide;m.p.l96-197°C; H-NMR (DMSO-d6) ppm 12.20 (s, 1H), 10.90 (s, 1H), 8.21 (s, 1H), 7.94 (d, J=8.4 Hz, 1H),7.76 (d, J=8.4 Hz, 1H), 6.29 (s, 1H), 1.87 (m, 1H), 0.92 (m, 2H), 0.67 (m, 2H); MS (FAB) m/z (rel. intensity) 296 (MH+, 100).N-(3-cyclopropyl-lH-pyrazol-5-yl)-2,4-dichlorobenzamide;m.p. 148-149 °C; 1H-NMR (DMSO-d6) ppm 12.15 (s, 1H), 10.82 (s, 1H), 7.68 (s, 1H), 7.49 (complex 2H), 6.25 (s, 1H), 1.87 (m, 1H), 0.92 (m, 2H), 0.67 (m, 2H); MS (FAB) m/z (rel. intensity) 296 (MH+, 100).N-(3-cyclopropyl-lH-pyrazol-5-yl)-lH-indole-2-carboxamide;m.p. 268-269 °C; 1H-NMR (DMSO-d6) ppm 12.05 (br. s, 1H), 11.67 (s, 1H), 10.75 (s, 1H), 7.58 (d, 1H), 7.41(m, 2H), 7.18 (t, 1H), 7.02 (t, 1H), 6.30 (s, 1H), 1.88 (m, 1H), 0.92 (m, 2H), 0.68 (m, 2H); MS (FAB) m/z (rel. intensity) 267 (MH+, 100).N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-[5-(2,6-difluorobenzyl)-2-methoxyphenyl]aeetamide; SUBST1TUTE SHEET (RULE 26) wma 1 2046 PCT/US00/06699 WO 01/12189 74 1H-NMR (DMSO-d6) ppm 7.65 (s, 1H), 7.65 (m, 2H), 7.30 (t, 1H), 7.10 (d, 2H), 6.07 (s,1H), 3.84 (s, 3H), 3.63 (s, 2H), 1.81 (m, 1H), 0.85 (m, 2H), 0.60 (m, 2H); MS (FAB) m/z (rel. intensity) 412 (MH+, 99).N-(3-cyclopropyl-lH-pyrazol-5-yl)-3,5-ditrifluoromethylbenzamide;N-(3-cyclopropyl-lH-pyrazol-5-yl)-3,3-dimethylbutanaraide;N-(3-cyclopropyl-lH-pyrazol-5-yl)-4-iodobenzamide;N-(3-cyclopropyl-lH-pyrazol-5-yl)-l-naphtamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-3-cyanobenzamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-1,3-benzodioxol-5-carboxamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-4-morpholinocarboxamide; 3-(2-chlorophenyl)-N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-propenamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(propylsulfanyl)-nicotinamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-2,2,5,7-tetramethyl-1 - l-oxo-4-indanecarboxamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-pyridinecarboxamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-adamantanecarboxamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-4-methylbenzamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-2,6-dichlorobenzamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-methoxybenzamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-methylbenzamide; N-(3-cyclopropyl- ΙΗ-pyrazo 1 -5-yl)-3-fluorobenzamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-3-chlorobenzamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-3,5-dimethoxybenzamide N-(3-cyclopropyl-lH-pyrazol-5-yl)-3-methylbenzamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-4-fluorobenzamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-4-trifluoromethylbenzaniide;
Methyl-4-[(3-cyclopropyl-lH-pyrazol-5-yl)-amino-]-4-oxobutanoate; N-(3-cyclopropyl-lH-pyrazol-5-yl)-cyclopropancaiboxamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-4-cyanobaizamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-naphthamide; N-(3-cyclopropyHH-pyrazol-5-yl)-2-thiophenecarboxamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-quinoxalinecarboxamide; SUBSTITUTE SHEET (RULE 26) wma WO 01/12189 1 2046 PCT/USOO/06699 75 N-(3-cyclopropyl-lH-pyrazol-5-yl)-3,4-difluorobenzamide; N-(3-cyclopropyl-1 -pyrazol-5-yl)-3,5-difluorobenzamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(2,5-dimethoxyphenyl)acetamide; 2- (4-chlorophenoxy)-N-(3-cyclopropyl-lH-pyrazol-5-yl)-nicotinamide; 3- chloro-N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-thiophenecarboxamide; 2,5-dichloro-N-(3-cyclopropyl-lH-pyrazol-5-yl)-3-thiophenecarboxamide;N-(3-cyclopropyl-lH-pyra2ol-5-yl)-2-ethoxybenzamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-phenylbutanamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-4-trifluoromethoxybenzamide; 3-chloro-N-(3-cyclopropyl-lH-pyrazol-5-yl)-benzo[b]thiophene-2-carboxamide.
Ail compounds were characterized by mass spectrometry (MS). LC-MS confirmed that ineach case the principle component had a molecular ion corresponding to the expectedproduct. The compounds showed an HPLC area % ranging from 70 to 100. HPLC analysis:
Solvent A: H20/CH3CN=90/10 + 0.1% TFASolvent B: H20/CH3CN=10/90 + 0.075% TFA
Time (min) %A %B 0 0 100 6.5 0 100 7 100 0 10 100 0
Rate: 1.5ml/min Détection: UV254nm
Température: room température
Column: Supelco™, Discovery RP Amide C16,5«m, (50x4.6)mm
Example 10 g-(a=<;ycloia:«myI-lH-pyrazQ.l"i:ylMHrpyrrolft-2-€arfeoxamide SUBSTITÙTE SHEET (RULE 26) 1 2046 PCT/US00/06699 WO 01/12189 76
To a solution of 5-amino-3-cyclopropylpyrazole (274 mg, 2.2 mmol) in 6 mL of acetonitrilewas added a solution of 2-trichloroacetylpyrrole (430 mg, 2.0 mmol) in 6 mL of acetonitrile,followed by 250 pL of triethylamine. The mixture was stirred and heated at reflux, undernitrogen, for 8 hours. The mixture was poured into ethyl acetate and 1 M KH2PO4. Theorganic phase was dried over NajSO4, concentrated, and the residue taken up in ether. Whiteneedles precipitated from ether, whose NMR spectrum revealed a one-to-one complex of theproduct and ether. The solid was heated to 62 °C under vacuum ovemight to afford 190 mg(0.41 mmol, 44%) of ether-free product, m.p. 220-221 °C, Ή NMR (DMSO-J6) δ 12.1 (s, 1H), 11.5 (s, 1 H), 10.2 (s, 1 H), 7.06 (s, 1 H), 6.89 (s, 1 H), 6.24 (s, 1 H), 6.08 (s, 1 H), 1.86(m, 1 H), 0.89 (m, 2 H), 0.66 (m, 2 H); IR (drift) 3263 (b), 3174 (b), 2351 (w), 2328 (w),1906 (w), 1645 (s), 1639 (s), 1587 (s), 1554,1538,1488, 1439, 1402, 1319, 786, cm Anal.Calcd for C„HI2N4O: C, 61.10; H, 5.59; N, 25.91. Found: C, 60.99; H, 5.63; N, 25.68.
Following the same method but employing 5-amino-3-cyclobutylpyrazole, N-(3-cyclobutyl-lH-pyrazol-5-yl)-lH-pyrrole-2-carboxamide,was prepared.
To 260 mg (1.9 mmol) of 5-amino-3-cyclobutylpyrazole in 7 mL of acetonitrile was added407 mg (1.9 mmol) of 2-trichloroacetylpyrrole and 220 pL of triethylamine. The mixture was stirred and heated at reflux, under nitrogen, for 12hours. TLC analysis showed some starting material still remained. The mixture wasconcentrated and chromatographed over silica gel, eluting with 5 % methanol in chloroform.The fractions containing the product were concentrated to an oil, which crystallized uponconcentration from ether and methanol, to afford 200 mg (0.87 mmol, 46 %) of a beige solid,m.p.207-209 °C, ’H NMR (DMSO-</«) δ 12.1 (s, 1 H), 11.5 (s, 1 H), 10.2 (s, 1 H), 7.08 (s, 1H), 6.89 (s, 1 H), 6.41 (s, 1 H), 6.09 (s, l H), 3.46 (m, 1 H), 2.24 (m, 2 H), 2.11 (m, 2 H), 2.0- 1.8 (m, 2 H); IR (drift) 3329,3294,3257,3225 (b), 2460 (w), 2351 (w), 2318 (w), 2257 (w),1643 (s), 1588 (s), 1541,1487 (s), 1416,757,747, cm'1 Anal. Calcd for CI2H,4N4O: C, 62.59; H, 6.13; N, 24.33. Found: C, 62.37; H, 6.22; N,24.13.
Analogously the following compounds were prepared: N-(5-cyclopropyl- lH-pyrazol-3-yl)-4-(3-methylbenzoyl)-1 H-pyrrole-2-carboxamide; SUBSTITUTE SHEET (RULE 26) WXXCA2&amp; 1 2046 PCT/US00/06699 WO 01/12189 77 1H-NMR (DMSO-d6) ppm 12.3 (s, 1H), 12.1 (s, 1H), 10.5 (s, 1H), 7.58 (m, 3H), 7.45 (m,1H), 7.42 (m, 2H), 6.27 (s, 1H), 2.39 (s, 3H), 1.88 (d, J=7.0 Hz, 1H), 0.92 (m, 2H), 0.69 (m,2H); N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-(3-fluorobenzoyl)-lH-pyrrole-2-carboxamide; 1H-NMR (DMSO-d6) ppm 7.67 (m, 1H), 7.58 (m, 3H), 7.49 (s, 1), 7.39 (dt, J=7.2 Hz, 1H), 6.25 (br s, 1H), 1.92 (m, 1H), 1.00 (m, 2H), 0.76 (m, 2H); N-(5-cyclopropyl-1 H-pyrazol-3-yl)-4-(2-fluorobenzoyl)-1 H-pyrrole-2-carboxamide; 1H-NMR (DMSO-d6) ppm 7.58 (m, 2H), 7.48 (s, 1), 7.42 (s, 1H), 7.30 (m, 2H), 6.18 (s, 1H), 1.92 (m, 1H), 0.98 (m, 2H), 0.74 (m, 2H). N-(5<yclopropyMH-pyrazol-3-yl)-4-(3,3-dimethylbutanoyl)-lH-pyrrole-2-carboxamide;N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-(cyclopropylcarbonyl)-lH-pyrrole-2-carboxamide;N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-(2-thienylcarbonyl)-lH-pyrrole-2-carboxamide;N-(5-cyclopropyl- lH-pyrazol-3-yl)-4-(2-methylbenzoyl)-1 H-pyrrole-2-carboxamide; 4-( 1 -benzothien-2-ylcarbonyl)-N-(5-cyclopropyl-1 H-pyrazol-3-yl)-1 H-pyrrole-2-carboxamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-(3-methylbutanoyl)-lH-pyiTole-2-carboxamide; 4-(cyclopentylcarbonyl)-N-(5-cyclopropyl-lH-pyrazol-3-yl)-lH-pyrrolle-2-carboxamide; N-(5>cyclopropyl-lH-pyrazol-3-yl)-4-pentanoyl-lH-pyrrole-2-carboxamide; 4-(3-chlorobisnzoyl)-N-(5-cyclopropyl-lH-pyrazol-3-yl)-lH-pyrrole-2-carboxamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-(phraiylacetyl)-lH-pyirole-2-carboxamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-[(4-fluorophenyl)acetyl]-lH-pyrrole-2-carboxamide; 4-butyryl-N-(5-cyclopropyl-lH-pyrazol-3-yl)-lH-pynOle-2-carboxamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-(4-fluorobenzoyl)-lH-pyrrole-2-carboxamide;N-(3-cyclopropyl- lH-pyrazol-5-yl)-4-(3,4-dimethylbenzoyl)-1 H-pyrrole-2-carboxamide;N-(3-cyclopropyl-lH-pyrazol-5-yl)-4-(4-fluorobenzoyl)-lH-pyrrole-2-carboxamide;N-(3-cyclopropyl-1 H-pyrazol-5-yl)-4-(4-methylbenzoyl)-1 H-pyrrole-2-carboxamide; 4-(4-chlorobenzoyl)-N-(3-cyclopropyl-lH-pyrazol-5-yl)-lH-pyrrole-2-caiboxamide; 4-(cyclohexylcarbonyl)-N-(3-cyclopropyl-lH-pyrazol-5-yl)-lH-pyrrole-2-carboxamide;methyl 5-(5- {[(3-cyclopropyl-l H-pyrazol-5-yl)amino]carbonyl) - lH-pyrrol-3-yl)-5- oxopentanoate 4-acetyl-N-(3-cyclopropyl-lH-pyrazol-5-yl)-lH-pyirole-2-carboxamide;
SUBSTITUTE SHEET (RULE 26)DUPLICATA WO 01/12189 1 2046 PCT/US00/06699 78 N-(3-cyclopropyl-lH-pyrazol-5-yl)-4-(2,6-dimethoxybenzoyl)-lH-pyrrole-2-carboxamide;N-(3-cyclopropyl-1 H-pyrazol-5-yl)-1 -methyl- lH-pyrrole-2-carboxamide; 4-bromo-N-(3-cyclopropyl-lH-pyrazol-5-yl)-lH-pyrrole-2-carboxamide;N-(3-cyclopropyl-lH-pyrazol-5-yl)-l-methyl-4-(3-methyIbenzoyl)-lH-pyrrole-2-carboxamide; N-(3-cyclopropyl-lH-pyrazoI-5-yl)-2-quinoxalinecarboxamide; (lR,2R)-N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-phenylcyclopropanecarboxamide; N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-phenylcyclopropanecarboxamide; 3- chloro-N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-thiophenecarboxamide; 4- benzoyl-N-(3-cyciopropyl-lH-pyrazol-5-yl)benzamide;
Example 11 2-il.l’-biphenvll-4-yl-N-f3-cvclQDroDvl-lH-PYrazQl-5-vnacetamide
To 5.1 g of trityl chloride resin (Novabiochem, loading 1.2 mmol/g) swelled in 76 ml ofDCM and 14 ml of DMF, 3.98 g of 2-(4-bromophenyl)-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide and 3 ml of DIPEA were added. The mixture was shaken 18 hrs at roomtempérature and then washed with DMF (3 x 50 ml), MeOH (3 x 50 ml) and DCM (3 x 50ml). Unreacted trityl chloride resin was capped adding 50 ml of DIPEA:MeOH:DCM(1:2:17), the mixture was shaken 1 hr and then washed with DMF (3 x 50 ml), MeOH (3 x 50ml) and DCM (3 x 50 ml). The resin was dried under high vacuum. Loading found 1.1mmol/g (HPLC calibration curve).
To 40 mg of 2-(4-bromophenyl)-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide resin linked 1ml of a 10.4M solution of CsF in DME:MeOH (3:1), phenylboronic acid (0,12 mmol) inDME (0.5 ml) and tetrakis triphenylphosphine palladium, (Pd(PPh3)4, 0.008 mmol) in DME(1 ml) were added. The mixture was shaken 18 hrs at 80 °C and then washed with DMF (3 x5 ml), MeOH (3x5 ml) and DCM (3x5 ml). To the resin 5 ml of TFA 10% in DCM wereadded and the mixture was shaken 1 hr at room température, the organic phase was filteredoff and the resin was washed with DCM (3x5 ml) and DMSO (2x5 ml). The organicfractions were collected and evaporated under reduced pressure and the residue was analyzedby HPLC-MS (area count 90%, 254 nm; M+l=318,2M+1=365) without further purification. SUBSTITÜTE SHEET (RULE 26) WO 01/12189 1 2046 PCT/US00/06699 79 IH-NMR (400 MHz, DMSO-d6) ppm 10.49 (s, 1H, NHCO), 7.6-73 (m, 9H, biphenyl), 6.09(s, 1H, CH-pyrazole), 3.59 (s, 2H, COCH2), 1.82 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 318 (100, MH+); N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(3 ’-ethoxy-[ 1,1 ’-biphenyl]-4-yl)acetamideIH-NMR (400 MHz, DMSO-d6) ppm 10.48 (s, 1H, NHCO), 7.4-73 (m, 3H, o,m-Ph), 6.09(s, 1H, CH-pyrazole), 4.03 (q, J=7 Hz, 2H, OCH2), 3.58 (s, 2H, COCH2), 1.82 (m, 1H,cyclopropyl-CH); ESI (+) MS: m/z 362 (100, MH+); N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3’-acetamido[l,r-biphenyl]-4-yl)acetamideIH-NMR (400 MHz, DMSO-d6) ppm 10.49 (s, 1H, NHCO), 7.8-7.2 (m, 8H, biphenyl), 6.09(s, 1H, CH-pyrazole), 2.04 (s, 3H, COCH3), 1.82 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 375 (100, MH+); N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4’-tert-butyl-(l,r-biphenylJ-4-yl)acetamideIH-NMR (400 MHz, DMSO-d6) ppm 10.49 (s, 1H, NHCO), 7.6-73 (m, 8H, biphenyl), 6.09(s, 1H, CH-pyrazole), 3.55 (s, 2H, COCH2), 1.29 (s, 9H, terbutyl), 1.82 (m, 1H, cyclopropyl-CH); N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3’-(triflnoromethoxy)[l,r-biphenyl]-4-yl)acetamideIH-NMR (400 MHz, DMSO-d6) ppm 10.49 (s, ÎH, NHCO), 7.7-73 (m, 8H, biphenyl), 6.09(s, 1H, CH-pyrazole), 3.61 (s, 2H, COCH2), 1.82 (m, 1H, cyclopropyl-CH); N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2’,3’-dimethyl-[l,r-biphenyl}-4-yl)acetamideIH-NMR (400 MHz, DMSO-d6) ppm 10.50 (s, 1H, NHCO), 7.4-6.9 (m, 7H, biphenyl), 6.10(s, 1H, CH-pyrazole), 232 (s, 3H, CH3), 2.10 (s, 3H, CH3), 1.82 (m, 1H, cyclopropyl-CH);N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2’,4’-dimethoxy-[l,r-biphenyl]-4-yl)acetamideIH-NMR (400 MHz, DMSO-d6) ppm 10.47 (s, 1H, NHCO), 7.65 (d, J=8 Hz, 2H, m-Ph),7.16 (d, J=83 Hz, 1H, o-Ph) 6.09 (s, 1H, CH-pyrazole), 3.55 (s, 2H, COCH2), 1.82 (m, 1H,cyclopropyl-CH); N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3’,5’-difhioro-[l,l'-biphenyl]-4-yl)acetamide IH-NMR (400 MHz, DMSO-d6) ppm 10.49 (s, 1H, NHCO), 7.65 (d, J=8.3 Hz, 2H, m-Ph), 7.15 (m, 1H, p-Ph) 6.09 (s, 1H, CH-pyrazole), 3.60 (s, 2H, COCH2), 1.82 (m, 1H, cyclopropyl-CH); N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2’-ethoxy-[l,l'-biphenyl]-4-yl)acetamide SUBSTITUTE SHEET (RULE 26) 1 2046 PCT/ÜSOO/06699 WO 01/12189 80 1H-NMR (400 MHz, DMSO-d6) ppm 10.48 (s, 1H, NHCO), 7.4-7.0 (m, 8H, biphenyl), 6.10(s, 1H, CH-pyrazole), 4.03 (q, J=7 Hz, 2H, OCH2), 3.58 (s, 2H, COCH2), 1.82 (m, 1H,cyclopropyl-CH); N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3’,4’-dimethoxy-[l,l'-biphenyl]-4-yl)acetamide1H-NMR (400 MHz, DMSO-d6) ppm 10.46 (s, 1H, NHCO), 7.55 (d, J=8.3 Hz, 2H, m-Ph),7.00 (d, J=8.4 Hz, 1H, m’-Ph) 6.08 (s, 1H, CH-pyrazole), 3.8-3.7 (2xs, 6H, 2xOCH3), 1.82(m, 1H, cyclopropyl-CH); N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-(4’-ethyl-[ 1,1 ’-biphenyl]-4-yl)acetamide 1H-NMR (400 MHz, DMSO-d6) ppm 10.47 (s, 1H, NHCO), 7.6-7.2 (m, 8H, biphenyl), 6.09(s, 1H, CH-pyrazole), 3.58 (s, 2H, COCH2), 2.61 (q, J=7 Hz, 2H, CH2CH3), 1.82 (m, 1H,cyclopropyl-CH); N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-(3 ’-chloro-4’-fluoro-[ 1,1 ’-biphenyl]-4-yl)acetamide1H-NMR (400 MHz, DMSO-d6) ppm 10.48 (s, 1H, NHCO), 7.8-7.4 (m, 7H, biphenyl), 6.08(s, 1H, CH-pyrazole), 1.82 (m, 1H, cyclopropyl-CH); N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-((4’-methylthio)-[ 1,1 ’-biphenyl]-4-yl)acetamide1H-NMR (400 MHz, DMSO-d6) ppm 10.48 (s, 1H, NHCO), 7.56 (d, J=8.3 Hz, 2H, m-Ph), 6.96 (d, J=6.6 Hz, 2H, m’-Ph), 6.09 (s, 1H, CH-pyrazole), 3.59 (s, 3H, SCH3), 1.82 (m, 1H,cyclopropyl-CH); N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-(4’-ethoxy-[ 1,1 '-biphenyl]-4-yl)acetamide1H-NMR (400 MHz, DMSO-d6) ppm 10.50 (s, 1H, NHCO), 7.52 (d, J=8.3 Hz, 2H, m-Ph), 6.96 (d, J=6.7 Hz, 2H, m’-Ph), 6.09 (s, 1H, CH-pyrazole), 4.03 (q, J=7 Hz, 2H, OCH2CH3), 1.82 (m, 1H, cyclopropyl-CH); N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4’-acetyl-[l,r-biphenyl]-4-yl)acetamide 1H-NMR (400 MHz, DMSO-d6) ppm 10.50 (s, 1H, NHCO), 8.00 (d, J=8.6 Hz, 2H, m’-Ph), 6.96 (d, J=8.3 Hz, 2H, m-Ph), 6.09 (s, 1H, CH-pyrazole), 2.59 (s, 3H, COCH3), 1.82 (m, 1H,cyclopropyl-CH); N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2’,5’-dimethoxy[l,l'-biphenyl]-4-yl)acetamide 1H-NMR (400 MHz, DMSO-d6) ppm 10.48 (s, 1H, NHCO), 7.38 (d, J=8.3 Hz, 2H, m-Ph), 6.81 (d, J=3.1 Hz, 1H, o’-Ph), 6.10 (s, 1H, CH-pyrazole), 3.55 (s, 2H, COCH2), 1.82 (m, 1H, cyclopropyl-CH); N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2’-fluoro[l,r-biphenyl]-4-yl)acetamide fleVSXOAft WO 01/12189 12046 PCT/US00/06699 81 1H-NMR (400 MHz, DMSO-d6) ppm 10.51 (s, 1H, NHCO), 7.5-73 (m, 8H, biphenyl), 6.10(s, 1H, CH-pyrazole), 3.62 (s, 2H, COCH2), 1.82 (m, 1H, cyclopropyl-CH);N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(3 ’-fluoro[ 1,1 '-biphenyl]-4-yl)acetamide1H-NMR (400 MHz, DMSO-d6) ppm 10.49 (s, 1H, NHCO), 7.63 (d, J=8.2 Hz, 2H, m-Ph), 7.38 (d, J=8.2 Hz, 2H, o-Ph), 6.09 (s, 1H, CH-pyrazole), 3.59 (s, 2H, COCH2), 1.82 (m, 1H,cyclopropyl-CH); N-(5-cyclopropyi-lH-pyrazol-3-yl)-2-(3’-methoxy[l,r-biphenyl]-4-yl)acetamide1H-NMR (400 MHz, DMSO-d6) ppm 10.48 (s, 1H, NHCO), 7.57 (d, J=8.0 Hz, 2H, m-Ph),6.09 (s, 1H, CH-pyrazole), 3.79 (s, 3H, OCH3), 3.59 (s, 2H, COCH2), 1.82 (m, 1H,cyclopropyl-CH); N-(5-cyclopropyl-lH-pyrazol-3-yl>2-(3’-formyl-4’-methoxy[l,r-biphenyl]-4-yl)acetamide1H-NMR (400 MHz, DMSO-d6) ppm 10.49 (s, 1H, NHCO), 8.0-7.9 (m, 2H, o’-Ph), 7.60 (d,J=8.3 Hz, 2H, m-Ph), 6.09 (s, 1H, CH-pyrazole), 3.60 (s, 2H, COCH2), 1.82 (m, 1H,cyclopropyl-CH); N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(4’-fluoro-3 ’ -methyl[ 1,1 ’-biphenyl J-4-yl)acetamide1H-NMR (400 MHz, DMSO-d6) ppm 10.47 (s, 1H, NHCO), 7.55 (d, J=8.3 Hz, 2H, m-Ph),6.09 (s, 1H, CH-pyrazole), 3.59 (s, 2H, COCH2), 2.28 (s, 3H, CH3), 1.82 (m, 1H,cyclopropyl-CH); N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(5 *-fluoro-2 ’-methoxy(l, 1 ’-biphenyl]-4-yl)acetamide1H-NMR (400 MHz, DMSO-d6) ppm 10.48 (s, 1H, NHCO), 7.8-7.7 (m, 3H, m,m’-Ph), 6.09(s, 1H, CH-pyrazole), 3.63 (s, 2H, COCH2), 1.82 (m, 1H, cyclopropyl-CH); N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(4’-methoxy[ 1,1 ’-biphenyl]-4-yl)acetamide1H-NMR (400 MHz, DMSO-d6) ppm 10.46 (s, 1H, NHCO), 7.52 (d, J=8.3 Hz, 2H, m-Ph),6.99 (d, >8.9 Hz, 2H, m’-Ph), 6.09 (s, 1H, CH-pyrazole), 3.62 (s, 2H, COCH2), 1.82 (m, 1H,cyclopropyl-CH); N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2’,5’-dimethyl[l,r-biphenyl]-4-yl)acetamide 1H-NMR (400 MHz, DMSO-d6) ppm 10.50 (s, 1H, NHCO), 7.34 (d, J=8.2 Hz, 2H, m-Ph), 7.13 (d, >7.8 Hz, 2H, m’-Ph), 6.11 (s, 1H, CH-pyrazole), 3.60 (s, 2H, COCH2), 1.82 (m, 1H, cyclopropyl-CH); N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2’,5’-difluoro[l,r-biphenyl]-4-yl)acetamide SUBSTITÜTE SHEET (RULE 26) 1 2046 PCT/US00/06699 WO 01/12189 82 1H-NMR (400 MHz, DMSO-d6) ppm 10.49 (s, 1H, NHCO), 7.5-7.2 (m, 7H, biphenyl), 6.09(s, 1H, CH-pyrazole), 3.62 (s, 2H, COCH2), 1.82 (m, 1H, cyclopropyl-CH);
Analogously, the following compounds were prepared: N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(pentafluoro[ 1,1 '-biphenyl]-4-yl)acetamideN-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4*-caiboxy[l,r-biphenyl]-4-yl)acetamideN-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(2’,5 ’-dichloro[ 1,1 ’-biphenyl]-4-yl)acetamideN-(5-cyclopropyl-1 H-pyrazol-3-y 1)-2-(4 ’-formyl[ 1,1 '-bipheny l]-4-yl)acetamideN-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2’,6-difluoro[l,r-biphenyl]-4-yl)acetamideN-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2’,6-dimethyl[l,r-biphenyl]-4-yl)acetamideN-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2’,6-dimethoxy[l,r-biphenyl]-4-yl)acetamideN-(5-cyclopropyl- lH-pyrazol-3-yl)-2-(2’-acetyl-[ 1,1 '-biphenyl]-4-yl)acetamideN-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3’,4’-difluoro-[l,r-biphenyl]-4-yl)acetamideN-(5-cyclopropyl- lH-pyrazol-3-yl)-2-(3 ’-(hydroxymethyl)[ 1,1 '-biphenyl]-4-yl)acetamideN-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3’-nitro-[l,r-biphenyl]-4-yl)acetamideN-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2’-chloro-[l,r-biphenyl]-4-yl)acetamide
Example 12 N-f5-cyclopropvl-lH-pvrazol-3-vB-2-f4-f3-thienvr>Dhenvllacetamide 330 mg (2.17 mmol) of CsF, 81 mg (0.63 mmol) of thienylboronic acid and 36 mg (0.031mmol) of tetrakis triphenylphosphine palladium (Pd(PPh})4 were added to 100 mg (0.31mmol) of 2-(4-bromophenyl)-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide) in 25 mL ofDME and 2 mL of MeOH. The mixture was shaken 48 hrs at 80 °C under nitrogen. Thereaction mixture is evaporated, redissolved in ethyl acetate and then washed with a saturatedsolution of NaHCO3. The organic layer was, after treatment with anhydrous sodium sulfate,evaporated under reduced pressure and the title compound was obtained by crystallizationfrom acetone (48 mg, 48 %yield). 1H-NMR (400 MHz, DMSO-d6) ppm 10.42 (s, 1H, NHCO), 7.79 (dd, J=3-1.4 Hz, 1H,CCHS), 6.11 (s, 1H, CH-pyrazole), 3.56 (s, 2H, COCH2); 1.82 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 324 (100, MH+);
Analogously, the following compounds were prepared: SUBSTITÜTE SHEET (RULE 26) KBICASi 1 2046 PCT/US00/06699 WO 01/12189 83 N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4’-fluoro[l,r-biphenyl]-4-yl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.44 (s, 1H, NHCO), 6.11 (s, 1H, CH-pyrazole), 3.59(s, 2H, COCH2); 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 336 (100, MH+); 2-(3'-acetyl[l,r-biphenyl]-4-yl)-N-(3-cyclopropyl-lH-pyrazol-5-yl)acetamide 1H-NMR (400 MHz, DMSO-d6) ppm 10.49 (s, 1H, NHCO), 7.66 (d, J=8 Hz, 2H, m-Ph), 7.59 (t, J=7.8 Hz, 1H, m’-Ph), 6.10 (s, 1H, CH-pyrazole), 3.62 (s, 2H, COCH2), 2.63 (s, 3H,COCH3), 1.82 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 360 (100, MH+); N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4’-trifluoromethoxy[l, 1 ’-biphenyl]-4-yl)acetamide;1H-NMR (400 MHz, DMSO-d6) ppm 10.51 (s, 1H, NHCO), 7.74 (d, J=, 6.5 Hz, 2H, o’-Ph), 7.60 (d, J=7.3 Hz, 2H, m-Ph), 6.09 (s, 1H, CH-pyrazole), 3.61 (s, 2H, COCH2); 1.82 (m, 1H,cyclopropyl-CH); ESI (+) MS: m/z 402 (100, MH+); 4’- {2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino)-2-oxethyl} [1,1 ’-biphenylJ-4-carboxylic acid1H-NMR (400 MHz, DMSO-d6) ppm 10.46 (s, 1H, NHCO), 6.09 (s, 1H, CH-pyrazole), 3.61(s, 2H, COCH2); 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 362 (100, MH+); N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4’-formyl[l,r-biphenyl]-4-yl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.47 (s, 1H, NHCO), 10.02 (s, 1H, CHO), 6.11 (s,1H, CH-pyrazole), 3.62 (s, 2H, COCH2); 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 346 (100, MH+); 4’-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)anuno]-2-oxethyl}[l,l’-biphenyl]-4-carboxamide;1H-NMR (400 MHz, DMSO-d6) ppm 10.46 (s, ÎH, NHCO), 6.09 (s, 1H, CH-pyrazole), 3.61(s, 2H, COCH2); 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 361 (100, MH+);· N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4'-(hydroxymethyl)[ 1,1 ’-biphenyl]-4-yl]acetamide;1H-NMR (400 MHz, DMSO-d6) ppm 7.7-7.4 (m, 8H, biphenyl), 6.10 (s, 1H, CH-pyrazole), 3.60 (s, 2H, COCH2); 1.81 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 348 (100, MH+); N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(2-thienyl)phenyl]acetamide;
SUBST1TÜTE SHEET (RULE 26)DUPLICATA 1 2046 PCT/US00/06699 WO 01/12189 84 1H-NMR (400 MHz, DMS0-d6) ppm 10.47 (s, 1H, NHCO), 7.6-7.1 (m, 7H, aromatic), 6.08(s, 1H, CH-pyrazole), 1.82 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 324 (100, MH+); N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-I4-(5-methyl-2-thienyl)phenyl]acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.46 (s, 1H, NHCO), 7.48 (d, J=8.3 Hz, 2H, m-Ph), 3.55 (s, 2H, COCH2), 2.43 (s, 3H, CH3), 6.09 (s, 1H, CH-pyrazole), 1.82 (m, 1H,cyclopropyl-CH); N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-[4-(2-naphthyl)phenyl]acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.50 (s, 1H, NHCO), 8.2-7.4 (m, 11H, aromatic), 6.10 (s, 1H, CH-pyrazole), 3.55 (s, 2H, COCH2), 1.82 (m, 1H, cyclopropyl-CH); 2-(4-(1,3-benzodioxol-5-yl)phenyl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.48 (s, 1H, NHCO), 7.50 (d, J=8.3 Hz, 2H, m-Ph), 6.96 (d, J=8.1 Hz, 1H, m’-Ph), 6.09 (s, 1H, CH-pyrazole), 6.02 (s, 2H, OCH2O), 1.82 (m, 1H,cyclopropyl-CH); 2-(4-(1 -benzofuran-2-yl)phenyl]-N-(5-cyclopropyl-1 H-pyrazol-3-yl)acetamide 1H-NMR (400 MHz, DMSO-d6) ppm 10.51 (s, 1H, NHCO), 7.8-7.2 (m, 9H, aromatic), 6.09(s, 1H, CH-pyrazole), 1.82 (m, 1H, cyclopropyl-CH); 2-[4-(l-benzothien-2-yl)phenyl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; 1H-NMR (400 MHz, DMSO-d6) ppm 10.49 (s, 1H, NHCO), 7.70 (d, J=8.3 Hz, 2H, m-Ph), 6.10 (s, 1H, CH-pyrazole), 3.62 (s, 2H, COCH2), 1.82 (m, 1H, cyclopropyl-CH); N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-(l-naphtbyl)phenyl]acetamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-(2-fiiryl)phenyl]acetamide; 2-[4-(5-acetyl-2-thienyl)phenyl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; 2-(4-(5-chloro-2-thienyl)phenyl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3'-({[5-(dimethylamino)-l- naphthyljsulfonyl) amino)( 1,1 '-biphenyl]-4-yl]acetamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(3-fonnyl-2-thienyl)phenyl]acetamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(3-formyl-2-thienyl)phenyl]acetamide; SUBSTITUTE SHEET (RULE 26)
WïUMM 1 2046 PCT/USOO/06699 WO 01/12189 85
Example 13 N-i3-cyclopropyl-lH-pyrazol-5-yl)-2-f4'-(trifluoromethyD[l.r-biphenyl]-4-vl)acetamide
The bis(pinacolato)diboron (102 mg, 0,4mmol), potassium acetate (66mg., 0,6mmol) andPdCl2(dppf) (l,6mg., 0,018mmol) were added sequentially to a degassed suspension of 2-(4-bromophenyl)-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide resin linked (200mg, 0,2mmol)in anhydrous DMF (10ml).The résultant mixture was heated at 80° C under argon for 16h.,cooled down at room température and filtered. The resin was washed with DMF (3*3ml),MeOH (3*3ml) and CH2C12 (3*3ml) and dried under vacuum. l-bromo-4-(trifiuoromethyl)benzene (225mg, Immol), tetrakis(triphenylphosphine)palladium(4,6mg,0,004mmol) and 2M aqueous solution of K3PO4 (0,5ml) we added to the N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(4,4,5,5-tetramefliyl-l,3,2-dioxaborolan-2- yl)phenyl]acetamide resin linked suspended in 10 ml of anhydrous DMF. The mixture washeated at 80°C under argon for 20 h. and cooled at room température. The resin filtered, waswashed with DMF (3*3ml), MeOH (3*3ml), and DCM (3*3ml).
The cleavage of the final product was carried out in TFA 15% in DCM (5ml, lh.). 1H-NMR (400 MHz, DMSO-d6) ppm 10.50 (s, 1H, NHCO), 7.8-7.4 (m, 8H, biphenyl), 6.09(s, 1H, CH-pyrazole), 3.62 (s, 2H, COCH), 1.82 (m, 1H, cyclopropyl-CH); ESI (+) MS: m/z 386 (100, MH+).
Analogously the following compounds were prepared: 5-(4-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoetiiyl)phenyl)-2-furoicacid N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(3-methyl-lH-pyrazol-4-yl)phenyl]acetamide N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(3,5-dimethyl-lH-pyrazol-4-yl)phenyl]acetamide N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(3-furyl)phenyl]acetamide N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(5-formyl-3-thienyl)phenyl3acetamide [5-(4-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}phenyl)-lH-indol-3-yl]acetic acid 5-(4-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}phenyl)tryptophan N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(2-pyridinyl)phenyl]acetamide l-acetyl-5-(4-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl)phenyl)-lH-indol-3-yl acetate SUBSTITÜTE SHEET (RULE 26) anuem 1 2046 PCT/US00/06699 WO 01/12189 86 2-[4-(2-amino-4-hydroxy-6-methyl-5-pyrimidinyl)phenyl]-N-(5-cyclopropyl-lH-pyrazol-3- yl)acetamide N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(5-pyrimidinyl)phenyl3acetamideN-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(2-pyridinyl)phenyl]acetamideN-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(5-nitro-2-pyridinyl)phenyl]acetamideN-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(6-amino-3-pyridinyl)phenyl]acetaniideN-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(3-pyridinyl)phenyl]acetamideN-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(3-quinolinyl)phenyl]acetamideN-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(4-isoquinolinyl)phenyl]acetamide 5-(4-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}phenyl)nicotinic acidN-(5-cycIopropyl-lH-pyrazol-3-yl)-2-[4-(2-amino-5-pyrimidinyl)phenyl]acetamideN-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(4-pyridinyl)phenyl]acetamideN-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(5-acetyl-2-thienyl)phenyl]acetamideN-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(9H-purin-6-yl)phenyl]acetamide 2-[4-(l-benzothien-3-yl)phenyl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide 5-(4-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}phenyl)-lH-indol-3-ylacetateN-(5-cyclopropyl-lH-pyraz»l-3-yl)-2-[4-(2,4-dimethoxy-5-pyrimidinyl)phenyl]acetainideN-(5-cyclopropyI-lH-pyrazol-3-yl)-2-[4-(2-chloro-3-thienyl)phenyl]acetamideN-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(6-methyl-2-pyridinyl)phenyl]acetamideN-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(lH-imidazol-5-yl)phenyl]acetamide 2-[4-(6-amino-5-nitro-3-pyridinyl)phenyl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamideN-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(2,3,5,6-tetrafluoro-4-pyridinyl)phenyl]acetamideN-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(4-methyl-2-pyridinyl)phenyl]acetamideN-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-[4-( lH-pyrazol-4-yl)phenyl]acetamide 5- (4- {2-[(5-cyclopropyl-l H-pyrazol“3-yl)amino]-2-oxoethyl}phenyl)-2-thiophene acidN-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(6-methoxy-2-pyridinyl)phenyl]acetamide 6- (4-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)ammo]-2-oxoethyl}phenyl)-2-pyridinecarboxylicacid N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(2,4-dichloro-5-pyrimidinyl)phenyl]acetainide N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(4-methyl-3-thienyl)phenyl]acetamide N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(5-fonnyl-2-furyl)phenyl]acetamide SUBSTITÜTE SHEET (RULE 26) 1 2046 PCT/US00/06699 WO 01/12189 87 N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(6-nitro-3-pyridinyl)phenyl]acetaniide N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(8-quinolinyl)phenyl]acetaniide N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(5-methyl-2-pyridinyl)phenyl]acetamide N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(3-methyî-2-pyridinyl)phenyl]acetamide N-(5-cyclopropyl-lH-pyrazol-3-y))-2-[4-(lH-indol-7-yl)phenyl]acetamide N-(5-cyclopropyl-lH-pyrazol-3-yI)-2-[4-(6-raethoxy-3-pyridinyl)phenyl]acetamide N-(5-cyclopropyMH-pyrazol-3-yl)-2-[4-(2-amino-9H-purin-6-yl)phenyl]acetamide N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(2-methyl-lH-indol-5-yl)phenyl]acetamide N-(5“CyclopropyHH-pyrazol-3-yl)-2-[4-(6-fluoro-3-pyridinyl)phenyl]acetamide N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4*-(ethyîsulfanyl)[l,r-biphenyl]-4-yl]acetainide; N-(5-cyclopropy]-lH-pyrazol-3-yl)-2-(3’,4'-dimethyl[l,r-biphenyl]-4-yl)acetamide; N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-(4'-hydroxy[ 1,1 ’-biphenyl]-4-yl)acetamide; (2E>3-(4- {2-[(5-cyclopropyl-1 H-pyrazol-3-yl)aœino]-2-oxoethyl} [1,1 '-biphenyl]-3-yl)-2-propenoic acid; N-(5-cyclopropyHH-pyra2»l-3-yl)-2-[3-(trifluoromethyl)[l,r-biphenyl]-4-yl]acetamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4*-methyl[l, 1 '-biphenyl]-4-yl)acetamide; N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[2'-(methylsulfanyl)[l,r-biphenyl3-4-yl]acetamide; 4’-{2-[(5-cyclopropyHH-pyrazoI-3-yl)amino]-2-oxoethyl}[l,r-biphenyl]-2-carboxylicacid; 3-(4'-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}[l,r-biphenyl]-4-yl)propanoic acid; 2-[4'-(benzyloxy)[l, 1 ’-biphenyl]-4-yl]-N-(5-cyclopropyl- lH-pyrazol-3-yl)acetamide;N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2',3'-dichloro[l,r-biphenyl]-4-yl)acetamide;N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3'-isopropyl[l,r-biphettyl]-4-yl)acetamide;N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-[4-(3-formyl-2-iuryl)phenyl]acetaniide;(2E)-3-(4’-{2-[(5-cyclopropyHH-pyraz»l-3-yl)ainino]-2-oxoethyl} [1,1 '-biphenyl]-4-yl)-2-propenoic acid; N-(5-cyclopropyl- lH-pyrazol-3-yl)-2- {4’-[(E)-2-nitroethenyl][ 1,1 ’-biphenyl]-4-yl} acetamide; 2-(4'-chloro[ 1,1 '-biphenyl]-4-yl)-N-(5-cyclopropyl-l H-pyrazol-3-yl)acetamide;N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-(3’-methyl[l, 1 '-biphenyl]-4-yI)acetamide; 2-(4'-phenyl[ 1,1 '-biphenyl]-4-yl)-N-(5-cyclopropyl-1 H-pyrazol-3-yl)acetamide;N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-(4’-phenoxy[ 1,1 '-biphenyl]-4-yl)acetamide; SUBSTITÜTE SHEET (RULE 26) wnxom 1 2046 PCT/USOO/06699 WO 01/12189 88 N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(2'-formyl[ 1,1 ’-biphenyl]-4-yl)acetamide; 2-(3'-chloro[l,r-biphenyl]-4-yl)-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(3'-fonnyl[ 1,1 '-biphenyl]-4-yl)acetamide; tert-butyl 2-(4- {2-[(5-cyclopropyl- lH-pyrazol-3-yl)amino]-2-oxoethyl} phenyl)-1 H-pyrrole-1 -carboxylate; 2-(3’-cyano[l,r-biphenyl]"4-yl)-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(4-dibenzo[b,d]fiiran-4-ylphenyl)acetamide;
Obviously, numerous modifications and variations of the présent invention are possible in thelight of the above teachings. It is therefore to be understood that within the scope of theappended daims, the invention may be practiced otherwise than as specifically describedherein. SUBSTITUTE SHEET (RULE 26)

Claims (32)

WO 01/12189 89 1 2046 PCT/US00/06699 C.LAJMS:
1. A method of treating cell proliférative disorders associated with an altered celldépendent kinase activity, comprising: administering to a mammal in need thereof an effective amount of a compound representedby formula (I):
wherein R is a C3-C6 cycloalkyl group optionally substituted by a straight or branched C,-C6alkyl or arylalkyl group; R, is a straight or branched C,-C6 alkyl, C2-C4 alkenyl, cycloalkyl, cycloalkenyl,heterocyclyl, aryl, arylalkyl, arylcarbonyl, aiyloxyalkyl or arylalkenyl group, each ofwhich may be optionally further substituted; or a pharmacetically acceptable sait therof.
2. The method of Claim 1, wherein the cell proliférative disorder is selected from thegroup consisting of cancer, Alzheimer's disease, viral infections, auto-immune diseases andneurodegenerative disorders.
3. The method of Claim 2, wherein the cancer is selected from the group consisting ofcarcinoma, squamous cell carcinoma, hematopoietic tumors of myeloid or lymphoid lineage,tumors of mesenchymal origin, tumors of the central and peripheral nervous System,melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum,keratoctanthoma, thyroid follicular cancer and Kaposi's sarcoma.
4. The method of Claim 1, wherein the cell proliférative disorder is selected from thegroup consisting of benign prostate hyperplasia, familial adenomatosis polyposis, neuro- DUPLICATA SUBST1TUTE SHEET (RULE 26) 1 2 04 6 WO 01/12189 PCT/US00/06699 90 fibromatosis, psoriasis, vascular smooth cell prolifération associated with atherosclerosis,pulmonary fibrosis, arthritis glomerulonephritis and post-surgical stenosis and restenosis.
5. The method of Claim 1, which provides tumor angiogenesis and metastasisinhibition.
6. The method of Claim 1, which provides cell cycle inhibition or cdk/cyclindépendent inhibition.
7. The method of Claim 1, which provides treatment or prévention of radiotherapy-induced or chemotherapy-induced alopecia.
8. The method of Claim 1, further comprising subjecting the mammal in need thereofto a radiation therapy or chemotherapy regimen in combination with at least one cytostatic orcytotoxic agent.
9. The method of Claim 1, wherein the mammal in need thereof is a human.
10. The method of Claim 1, wherein R is a cycloalkyl group and R, is a C,-C4 alkyl,cycloalkyl, aiyl, arylalkyl, 5 or 6 membered heterocyclyl or heterocyclylalkyl group, whichmay be optionally further substituted as described above.
11. The method of Claim 1, wherein R is cycloalkyl and R, is C,-C4 alkyl, phenyl,phenylalkyl, phenylalkenyl, biphenyl, biphenylalkyl, a- or β-naphthyl, a- or β-naphthylalkyl,pyridyl, thienyl, thienylalkyl, isoxazolyl, isoxazolylalkyl, pyrazolyl, pyrazolylalkyl, furyl,thiazolyl, thiazolylalkyl, pyrrolyl, dihydropyrrolyl, indolyl, indolylalkyl, benzothienyl,benzothienylalkyl, fluorenylalkyl, pyrimidinylalkyl, quinoxalynyl and cyclopropyl.
12. The method of Claim 10 or 11, wherein R is cyclopropyl. SUBSTI wyssiRULE2e) WO 01/12189 91 1 2046 PCT/US00/06699
13. The method of Claim 1, wherein R, is any of the groupe defined in claim 1optionally substituted in any of the free positions by one or more groups independentlyselected from: halogen, nitro, oxo groups (C=O), cyano, alkyl, perfluorinated alkyl,hydroxyalkyl, aiyl, arylalkyl, heterocyclyl, cycloalkyl, hydroxy, alkoxy, perfluorinatedalkoxy, aryloxy, heterocyclyloxy, methylenedioxy, alkylcarbonyloxy, arylcarbonyloxy,carboxy, alkoxycarbonyl, aryloxycarbonyl, cycloalkyloxycarbonyl, amino, ureido,alkylamino, dialkylamino, arylamino, diarylamino, fortnylamino, alkylcarbonylamino,arylcarbonylamino, heterocyclylcarbonylamino, alkoxycarbonylamino, alkoxyimino,alkylsulfonylamino, arylsulfonylamino, formyl, alkylcarbonyl, arylcarbonyl,cycloalkylcarbonyl, heterocyclylcaibonyl, aminocarbonyl, alkylaminocarbonyl,dialkylaminocarbonyl, alkylsulfonyl, arylsulfonyl, aminosulfonyl, alkylaminosulfonyl,dialkylaminosulfonyl, arylthio and alkylthio.
14. A 3-amino-pyrazole dérivative represented by formula (I): R
wherein R is a C3-C6 cycloalkyl group optionally substituted by a straight or branched C,-C6alkyl or arylalkyl group; R, is a straight or branched C,-C6 alkyl, C2-C4 alkenyl, cycloalkyl, cycloalkenyl,heterocyclyl, aiyl, arylalkyl, arylcarbonyl, aiyloxyalkyl or arylalkenyl group, each ofwhich may be optionally fùrther substituted; or a pharmacetically acceptable sait therof.
15. The 3-amino-pyrazole dérivative of Claim 14, wherein R is a C3-C6 cycloalkylgroup optionally substituted by a straight or branched C,-C6 alkyl group; R, is a straight orbranched C,-Ce alkyl group, C2-C4 alkenyl, cycloalkyl, aryl, arylalkyl, arylcarbonyl,aryloxyalkyl or arylalkenyl group, which is optionally substituted with one or more groupsselected from the group consisting of cycloalkyl, hydroxy, alkylthio, alkoxy, amino, SUBSTITUTE SHEET (RULE 26) MÉ&amp;ICACA 1 2046 PCT/US00/06699 WO 01/12189 92 alkylamino, dialkylamino, alkoxycarbonylamino, alkoxycarbonylalkylamino, alkylcarbonyl,alkylsulphonyl, alkoxycarbonyl, carboxy, halogen, nitro, aryloxy, arylthio, arylsulphonyl, N-alkyl-piperazinyl, piperidinyl, 4-morpholinyl, arylamino, cyano, alkyl, aryl, oxo, haloaryl,haloarylalkyl, haloaryloxy, haloarylsulphonyl, aminosulphonyl, aminocarbonyl, arylcarbonyl,perfluorinated alkyl, and perfluorinated alkoxy groups; or a pharmaceutically acceptable saitthereof.
16. The 3-amino-pyrazole of Claim 14, wherein R is a cycloalkyl group and R, is aC,-C4 alkyl, cycloalkyl, aryl, arylalkyl, 5 or 6 membered heterocyclyl or heterocyclylalkylgroup, which may be optionally further substituted as described above.
17. The 3-amino-pyrazole of Claim 14, wherein R is cycloalkyl and R, is C,-C4 alkyl,phenyl, phenylalkyl, phenylalkenyl, biphenyl, biphenylalkyl, a- or β-naphthyl, a- or β-naphthylalkyl, pyiidyl, thienyl, thienylalkyl, isoxazolyl, isoxazolylalkyl, pyrazolyl,pyrazolylalkyl, furyl, thiazolyl, thiazolylalkyl, pyrrolyl, dihydropyrrolyl, indolyl,indolylalkyl, benzothienyl, benzothienylalkyl, fluorenylalkyl, pyrimidinylalkyl, quinoxalynyland cyclopropyl.
18. The 3-amino-pyrazole of Claim 16 or 17, wherein R is cyclopropyl. alkylsulfonylamino, cycloalkylcarbonyl,
19. The 3-amino-pyrazole of Claim 14, wherein R, is any of the groups defîned inclaim 14 optionally substituted in any of the free positions by one or more groupsindependently selected from: halogen, nitro, oxo groups (C=O), cyano, alkyl, perfluorinatedalkyl, hydroxyalkyl, aryl, arylalkyl, heterocyclyl, cycloalkyl, hydroxy, alkoxy, perfluorinatedalkoxy, aryloxy, heterocyclyloxy, methylenedioxy, alkylcarbonyloxy, arylcarbonyloxy,carboxy, alkoxycarbonyl, aryloxycarbonyl, cycloalkyloxycarbonyl, amino, ureido,alkylamino, dialkylamino, arylamino, diarylamino, formylamino, alkylcarbonylamino,arylcarbonylamino, heterocyclylcarbonylamino, alkoxycarbonylamino, alkoxyimino,arylsulfonylamino, formyl, alkylcarbonyl, arylcarbonyl,heterocyclylcarbonyl, aminocarbonyl, alkylaminocarbonyl, SUBSTITÜTE SHEET (RULE 26) MKtom 1 2 046 PCT/US00/06699 WO 01/12189 93 dialkylaminocarbonyl, alkylsulfonyl, arylsulfonyl, aminosulfonyl, alkylaminosulfonyl,dialkylaminosulfonyl, arylthio and alkyltbio.
20. The 3-amino-pyrazole dérivative of Claim 14, which is selected from the groupconsisting of: 1. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2,2-diphenylacetamide; 2. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(4-nitK)phenyl)acetamide; 3. N-(3-cyclopropyl- lH-pyrazol-5-yl)-4-methoxybenzamide; 4. N-(3-cyclopropyl- lH-pyrazol-5-yl)-2-(3-methoxyphenyl)acetamide; 5. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-[4-(dimethylamino)phenyl]acetamide; 6. N-(3-cyclopropyl-lH-pyrazol-5-yl)-l -phenylcyclopropancarboxamide; 7. 2-( 1,3-benzodioxol-5-yl-N-(3-cyclopropyl-lH-pyrazol-5-yl)acetamide; 8. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(4-methoxyphenyl)acetamide; 9. N-(3-cyclopropyl- lH-pyrazol-5-yl)-2-phenylpropanamide; 10. N-(3-cyclopropyl- lH-pyrazol-5-yl)-2-(3,4-dimethoxyphenyl)acetamide; 11. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(lH-indol-3-yl)acetamide; 12. N-(3 -cyclopropyl-1 H-pyrazol-5-yl)-2-(5-methoxy- 1 H-indol-3-yl)acetamide; 13. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(l-methyl-lH-indol-3-yl)acetamide; 14.2- (5-chloro-l-benzothiophen-3-yl)-N-(3-cyclopropyl-lH-pyrazol-5-yl)acetamide; 15.2- (l-benzothiophen-3-yl)-N-(3-cyclopropyl-lH-pyrazol-5-yl)acetamide; 16. N-(3-cyclopropyl-lH-pyrazol-5-yl)-3-cyclppentylpropanamide; 17.2- (4-chlorophenyl)-N-(3-cyclopropyl-lH-pyrazol-5-yl)acetamide; 18. N-(3-cyclopropyl-lH-pyrazol-5-yl)-4-oxo-4-phenylbutanamide; 19. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(2,3-dihydro-lH-inden-5-yl)acetamide; 20.3- (2-chlorophenoxyl)-N-(3-cyclopropyl- lH-pyrazol-5-yl)propanamide; 21. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-oxo-2-phenylacetamide; 22. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(4-methylphenyl)acetamide; 23. 2-[l,l'-biphenyl]-4-yl-N-(3-cyclopropyl-lH-pyrazol-5-yl)acetamide; 24. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(3-chlorophenyl)acetamide; 25. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(l-naphtyl)acetamide; SUBSTITUTE SHEET (RULE 26) 1 2046 PCT/US00/06699 WO 01/12189 94 26. N-(3-cyciopropyl- lH-pyrazol-5-yl)-2-(2-fluorophenyl)acetamide; 27. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(2-chlorophenyl)acetamide; 28. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(4-fluorophenyl)acetamide; 29. N-(3-cyclopropyl-lH-pyraz»l-5-yl)-2-(4-trifluoromethyl-phenyl)acetaniide; 30. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-methoxy-2-phenylacetamide; 31. N-(3-cyclopropyl-lH-pyrazol-5-yl)-3-oxo-l-indanecarboxainide; 32. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(3-tliienyl)acetannde; 33. N-(3-cyclopropyl-lH-pyrazol-5-yl)bicyclo[4.2.0]octa-l,3»5-triene-7-carboxamide; 34. N-(3-cyclopropyÎ-lH-pyrazol-5-yl)-4-phenyl-3-butenamide; 35.4- [(4-chlorophenyl)sulphonyl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)-3-methyl-2-thiophenecarboxamide; 36. 5-[(4-chlorophenyl)sulphonyl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)-3-methyl-2-thiophenecarboxamide; 37. N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-phenoxybenzamide; 38.4- bromo-N-(5-cyclopropyl- lH-pyrazol-3-yl)benzamide; 39. N-(5-cyclopropyl-ÎH-pyrazol-3-yl)-3,5-bis(trifluoromethyl)benzamide; 40. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-3,3-dünethylbutanamide; 41. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-4-iodobenzamide; 42. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-1 -napthamide; 43. N-(5-cyclopropyl- lH-pyrazol-3-yl)-3-cyanobenzamide; 44. N-(5-cyclopropyl-lH-pyraz»l-3«yl)-l,3-benzodioxole-5-carboxaiiiide; 45. 3-(2-chlorophenyl)-N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-propenamide; 46.2,5-dichloro-N-(5-cyclopropyl-lH-pyïazol-3-yl)-3-thiophenecarboxamide; 47. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(propylsulfanyl)nicotinamide; 48. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2,2,5,7-tetramethyl-l-oxo-4-indanecarboxamide; 49. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2Tpyridinecarboxamide; 50. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-adamantancarboxainide; 51. N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-methylbenzamide; 52. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2,3,4,5,6-pentafluorobenzamide; 53. N-(5-cyclopropyl-l H-pyrazol-3-yl)-2-phenyIacetamide; 54. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-cyclopentancarboxamide; SUBSTITÜTE SHEET (RULE 26) DWICATA. 1 2046 PCT/US00/06699 WO 01/12189 95 55. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-thienyl)acetamide; 56. N-(5-cyclopropyl-lH-pyrazol-3-yl)-3,5-dichlorobenzamide; 57. 2-chloro-N-(5-cyclopropyl-lH-pyrazol-3-yl)-6-tnethylisonicotinamide; 58. N-(5-cyclopropyl-lH-pyrazol-3-yl)-5-isoxazolecarboxamide; 59.2,4-dichloro-N-(5-cyclopropyl- lH-pyrazol-3-yl)-5-fluorobenzamide; 60. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2,4-difluorobenzaniide; 61. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-chlorobenzamide; 62. N-(5-cyclopropyI-lH-pyrazol-3-yl)-2,4-dichlorobenzamide; 63. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2,6-dichlorobenzaniide; 64. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-methoxybenzamide; 65. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-methylbenzamide; 66. N-(5-cyclopropyl-lH-pyrazol-3-yl)-3-fluorobenzamide; 67. N-(5-cyclopropyl-lH-pyrazol-3-yl)-3-chlorobenzamide; 68. N-(5-cycIopropyl-1 H-pyrazol-3-yl)-3,5-dimethoxybenzamide; 69. N-(5-cyclopropyl-lH-pyrazol-3-yl)-3-methylben2amide; 70. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-4-fluorobenzamide; 71. N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-trifluoromethylbenzaniide;
72. Methyl 4-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-4-oxobutanoate; 73. N-(5-cyclopropyl-lH-pyraz»l-3-yl)-cyclopropanecarboxainide; 74. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-4-cyanobenzamide; 75. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-napthamide; 76. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-thiophenecarboxamide; 77. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-quinoxalmecarboxamide; 78. N-(5-cyclopropyl-lH-pyrazol-3-yl)-3,4-difluorobenzamide; 79. N-(5-cyclopropyl-lH-pyrazol-3-yl)-3,5-difluorobenzamide; 80. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2,5-dimethoxyphenyl)acetamide; 81. N-(5-cyclopropyl-lH-pyraz»l-3-yl)-2-ethoxybenzaxnide; 82. N-(5-cyclopropyl-lH-pyrazol-3-yl)-3,4-dimethoxybenzamide; 83. N-(5-cyclopropyl-lH-pyrazol-3“yl)-2-phenylbutanamide; 84. N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-(trifluoromethoxy)benzamide; 85.3-chloro-N-(5-cyclopropyI-lH-pyrazol-3-yl)-l-benzothiophene-2-carboxamide; SUBSTITUTE SHEET (RULE 26)ΒΠΡΕΕάΑΕΙ WO 01/12189 1 2046 PCT/US00/06699 96 86.2- (4-chlorophenoxy)-N-(5-cyclopropyl-lH-pyrazol-3-yl)nicotinamide; 87.3- chloro-N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-thiophenecarboxamide; 88. N-(3-cyclopropyl- lH-pyrazol-5-yl)acetamide; 89. N-(3-cyclopropyl-1 H-pyra2©l-5-yl)benzamide; 90.4- chloro-N-(3-cyclopropyl- lH-pyrazol-5-yl)benzamide; 91. N-(3-cyclopropyl-lH-pyrazol-5-yl)-l-benzothiophene-2-carboxamide; 92. N-(3-cyclopropyl-1 H-pyrazol-5-yl)[ 1,1 ’-biphenylJ-4-carboxamide; 93. N-(3-cyclopropyHH-pyrazoI-5-yl)-3-phenylpropanamÎde;
94. Methyl 4-{[(3-cyclopropyl-lH-pyrazol-5-yl)amino]caibonyl}benzoate; 95.4- {[(3-cyclopropyHH-pyrazol-5-yl)amino]carbonyl}benzoic acid; 96. N-(3-cyclopropyl-lH-pyrazol-5-yl)-3-bromobenzamide; 97. N-(3-cyclopropyl- lH-pyrazol-5-yl)-3,4-dichlorobenzamide; 98. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-bromobenzamide; 99. N-(3-cyclopropyl-lH-pyrazol-5-yl)-3-methoxybenzamide; 100. N-(3-cyclopropyl-1 H-pyrazol-5-yl)-3-trifluoromethylbenzamide; 101. 4-butoxy-N-(3-cyclopropyl-lH-pyrazol-5-yl)benzamide; 102. N-(3-cyclopropyl-lH-pyrazol-5-yl)-lH-indole-2-carboxamide; 103. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-[5-(2,6-difluorobenzyl)-2-methoxyphenyl]acetamide; 104. N’-(3-cyclopropyl-lH-pyrazol-5-yl)therephthalamide. 105. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-4-(3,3-dimethylbutanoyl)-1 H-pyirole-2-carboxamide; 106. N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-(cyclopropylcarbonyl)-lH-pyirole-2-carboxamide; 107. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-4-(2-thienylcarbonyl)- lH-pyrrole-2-carboxamide; 108. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-4-(2-methylbenzoyl)-1 H-pytrole-2-caiboxamide; 109. 4-(l-benzothien-2-ylcafbonyl)-N-(5-cyclopropyl-lH-pyrazol-3-yl)-lH-pyïrole-2- carboxamide; 110. 2-[(4-acetylamino)phenyl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetainide; 111. 4-bromo-N-(5-cyclopentyl-lH-pyrazol-3-yl)benzamide; 112. 4-bromo-N-(5-cycloHexyl-lH-pyrazol-3-yl)benzamide; SUBSTITUTE SHEET (RULE 26) I 1 2046 WO 01/12189 PCT/US00/06699 97 113. N-[5-(2-benzylcyclopropyl)-lH-pyrazol-3-yl]4-bromobenzamide; 114. 4-bromo-N-(5-cyclobutyl-1 H-pyrazol-3-yl)benzamide; 115. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2,4-dimethoxybenzamide; 116. N-(5-cyclopropyl-lH-pyrazoI-3-yl)-4-(3-methylbenzoyl)-lH-pyrrole-2-carboxamide; 117. N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-(3-methylbutanoyl)-lH-pyrrole-2-carboxamide; 118. N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-(3-fluorobenzoyl)-lH-pyrrole-2-carboxamide; 119. N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-(2-fluorobenzoyl)-lH-pyrrole-2-caiboxamide; 120. 4-(cyclopentylcarbonyl)-N-(5-cyclopropyl-lH-pyrazol-3-yl)-lH-pyrrole-2-carboxaxnide; 121. N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-pentanoyl-lH-pyrrole-2-carboxamide; 122. 4-(3-chlorobenzoyl)-N-(5-cyclopropyl-1 H-pyrazol-3-yl)-1 H-pyrrole-2-carboxamide; 123. N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-(phenylacetyl)-lH-pyrrole-2-carboxamide; 124. N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-[(4-fluorophenyl)acetyl]-lH-pyrrole-2-carboxamide; 125. 4-butyiyl-N-(5-cyclopropyl-lH-pyrazol-3-yl)-lH-pyrrole-2-carboxamide; 126. N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-(4-fluorobenzoyl)-lH-pyrrole-2-carboxaniide; 127. 2-(4-bromophenyl)-N-(5-cyclopropyl-1 H-pyrazol-3-yl)-acetamide; 128. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(l -pyirolidinyl)phenyl]acetamide; 129. (2S)-N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-naphtyl)propanamide; 130. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4‘-(hydroxyinethyl)[l ,1 '-biphenyl]-4-yl)acetamide; 131. 3-tert-butyl-N-(5-cyclopropyl-1 H-pyrazol-3-yl)-1 -(2-thienylcarbonyl)-1 H-pyrazole-5-carboxamide; 132. N-(3-{[(3-cyclopropyl-lH-pyrazol-3-yl)amino3caibonyl}-2-thienyl)-2-thiophenecarboxamide; 133. N-(5-cyclopropyl-lH-pyrazol-3-yl)-5-(inethylsulfonyl)-2-thiopheiiecarboxaniide; 134. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-oxo-4-phenyl-3-butenamide; 135. N-5-cyclopropyl-lH-pyrazol-3-yl>2-[4-<3-thienyl)phenyl]acetamide; 136. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4’-fluoro[l ,1 ‘-biphenyl3-4-yl)acetamide; 137. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2,4-dimethyl-5-phenyl-1 H-pyrrole-3-carboxamide; SUBSTITÜTE SHEET (RULE 26) 1 2046 WO 01/12189 PCT/US00/06699 98 138. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2,5-dimethyl-l -(2-thienylmethyl)-l H-pyrrole-3-carboxamide; 139. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-methyl-5-phenyl-3-furainide; 140. N- {2-[(5 -cyclopropy 1-1 H-pyrazol-3-yl)amino]-2-oxoethy 1} benzamide; 141. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(2-naphtyl)acetamide; 142. 5-chloro-N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-thiophenecarboxamide; 143. 4'-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxethyl}[l.l'-biphenyl]-4-carboxylic acid; 144. 4'- {2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxethyl} [1,1 *-biphenyl]-4-carboxamide; 145. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(41-formyl[l,l'-biphenyl]-4-yl)acetamide; 146. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2- {4' -[(dimethylamino]methyl)[ 1,1' -biphenyl]-4-yl} acetamide; î 47. 2-amino-N-(4- {2-[(5-cyclopropyl-1 H-pyrazol-3-yl)ammo]-2- oxethyl}phenyl)acetamide; 148. 2-[4-aminomethyl)phenyl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; 149. 2- [4'-(aminomethyl)[ 1,1 '-biphenyl]-4-yl]-N-(5 -cyclopropyl-1 H-pyrazol-3-yl)acetamide; 150. N-(5*cyclopropyl-l H-pyrazol-3-yl)-2- {4'-[(methylamino)methyl][ 1, l'-biphenyl]-4-yl} acetamide; 151. N-(5-cyclopropyHH-pyrazol-3-yl)-2-[4’-(l-pytrolidinylmethyl)[l,r-biphenyl]-4- yl]acetamide; ’ * 152. N-(5-Cyclopropyl-1 H-pyrazol-3-yl)-2-[4'-(l -piperidinylmethyl)[ 1,1 ’-biphenyl]-4-yljacetamide; 153. N-(5-cyclopropyl-l H-pyrazol-3-yl)-2-[4'-(4-moipholinylmethyl)[ 1 ,l'-biphenylJ-4-yljacetamide; 154. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-{4'-[(4-methyl-l-piperazinyl)methyl][l,l'-biphenyl]-4-yl} acetamide; 155. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-[4’-( 1 H-imidazol-2-yl)[ 1,1 '-biphenyl]-4-yljacetamide; SUBSTITUTE SHEET (RULE 26) swacm 1 2046 WO 01/12189 PCT/US00/06699 99 · 156. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-{[(dimethylamino)carbonyl]amino}phenyl)acetamide; 157. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2- {4-[(methylsulfonyl)amino]phenyl} acetamide; 158. 2-[4-(aminomethyl)phenyl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; 159. 2-{4-((acetylamino)methyl]phenyl}-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; 160. 2-[4-(aminosulfonyl)phenyl]-N-(5-cyclopropyl-lH-pyra2»l-3-yl)acetaniide; 161. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(2-oxo-l-pyrTolidinyl)phenyl]acetamide; 162. N-(3-cyclopropyl-lH-pyrazol-5-yl)-4-(2-methoxyphenoxy)benzamide; 163. 4-(4-chlorophenoxy)-N-(3-cyclopropyl-lH-pyrazol-5-yl)benzamide; 164. 4-(4-chlorophenoxy)-N-(3-cyclopropyl-lH-pyrazol-5-yl)-3-nitrobenzamide; 165. 4-[3,5-bis(trifluoromethyl)ph«aoxy)-N-(3-cyclopropyl-lH-pyrazol-5-yl)benzamide; 166. N-(3-cyclopropyl- lH-pyrazol-5-yl)-4-(4-fluorophenoxy)bertzamide; 167. N-(3-cyclopropyl- lH-pyrazol-5-yl)-4-(4-methylphenoxy)benzamide; 168. 4-(4-cyanophenoxy>N-(3-cyclopropyl-1 H-pyrazol-5-yl)benzamide; 169. N-(3-cyclopropyl- lH-pyrazol-5-yl)-4-(4-hydroxyphenoxy)benzamide; 170. N-(3-cyclopropyl-1 H-pyrazol-5-yl)-4-(3-hydroxyphenoxy)benzamide; 171. 2-[l,r-biphenyl]-4-yl-N-(3-cyclopropyl-lH-pyrazol-5-yl)propanamide; 172. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(4-phenoxyphenyl)acetamide; 173. N-(3-cyclopropyl-lH-pyrazol-5-yl)-3,5-diiodo-4-(4-methoxyphenoxy)benzamide; 174. N-(3-cyclopropyl-1 H-pyrazol-5-yl)-4-[3-(hydroxymethyl)phenyl]-3-butenamide; 175. N-(3-cyclopropyl-lH-pyrazol-5-yl)-4-{3-[(methylamino)methyl]phenyl}-3-butenamide; 176. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(2-phenylcyclopropyl)acetamide; 177. 2-(2-(1,3-benzodioxol-5-yl)cyclopropylJ-N-(3-cyclopropyl- lH-pyrazol-5-yl)acetamide; 178. 2-(3-(1,3-benzodioxol-5-yl)-2,2-difluorocyclopropyl]-N-(3-cyclopropyl-lH-pyrazol- 5-yl)acetamide; 179. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(2,2-dxfluoro-3-phenylcyclopropyl)acetamide; 180. N-(3-cyclopropyl-l H-pyrazol-5-yl)-2-(5-methyl-4-phenyl-3-isoxazolyl)acetamide; 181. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(5-methyl-3-phenyl-4-isoxazolyl)acetamide; SUBSTITUTE SHEET (RULE 26) 1 2046 WO 01/12189 PCT/US00/06699 100 182. 2-(3-(1,3-benzodioxol-5-yl)-5-methyl-4-isoxazolylj-N-(3-cyclopropyl-1 H-pyrazol-5-yl)acetamide; 183. 2-(4-( 1,3-benzodioxol-5-yl)-5-methyl-3-isoxazolyl]-N-(3-cyclopropyl-1 H-pyrazol-5-yl)acetamide; 184. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3-phenyl-2-oxiranyl)acetamide; 185. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-[2-(4-fluorophenyl)cyclopropyl]acetamide; 186. N-(3-cyclopropyl-1 H-pyrazol-5-yl)-2-[2,2-difluoro-3-(3-fluorophenyl)cyclopropyl]acetamide; 187. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(2-oxo-2,3-dihydro-lH-indol-5-yl)acetamide; 188. 2-[4-(acetylamino)phenyl]-N-(3-cyclopropyl-lH-pyrazol-5-yl)acetamide; 189. N-(4- {2-[(3-cyclopropyl-1 H-pyrazol-5-yl)amino]-2-oxoethyl} phenyl)-1 -pyirolidinecaiboxamide; 190. N-(4-{2-[(3-cyclopropyl-lH-pyrazol-5-yl)amino]-2-oxoethyl}phenyl)-l-piperidinecarboxamide; 191. N-(4- {2-[(3-cyclopropyl- lH-pyrazol-5-yl)amino]-2-oxoethyl} phenyl)-4-moipholinecarboxamide; 192. N-(4-{2-[(3-cyclopropyl-lH-pyrazol-5-yl)amino]-2-oxoethyl}phenyl)-4-methyl-l-piperazinecaxboxamide; 193. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(2-pyridinyl)acetamide; 194. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(3-pyridmyl)acetamide; 195. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(4-pyridinyl)acetamide; 196. N-(3-cyclopropyl-1 H-pyrazol-5-yl)-5-(3-rûtrophenyl)-2-furamide; 197. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(2,5-dioxo-4-imidazolidinyl)acetamide; 198. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(9-oxo-9H-fluoren-2-yl)acetamide; 199. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-(4’-ethyl[ 1,1 '-biphenyl]-4-yl)acetamide; 200. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-(4’-propyl[ 1,1 '-biphenyl]-4-yl)acetamide; 201. N-(5-cyclopiopyl-lH-pyrazol-3-yl)-2-(9H-fluoren-2-yl)acetamide; 202. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(9-methyl-9H-fluoren-2-yl)acetamide; 203. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(2-hydroxydibenzo[b,d]ftiran-3-yl)acetamide; 204. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(4'-hydroxy[ 1,1 ’-biphenyl]-4-y l)acetamide; 205. 2-(4’-cyano[ 1,1 ’-biphenyl]-4-yl)-N-(5-cyclopropyl- lH-pyrazol-3-yl)acetamide; SUBSTITUTE SHEET (RULE 26) umicASÀ 1 2046 WO 01/12189 PCT/US00/06699 101 206. 2-(4'-bromo[ 1,1 ’-biphenyl]-4-yl)-N-(5-cyclopropyl-1 H-pyrazol-3-yl)acetamide; 207. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4'-propoxy[ 1,1 '-biphenyl]-4-yl)acetamide; 208. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4'-butoxy[l,l'-biphenyl]-4-yl)acetamide; 209. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4'-pentoxy[l,r-biphenyl]-4-yl)acetamide; 210. 4’- {2-[(5-cyclopropyl-1 H-pyrazol-3-yl)amino]-2-oxoethyl} [1,1 *-biphenyI]-4-ylacetate; 211. 2-(4’-tert-butyl[ 1,1 ’-biphenyl]-4-yl)-N-(5-cyclopropyl-1 H-pyrazol-3-yl)aeetamide; 212. N-(5-cyclopropyHH-pyrazol-3-yl)-2-(3',4'-dichloro[l,r-biphenyl3-4-yl)acetamide; 213. N-(5-cyclopropyl-lH-pytazol-3-yl)-2“(3’-hydroxy[l,r-biphenyl]-4-yl)acetainide; 214. 2-(3 ’-bromop, 1 ’-biphenyl]-4-yl)-N-(5-cyclopropyl- lH-pyrazol-3-yl)acetamide; * 215. 2-(3’-aniino[l,r-biphenyl]-4-yl)-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetaraide; 216. 2-(4’-amino[ 1,1 '-biphenyl]-4-yl)-N-(5-cyclopropyl- lH-pyrazol-3-yl)acetamide; 217. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(3-hydroxy-2-naphthyl)acetamide; 218. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-(3,5-dihydroxy-2-naphthyl)acetamide; 219. 2-(3-amino-2-naphthyl)-N-(5-cyclopropyl-1 H-pyrazol-3-yl)acetamide; 220. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-(6-hydroxy-2-naphthyl)acetamide; 221. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-hydroxy-l-naphthyl)acetamide; 222. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(6-hydroxy-l-naphthyl)acetamide; 223. 3-amino-N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-[(2-fiuylmethyl)sulfonyl]-2-thiophenecarboxamide; 224. 3-amino-4-[(4-chlorophenyl)sulfonyl3-N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-thiophenecarboxamide; 225. 3-amino-N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-(phenylsulfonyl)-2-thiophenecarboxamide; 226. 3-chloro-N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-(methylsulfonyl)-2-thiophenecarboxamide; 227. 3-amino-N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-(isopropylsulfonyl)-2-thiophenecarboxamide; 228. 3-amino-N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-(propylsulfonyl)-2-thiophenecarboxamide; SUBSTITUTE SHEET (RULE 26)DUPLICATA 1 2046 WO 01/12189 PCT/US00/06699 102 229. 3-chloro-N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-(isopropylsulfonyl)-2-thiophenecarboxamide; 230. N-(5-cyclopropyl-lH-pyrazol-3-yl)-4-(isopropylsiilfonyl)-2-thiophenecarboxamide; 231. 4- {2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}benzamide; 232. 4'-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}-N-[2-(l-pyirolidinyl)ethyl][ 1,1 '-biphenyl]-4-carboxamide; 233. 4’-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}-N-[2-(l-pyrrolidinyl)propyl] [1,1 ’-biphenyl]-4-carboxamide; 234. 4'- {2-[(5-cyclopropyl- lH-pyrazol-3-yl)aniino]-2-oxoethyl} -N-[2-( 1 -piperidinyl)ethyl][ 1, l’-biphenyl]-4-carboxamide; 235. 4’-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}-N-[2-(l-piperidinyl)propyl] [1,1 *-biphenyl]-4-carboxamide; 236. 4’-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}-N-[2-(4-morpholinyl)ethyl][l,r-biphenyl]-4-carboxamide; 237. 4*-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}-N-[2-(4-morpholinyl)propyl][l, l'-biphenyl]-4-carboxamide; 238. 4'-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}-N-[2-(4-methyl-l-piperazinyl)ethyl] [1,1 *-biphenyl]-4-carboxamide; 239. 4'- {2-[(5-cyclopropyl- lH-pyrazol-3-yl)amino]-2-oxoethyl} -N-[2-(4-methyl-1 -piperazinyl)propyl][ 1,1 '-biphenyl]-4-carboxamide; 240. N-(3-cyclopropyl- lH-pyrazol-5-yl)-4-(3,4-dimethyIbenzoyl)-1 H-pyirole-2-carboxamide; 241. N-(3-cyclopropyl-1 H-pyrazol-5-yl)-4-(4-fluorobenzoyl)-1 H-pyrrole-2-carboxamide; 242. N-(3-cyclopropyl-lH-pyrazol-5-yl)-4-(4-methylbenzoyl)-lH-pyrrole-2-carboxamide; 243. 4-(4-chlorobenzoyl)-N-(3-cyclopropyl-lH-pyrazol-5-yl)-lH-pyrrole-2-carboxamide; 244. 4-(cyclohexylcarbonyl)-N-(3-cyclopropyl-1 H-pyrazol-5-yl)- lH-pyrrole-2-carboxamide; 245. methyl 5-(5-{[(3-cyclopropyl-lH-pyra2»l-5-yl)amino]carbonyl}-lH-pyrrol-3-yl)-5-oxopentanoate 246. 4-acetyl-N-(3-cyclopropyl-l H-pyrazol-5-yl)-1 H-pyirole-2-carboxamide; SUBS’ïïKâSüt«ÊJ'(RULE 26) 1 2046 WO 01/12189 PCT/US00/06699 103 247. N-(3-cyclopropyl-lH-pyrazol-5-yl)-4-(2,6-dimethoxybenzoyl)-lH-pyrrole-2-carboxamide; 248. N-(3-cyclopropyl-1 H-pyrazol-5-yl)-1 H-pyrrole-2-carboxamide; 249. N-(3-cyclobutyl-lH-pyrazol-5-yl)-lH-pyrrole-2-carboxamide 250. N-(3-cyclopropyl-1 H-pyrazol-5-yl)-1 -methyl-1 H-pynOle-2-carboxamide; 251. 4-bromo-N-(3-cyclopropyl-lH“pyrazol-5-yl)-lH-pytTole-2-carboxaxnide; 252. N-(3-cyclopropyl-lH-pyrazol-5-yl)-l-methyl-4-(3-methylbenzoyl)-lH-pyrrole-2-carboxamide; 253. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-quinoxalinecarboxamide; 254. (lR,2R)-N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-phenylcyclopropanecarboxamide; 255. N-(3-cyclopropyl-iH-pyrazol-5-yl)-2-phenylcyclopropanecarboxamide; 256. 3-chloro-N-(3-cyclopropyl- lH-pyrazol-5-yl)-2-thiophenecarboxamide; 257. 4-benzoyl-N-(3-cyclopropyl-lH-pyrazol-5-yl)benzamide; 258. (2S)-N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(6-methoxy-2-naphthyl)propanamide; 259. N-(3-cyclopropyl-lH-pyrazol-5-yl)-4-morpholinocarboxamide; 260. (2S)-N-(3-cyclopropyHH-pyrazol-5-yl)-3,3,3-trifluoro-2-methoxy-2-phenylpropanamide; 261. (2S)-N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-methoxy-2-phenylethanamide; 262. 2-[5-(benzyloxy)-lH-mdol-3-yl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; 263. N-(5-cyclopropyl-lH-pyrazol-3>yl)-2-(5-methoxy-2-methyl-lH-mdol-3-yl)acetamide; 264. (2S)-N-(3-cyclopropyl-lH-pyrazol-5-yl)-2,5-dihydro-lH-pyrrole-2-carboxamide; 265. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2,5-difluorophenyl)acetamide; 266. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(5-hydroxy-lH-indole-3-yl)acetamide; 267. 2-[ 1 -(4-chlorobenzoyl)-5-methoxy-2-methyl-1 H-indol-3-yl]-N-(5-cyclopropyl-1H-pyrazol-3-yl)acetamide; 268. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3-methylphenyl)acetamide; 269. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3-hydroxyphenyl)acetamide; 270. (2S)-2-amino-N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-phenylethanamide; 271. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-(4-nitrophenyl)propanamide; 272. N-(5-cyclopropyl-lH>pyrazol-3-yl)-2-(4-hydroxy-3-methoxyphenyl)acetamide; 273. N-(5-cyclopropyI-lH-pyrazol-3-yl)-2-[3,5-bis(trifluoromethyl)pheny]lacetaxnide; SUBSTITUTE SHEET {RULE 26) I 12046 WO 01/12189 PCT/US00/06699 • »V# WW V I wwfc.fc.www 104 274. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-chloro-6-fluorophenyl)acetamide; 275. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-hydroxy-2-(4-hydroxy-3-methoxyphenyl)acetamide; 276. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2- {4-[(2S)-2-aminopropanoyloxymethyl]phenyl}acetamide; 277. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-bromomethylphenyl)acetamide; 278. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-methylsulphonylphenyl)acetamide; 279. (2R)-N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-methoxy-2-phenylethanamide; 280. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(2-methylphenyl)acetamide; 281. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[2-(fonnylamino)-l ,3-thiazol-4-yl]-2-(methoxyimino)ethanamide; 282. 2-[5-(chloroacetyl)-2-thienyl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; 283. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-oxo-2-(2-thienyl)acetamide; 284. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-methyl-lH-indol-3-yl)acetamide; 285. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(3,5-dimethoxyphenyI)acetamide; 286. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3,4-difluorophenyl)acetamide; 287. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3,4-dichlorophenyl)acetamide; 288. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3-bromophenyl)acetamide; 289. 2-cyclohexyl-N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-phenylacetamide; 290. (lR)-2-[(3-cyclopropyl- lH-pyrazol-5-yl)amino]-2-oxo-1 -phenylethyl acetate; 291. 2-chloro-N-(5- {2-[(5-cyclopropyHH-pyrazol-3-yl)amino]-2-oxoetiiyl} -1,3-thiazol-2-yl)acetamide; 292. 9H-fluoren-9-yl(2S)-2-{[(3-cyclopropyl-lH-pyrazol-5-yl)amino]carbonyl}-2,5-dihydro-1 H-pyirole-1 -carboxylate; 293. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-hydroxy-2-diphenyl)acetainide; 294. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-methylsulfanylphenyl)acetamide; 295. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-bromophenyl)acetamide; 296. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2,6-dihydroxy-4-pyrimidinyl)acetamide; 297. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-hydroxy-3-nitrophenyl)acetamide; 298. N-(5-cyclopropyl-lH-pyrazol-3-yl>2-(3-chloro-4-hydroxyphenyl)acetamide; 299. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(7-methoxy-2-oxo-2H-chromen-4-yl)acetamide; SUBSTITUTE SHEET (RULE 26) 1 2046 WO 01/12189 PCT/US00/06699 105 300. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-acetylamino-2-phenyl)acetamide; 301. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(l-methylimidazol-4-yl)acetamide; 302. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3-nitrophenyl)acetamide; 303. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-bromo-2-phenyl)acetamide; 304. N-(5-cyclopropyl-lH-pyra2»l-3-yl)-2-(4-benzyloxy-3-methoxyphenyl)acetamide; 305. (2S)-N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-hydroxy-2-phenylethanamide; 306. l-(4-chlorophenyl)-N-(5-cyclopropyl-lH-pyrazol-3-yl)cyclopentanecarboxainide; 307. N-(5-cyclopropyl-lH-pyraajl-3-yl)-2-(3-trifluoromethylphenyl)acetamide; 308. N-(5-cyclopropyl-lH-pyra2»l-3-yl>2-(lH-Îndol-3-yl)-2-oxoacetamide; 309. N-(5-cyclopropyl-lH-pyrazol-3-yl>2-(2,4-<lichlorophenyl>acetamide; 310. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(3,4-dihydroxyphenyl)acetamide; 311. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(3,5-di-tert-butyl-4-hydroxyphenyl)acetamide; 312. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3,5-difluorophenyl)acetainide; 313. N-(5-cyclopropyl-lH-pyra2»l-3-yl)-2-benzyloxycarbonyl-2-phenylacetanùde; 314. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3-methyl-l-ben2»thien-2-yl)acetamide; 315. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-butoxyphenyl)acetaniide; 316. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-thienyl)acetamide; 317. N-(5-cyclopropyl- lH-pyra2»l-3-yl)-2-(3-fluorophenyl)acetamide; 318. 5-cyélohexyl l-(4-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}benzyl) 2-aminopentanedioate; 319. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-isobutylphenyl)pfopanamide; 320. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(7-hydroxy-2-oxo-2H-chromen-4-yl)acetamide; 321. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-hydroxyphenyl)acetamide; 322. 2-cyclopentyl-N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-phenylacetamide; 323. (lS)-2-[(3-cyclopropyl-lH-pyrazol-5-yl)amino]-2-oxo-l-phenylethyl acetate; 324. N-(3-cyclopropyl-lH-pyra2»l-5-yl)-2-fluoro-2-phenylacetamide; 325. N-(5-cyclopropyl-lH-pyraz»l-3-yl)-2-(2-fiuyl)-2-oxoacetainide; 326. N-(5-cyclopropyl-1 H-pyra2»l-3-yl)-2-(5-broino-1 H-indol-3-yl)acetamide; 327. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-trifluoromethyIphenyl)acetainide; 328. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-methoxyphenyl)acetamide; 329. N-(5-cyclopropyl-lH-pyra2ol-3-yl)-2-(3,4,5-trimethoxyphenyl)acetamide; SUBSTITÜTE SHEET (RULE 26) WPUCÀÎA 1 2046 WO 01/12189 , PCT/USOO/06699 106 330. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2,5-dioxo-2,5-dihydro-3-fiiranyl)acetamide; 331. 2-chloro-2,2-bis(2-chlorophenyl)-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; 332. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-hydroxy-2-(3-hydroxy-4-methoxyphenyl)acetamide; 333. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(pentafluorophenyl)acetamide; 334. N-(3-cyclopropyl-lH-pyrazol-5-yl)-3-methyl-2-phenylpentanamide; 335. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-nitrophenyl)acetamide; 336. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-1 -phenylcyclopentane-1 -carboxamide; 337. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-trifluoromethoxyphenyl)acetamide; 338. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-ethoxyphenyl)acetamide; 339. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-fluorophenyl)acetamide; 340. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(2-nitro-4-trifluoromethylphenyl)acetamide; 341. 2-(5-bromo-3-pyridinyl)-N-(5-cyclopropyl- lH-pyrazol-3-yl)acetamide; 342. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(2,6-dichlorophenyl)acetamide; 343. N-(5-cyclopropyl-lH-pyrazol-3-yl)- 2-oxo-2H-pyran-5-carboxamide; 344. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(2,4-dinitrophenyl)acetamide; 345. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2,4-difluorophenylacetamide; 346. N-(5-cyclopropyl-1 H-pyra2»l-3-yl)-2-(3-bromo-4-methoxyphenyl)acetamide; 347. N-(5-cyclopropyl-lH-pyrazol-3-yl)-3-hydroxy-2-phenylpropanamide; 348. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3-fluoro-4-hydroxyphenyl)acetamide; 349. 2-{2-[(chloroacetyl)amino]-l,3-thiazol-5-yl}-N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(methoxyimino)ethanamide; 350. N-(5-cyclopropyl-lH-pyrazol-3-yl)-l-phenylcyclopropanecarboxamide; 351. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2,6-difluorophenyl)acetamide; 352. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(2,5-dÎhydroxyphenyl)acetamide; 353. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2,4,6-triniethylphenyl)acetaxnide; 354. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[2,5-bis(trifluoromethyl)phenyl]acetamide; 355. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[2-(2,4-difluorophenyl)-l,3-thiazol-4-yl]acetamide; 356. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(5-methoxy-3-hydroxy-2-propylphenyl)acetamide; SUBSTITUTE SHEET (RULE 26)flUPLICATA 1 2 046 WO 01/12189 PCT/US00/06699 107 357. N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(2-fluoro[l,r-biphenyl]-4-yl)propanamide; 358. (2R)-N-(3-cyclopropyl-lH-pyrazol-5-yl)-2-(2-fluoro[l,r-biphenyl]-4-yl)propanamide;; 359. 2-{4-[(aminocarbonyl)amino]phenyl}-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; 360. 2- {4-[(2-amino-2-oxoethyl)amino]phenyl} -N-(5-cyclopropyl- lH-pyrazol-3-yl)acetamide; 361. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(5-methyl-2-phenyl-l,3-tbiazol-4-yl)acetamide; 362. 4-brorao-N-(4-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}-l,3-thiazol-2-yl)benzamide 363. 2-[2-(4-chlorophenyl)-4-hydroxy-l,3-thiazol-5-yl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; 364. N-(4-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}-l,3-thiazol-2-yl)-2-(2-pyridinylsulfanyl)acetamide; 365. N-(4-{2-[(5-cyclopropyHH-pyrazol-3-yl)amino]-2-oxoethyl}-l,3-thiazol-2-yl)-2-(isopropylsulfanyl)acetamide; 366. 2-(5-{[(4-chlorophenyl)sulfànyl]acetyl}-2>thienyl)-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; 367. 2-(5-chloro-3-methyl-l-benzothien-2-yl)-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; 368. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-iodophenyl)acetaniide; 369. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-9H-xanthene-9-carboxamide; 370. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-phenyl-l,3-thiazol-4-yl)acetamide; 371. 2-[2-(4-chlorophenyl)-5-methyl-l,3"thiazol-4-yl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; 372. N-(4-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}-l,3-thiazol-2-yl)benzamide; 373. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(6-methoxy-2-naphthyl)acrylamide; 374. N-(5-cycIopropyl- lH-pyrazol-3-yl)-2-(2-hydroxyphenyl)acetamide; 375. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2,3-di(2-thienyl)-2-propenamide; 376. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[2-(2-pyrazinyl)-l,3-thiazol-4-yl]acetamide; 377. N-(5-cyclopiOpyî-lH-pyrazol-3-yl)-2-(2,5-dibromo-3-thienyl)acetamide; SUBSTITUTE SHEET (RULE 26)DUPLICATA 17046 WO 01/12189 PCT/US00/06699 108 378. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3-methylsulfonylaminophenyl)acetamide; 379. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-inethylsulfonylaminophenyl)acetainide; 380. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2- {4-[2-(4-methyl-1 -piperazinyl)ethoxy]phenyl} acetamide; 381. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-{4-[2-(l-pyrrolidinyl)ethoxy]phenyl}acetamide; 382. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-{4-(2-amino-2-oxoethoxy)phenyl}acetamide; 383. N-(5-cyclopropyl-lH-pyrazol-3-yl)- 2-{4-[2-oxo-2-(l-pyrrolidinyl)ethoxy]phenyl} acetamide; 384. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[3-(2-amino-2-oxoethoxy)phenyl]acetamide; 385. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-phenoxyacetamide; 386. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2,4-dichlorophenoxy)acetamide; 387. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-phenoxy-2-methylpropanamide; 388. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-chlorophenoxy)propanamide; 389. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2-nitrophenoxy)acetamide; 390. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(5-isopropyl-2-methyl-1 H-indol-3-yl)acetamide; 391. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3-methoxyphenyl)acetamide; 392. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-methyl-2-(2-methyl-2,3-dihydro-l-benzofuran- 5-yl)propanamide; 393. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-[2-(4-methoxyphenyl)-4-oxo-4H-chromen-6-yljacetamide; 394. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(6-chloro-2,3-dihydro-1 H-inden-3-yl)butanamide; 395. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(l-oxo-l,3-dihydro-2H-isoindol-2-yl)phenyl]hexanamide; 396. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-phenyl-3-(4-pyridinyl)propenamide; 397. 2-[ 1,1 '-biphenyl]-4-yl-N-(5-cyclopropyl-1 H-pyrazol-3-yl)butanamide; 398. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(l ,3-dihydro-2H-isoindol-2- , yl)phenyl]propanamide; 399. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-[4-( 1 -oxo-1,3-dihydro-2H-isoindol-2-yl)phenyl]butanamide; SUBSTITUTE SHEET (RULE 26) MMHMI 1 2046 WO 01/12189 PCT/US00/06699 109 400. N-(5-cyclopropyl-lH-pyrazol-3-yl)-(2S)-2-[4-(l-oxo-l,3-dihydro-2H-isoindol-2-yl)phenyl]propanamide; 401. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-[4-(5-amino-4-phenyl- 1H-1,2,3-triazol-1 -yl)phenyl]acetamide; 402. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(l-oxo-l,3-dihydro-2H-isoindol-2-yl)phenyl]pentanamide; 403. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-benzyloxyphenyl)acetamide; 404. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2- {4-((3,3-diethyl-4-oxo-2-azetidinyl)oxy]phenyl) acetamide; 405. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(5,6-dimethyl-lH-benzimidazol-l-yl)acetamide; 406. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-pyridylsulfanyl)acetamide; 407. N-(5-cyclopropyl-lH-pyraz»l-3-yl)-2-(lH-tetrazol-l-yl)acetamide; 408. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(tetrazolo[l ,5-b]pyridazin-6-ylsulfanyl)acetamide; 409. 2-[l,r-biphenyl3-4-yl-N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-hydroxyacetamide; 410. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-cyclohexene-1 -carboxamide; 411. N-(5-cyclopropyl-lH-pyrazoI-3-yl)-2-oxo-2H-pyran-4-carboxamide; 412. N-(5-cyclopropyl-lH-pyrazol-3-yl)-3-bromo-2,2-diphenylpropananiide; 413. N-(5-cyclopropyl-lH-pyrazol-3-yl)-4,4-bis(4-methylphenyl)-3-butenamide; 414. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-hydroxy-5-isopropyl-2-methylphenyl)acetamide; 415. N-(5-cyclopropyl-lH-pyrazoI-3-yl)-2-(4-nitrophenyl)-2-butenaniide; 416. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-(3,4-dihydro-1 -naphthyl)butanamide; 417. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(2,3,6-trifluorophenyl)acetamide; 418. N-(3-cyclopropyl-lH-pyrazol-5-yl)-l,4-benzodioxine-2-carboxainide; 419. N-(3-cyclopropyl-lH-pyrazol-5-yl)-3-phenyl-l,4-benzodioxine-2-carboxamide; 420. N-(3-cyclopropyl-lH-pyraz»l-5-yl)-4-oxo-4H-chromene-2-carboxainide; 421. N-(3-cyclopropyl- lH-pyrazol-5-yl)-2-oxo-1,2-dihydro-4-quinolinecarboxamide; 422. 2-anilino-N-(3-cyclopropyl-lH-pyrazol-5-yl)acetainide; 423. N-(5-cyclopropyl-l H-pyrazol-3-yl)-2-(4’-fluoro[ 1,1 '-biphenyl]-4-yl)acetamide 424. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(2’-fluoro( 1,1 '-biphenyl]-4-yl)acetamide SUBSTITUTE SHEET (RULE 26) WUUb 12046 WO 01/12189 PCT/US00/06699 110 425. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3’-fluoro[l>r-bÎphenyl]-4-yl)acetamide 426. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(3’-methoxy[ 1,1 '-biphenyl]-4-yl)acetamide 427. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(pentafluoro[l,r-biphenyl]-4-yI)acetamide 428. N-(5-cyclopropyl-l H-pyrazol-3-yl)-2-(4’-(trifluoromethoxy)[ 1,1 '-biphenyl]-4-yl)acetamide 429. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4’-carboxy[l,r-biphenyl]-4-yl)acetamide 430. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(3 ’-formyl-4’-methoxy[ 1,1 '-biphenyl]-4-yl)acetamide 431. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-(4’-fluoro-3 ’-methyl[ 1,1 ’-biphenyl]-4-yl)acetamide 432. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2’,5’-dichloro[l, 1 '-biphenyl]-4-yl)acetamide 433. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3 ’-acetyl[ 1,1 ’-biphenyl]-4-yl)acetamide 434. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(4’-formyl[ 1,1 ’-biphenyl]-4-yl)acetamide 435. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2’,5’ difluoro[l,l'-biphenyl]-4-yl)acetamide 436. N-(5-cyclopropyHH-pyrazol-3-yl)-2-(2’,5’-dimethyl[l,r-biphenyl]-4-yl)acetamide 437. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2’,6-difluoro[l,r-biphenyl]-4-yl)acetamide 438. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4’-methoxy[l,r-biphenyl]-4-yl)acetamide 439. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2’,6-dimethyl[l,r-biphenyl]-4-yl)acetamide 440. N-(5-cyclopropyl-l H-pyrazoI-3-yl)-2-(5 ’-fluoro-2 ’-methoxy[ 1,1 ’-biphenyl]-4-yl)acetamide 441. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(2’,5 ’-dimethoxy[ 1,1 '-biphenyl]-4-yl)acetamide 442. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(2’,6-dimethoxy[ 1,1 '-biphenyl]-4>yl)acetamide 443. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4’-acetyl-[l,r-biphenyl]-4-yl)acetamide 444. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4’-ethoxy-[l,r-biphenyl]-4-yl)acetamide 445. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-((4’-methylthio)-[ 1,1 '-biphenyl]-4-yl)acetamide 446. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-(3 ’-chloro-4’-fluoro-[ 1,1 '-biphenyl]-4-yl)acetamide 447. N-(5~cydopropyl- lH-pyrazol-3-yl)-2-(2’-acetyl-[ 1,1 '-biphenyl]-4-yl)acetamide 448. N-(5-cyclopropyl-lH-pyra2ol-3-yl)-2-(4’-ethyl-[l,r-biphenyl]-4-yl)acetamide T 449. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-(3 ’-ethoxy-[ 1,1 '-biphenyl]-4-yl)acetamide SUBSTITÜTE SHEET (RULE 26) miem 1 2046 WO 01/12189 PCT/US00/06699 .111 450. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3’,4’-dimethoxy-[l,r-biphenyl]-4-yl)acetamide 451. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(2 ’-ethoxy-[ 1,1 '-biphenyl]-4-yl)acetamide 452. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3’,5’-difluoro-[l,r-biphenyl]-4-yl)acetainide 453. N-(5-cyclopropyl-lH-pjnrazol-3-yl>2-(2’,4’-dimethoxy-[l,l'-biphenyl]-4-yl)acetamide 454. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2’,3’-dimeihyI-[l,l'-biphenyl]-4-yl)acetamide 455. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(3 ’-(trifluoromethoxy)[ 1,1 '-biphenyl]-4-yl)acetamide 456. N-(5-cyclopropyI-lH-pyrazol-3-yl)-2-(3’,4’-difluoro-[l,r-biphenylJ-4-yl)acetamide 457. N<5-cyclopropyl-lH-pyrazol-3-yl)-2-(4’-tert-butyl-[l,r-biphenyl]-4-yl)acetarnide 458. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3’-acetaraido[l,r-biphenyl]-4-yl)acetamide 459. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(4’-trifluoromethyl-[ 1,1 '-biphenyl]-4-yl)acetamide 460. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(3 ’-(hydroxymethyl)[ 1,1 ’-biphenyl)-4-yl)acetamide 461. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3’-nitro-[l,r-biphenyl]-4-yl)acetamide 462. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4’-(hydroxymethyl)[l,l'-biphenyl]-4-yl)acetamide 463. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2’-çhloro-[l,r-biphenyl]-4-yl)acetamide 464. 2-(4-(1,3-benzodioxol-5-yl)phenyl]-N-(5-cyclopropyl- lH-pyrazol-3-yl)acetamide; 465. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(l-naphthyl)phenyl]acetamide; 466. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-[4-(2-naphthyl)phenyl]acetamide; 467. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(2-furyl)phenyl]acetaniide; 468. 2-[4-(5-acetyl-2-thienyl)phenyl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; 469. 2-[4-(5-chloro-2-thienyl)phenyl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; 470. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-(5-mefliyl-2-thienyl)phenyl]acetamide; 471. 2-[4-(l-benzofuran-2-yl)phenyl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetajnide; 472. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-(2-thienyl)phenyl]acetainide; 473. N-(5-cycIopropyl-lH-pyrazol-3-yl)-2-[3'-({[5-(dimethylamino)-l-naphthyl]sulfonyl}amino)[l,l'-biphenyl]-4-yl]acetamide; *»►* SUBSTITUTE SHEET (RULE 26) ÛSPLÏCAÏA 1 2046 WO 01/12189 PCT/US00/06699 112 474. 2-[4-( 1 -benzothien-2-yl)phenyl]-N-(5-cyclopropyl-1 H-pyrazol-3-yl)acetamide; 475. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(3-formyl-2-thienyl)phenyl]acetaniide; 476. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(3“formyl-2-thienyl)phenyl]acetamide; 477. 5-(4-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}phenyl)-2-ftiroic acid; 478. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(3-methyl-lH-pyrazol-4-yl)phenyl]acetamide; 479. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(3,5-dimethyl-lH-pyrazol-4-yl)phenyl]acetamide; 480. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-[4-(3-furyl)phenyl]acetamide; 481. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(5-formyl-3-thienyl)phenyl]acetamide; 482. [5-(4-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino)-2-oxoethyl}phenyl)-lH-indol-3-yljacetic acid; 483. 5-(4-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}phenyl)tryptophan; 484. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(2-pyridinyl)phenyl]acetamide; 485. l-acetyl-5-(4-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)ammo]-2-oxoethyl}phenyl)-lH-indol-3-yl acetate; 486. 2-[4-(2-amino-4-hydroxy-6-methyl-5-pyrimidinyl)phenyl]-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; 487. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(5-pyrimidmyl)phenyl)acetamide; 488. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(2-pyridmyl)phenyl]acetainide; 489. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(5-nitro-2-pyridinyl)phenyl]acetamide; 490. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(6-ainino-3-pyridinyl)phenyl]acetamide; 491. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(3-pyridinyl)phenyl]acetamide; 492. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(3-quinolinyl)phenyl]acetamide; 493. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(4-isoquinolmyl)phenyl]acetaniide; 494. 5-(4-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}phenyl)nicotinicacid; 495. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(2-amino-5-pyrimidinyl)phenyl]acetamide; 496. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(4-pyridinyl)phenyl]acetamide; 497. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-[4-(5-acetyl-2-thienyl)phenyl]acetamide; 498. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(9H-purin-6-yl)phenyl]acetamide; 499. 2-[4-(l-benzoliiien-3-yl)phenyl]-N-(5-cyclopropyl-lH-pyra2ol-3-yl)acetamide; SUBSTITUTE SHEET (RULE 26)WMOÀSÀ 1 2 04 6 WO 01/12189 PCT/US00/06699 113 500. 5-(4-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}phenyl)-lH-indol-3-ylacetate; 501. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(2,4-dimethoxy-5-pyritnidinyl)phenyl]acetamide; 502. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(2-chloro-3-thienyl)phenyl]acetamide; 503. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(6-methyl-2-pyridinyl)phenyl]acetaniide; 504. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(lH-imidazol-5-yl)phenyl]acetamide; 505. 2-[4-(6-amino-5-nitro-3-pyridinyl)phenyl]-N-(5--cyclopropyl-lH-pyrazol-3-yl)acetamide; 506. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(2,3,5,6-tetrafluoro-4-pyridinyl)phenyl]acetamide; 507. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(4-methyl-2-pyridinyl)phenyl]acetainide; 508. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(lH-pyrazol-4-yl)phenyl]acetamide; 509. 5-(4-{2-[(5-cyclopropyl-lH-pyraz»l-3-yl)amino]-2-oxoethyl}phenyl)-2-thiopheneacid; 510. N-(5’Cyclopropyl-1 H-pyrazol-3-yl)-2-[4-(6-methoxy-2-pyridinyl)phenyl]acetamide; 511. 6-(4-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}phenyl)-2-pyridinecarboxylic acid; 512. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(2,4-dichloro-5-pyrimidinyl)phenyl]acetamide; 513. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(4-methyi-3-thienyl)phenyl]acetamide; 514. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(5-formyl-2-ftiryl)phenyl]acetamide; 515. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(6-nitro-3-pyridinyl)phenylîacetaniide; 516. N-(5-cycIopropyl-lH-pyrazol-3-yl)-2-[4-(8-quinolinyl)phenyl]acetamide; 517. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-[4-(5-methyl-2-pyridinyl)phenyl]acetamide; 518. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(3-methyl-2-pyridinyl)phenyl]acetamide; 519. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(lH-indol-7-yl)phenylÎacetainide; 520. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(6-methoxy-3-pyridinyl)phenyl]acetamide; 521. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(2-amino-9H-purin-6-yl)phenyl]acetamide; 522. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(2-methyl-lH-indol-5-yl)phenyl]acetamide; 523. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(6-fluoro-3-pyridinyl)phenyl]acetamide; SUBSTITUTE SHEET (RULE 26)DUPLICATA 1 2046 WO 01/12189 PCT/US00/06699 114 524. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-[4’-(ethylsulfanyl)[ 1,1 ’-biphenyl]-4-yljacetamide; 525. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3',4'-dimethyl[l,r-biphenyl]-4-yl)acetamide; 526. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(4'-hydroxy[ 1,1 '-biphenyl)-4-yl)acetamide; 527. (2E)-3-(4'-{2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl}[l,r-biphenyl]-3-yl)-2-propenoic acid; 528. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[3'-(trifluoromethyl)[ 1,1 '-biphenyl]-4-yljacetamide; 529. N-(5-cyclopropyl- lH-pyrazol-3-yl)-2-(4’-methyl[ 1,1 ’-biphenyl]-4-yl)acetamide; 530. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-[2*-(methylsulfanyl)[ 1,1 '-biphenyl]-4-yl]acetamide; 531. 4'- {2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl} [1,1 '-biphenyl]-2-carboxylic acid; 532. 3-(4'- {2-[(5-cyclopropyl-1 H-pyrazol-3-yl)amino]-2-oxoethyl} [1,1 '-biphenyl]-4-yl)propanoic acid; 533. 2-[4'-(benzyloxy)[ 1, l’-biphenyl]-4-yl]-N-(5-cyclopropyl- lH-pyrazol-3-yl)acetamide; 534. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2’,3'-dichloro[l,r-biphenyl]-4-yl)acetamide; 535. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3’-isopropyl[l,l'-biphenyl]-4-yl)acetamide; 536. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-[4-(3-formyl-2-furyl)phenyl]acetamide; 537. (2E)-3-(4'- {2-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-oxoethyl} [1 ,l'-biphenyl]-4-yl)-2-propenoic acid; 538. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-{4'-[(E)-2-nitroethenyl][l,l'-biphenyl]-4-yljacetamide; 539. 2-(4’-chloro[ 1,1 '-biphenyl]-4-yl)-N-(5-cyclopropyl-1 H-pyrazol-3-yl)acetamide; 540. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(3'-methyl[l,r-biphenyl]-4-yl)acetainide; 541. 2-(4'-phenyl[l,l'-biphenyl]-4-yl)-N-(5-cyclopropyl-lH-pyrazol-3-yl)acetamide; 542. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(4'-phenoxy[ 1,1 '-biphenÿl]-4-yl)acetamide; 543. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(2'-fonnyl[l,r-biphenyl]-4-yl)acetamide; 544. 2-(3’-chloro[ 1,1 '-biphenyl]-4-yl)-N-(5-cyclopropyl-1 H-pyra2»l-3-yl)acetamide; 545. N-(5-cyclopropyl-1 H-pyrazol-3-yl)-2-(3'-fonnyl[ 1,1 '-biphenyl]-4-yl)acetamide; SUBSTITUTE SHEET (RULE 26) 1 2046 WO 01/12189 PCT/US00/06699 115 546. tert-butyl 2-(4- {2-[(5-cyclopropyl-1 H-pyrazol-3-yl)amino]-2-oxoethyl} phenyl)-1H-pyrrole-1 -carboxylate; 547. 2-(3’-cyano[ 1,1 ’-biphenyl]-4-yI)-N-(5-cyclopropyl-1 H-pyrazol-3-yl)acetamide; 548. N-(5-cyclopropyl-lH-pyrazol-3-yl)-2-(4-dibenzo[b,d]fiiran-4-ylphenyl)acetamide;or a pharmaceutically acceptable sait thereof.
21. A process for preparing the 3-amino-pyrazole dérivative of Claim 14, or thepharmaceutically acceptable sait thereof, comprising: (a) reacting a compound represented by formula (ïï): R-COORj ai) where R is as defined in Claim 14 and R2 is an alkyl group, with acetonitrile in the presenceof a basic agent, to obtain a compound represented by formula (III): R-CO-CH2-CN (III) where R is as defined above; (b) reacting a compound represented by formula (ΠΙ) with hydrazine hydrate toobtain a compound represented by formula (IV):
H (IV) where R is as defined above; (c) oxidizing a compound represented by formula (IV) to obtain a compoundrepresented by formula (V):
N NO, (V) where R is as defined above; (d) reacting a compound represented by formula (V) with tert-butoxycarbonylanhydride (Boc2O) to obtain a compound represented by formula (VI): SUBSTITüTE SHEET (RULE 26) MS9@A*fc 1 2046 WO 01/12189 PCT/US00/06699
where R is as defined above; (e) reducing a compound represented by formula (VI) to obtain a compoundrepresented by formula (VII):
(VII) where R is as defined above; (f) reacting a compound represented by formula (VII) with a compound representedby formula (VIII): R.-COX (Vfil) where X is hydroxy or a suitable leaving group and R, is as defined in claim 14, to obtain acompound represented by formula (IX):
(IX) where R and R, aie as defined above; and (g) hydrolyzing a compound represented by formula (IX) in an acidic medium toobtain a compound of formula (1), where R and R, are as defined above. SUBSTITÜTE SHEET (RULE 26) wraoira 1 2046 PCT/US00/06699 WO 01/12189 117
22. A process for preparing the 3-amino-pyrazole dérivative of Claim 14, or thepharmaceutically acceptable sait thereof, comprising: (a) reacting a compound represented by formula (IV):
with a compound represented by formula (VIII): R.-COX (VIII) where R and R, are as defined in claim 14 and X is hydroxy or a suitable leaving group suchas chlorine or bromine, to obtain a compound represented by formula (X):
where R and R, are as defined above; and (c) selectively hydrolyzing a compound of formula (X) in a basic medium, toobtain a compound represented by formula (I).
23. A process for preparing the 3-amino-pyrazole dérivative of Claim 14, or thepharmaceutically acceptable sait thereof, comprising reacting a compound represented byformula (TV):
with a compound represented by formula (XI): R,-COCC13 (XI) wherein R and R, are as defined in claim 14. SUBSTITUTE SHEET (RULE 26) 1 2046 PCT/US00/06699 WO 01/12189 118
24. A process for preparing the 3-amino-pyrazole dérivative of Claim 14, or thepharmaceutically acceptable sait thereof, comprising reacting a compound of formula (I)wherein R, is a 4-halogeno-phenylacetyl group, or a polymer supported form of it (Ib)
wherein X is a halogen atom such as bromine or iodine, with a compound of formula (ΧΠ) OH I r3"b"oh (Xii) where R3 is an aryl group, to obtain a compound of formula (I) wherein R3 is aryl, or apolymer supported form of it (Ib)
and, in the case of a polymer supported compound (Ib), hydrolizing it by acidic treatment toobtain the above compound of formula (I).
25. A process for preparing the 3-amino-pyrazôle dérivative of Claim 14, or thepharmaceutically acceptable sait thereof, comprising: a) reacting a compound of formula (I) wherein R, is a 4-halgeno-phenylacetylgroup, or a polymer supported form of it (Ib) with a pinacol ester of a diboron compound, toobtain a compound of formula (ΧΠΙ) or a polymer supported form of it (XlIIb) SUBSTITÜTE SHEET (RULE 26) imiCASA WO 01/12189 PCT/US00/06699 1 2046
(XlIIb) with a compound of formula (XIV) R3X (XIV) where R3 is aryl and X is bromine or iodine, to obtain a compound of formula (I) wherein R3
c) and, in the case of a polymer supported compound (Ib), hydrolizing it byacidic treatment to obtain the above compound of formula (I).
26. The process according to any one of Claims fiom 21 to 25, further comprisingconverting the 3-amino-pyrazole dérivative represented by formula (I) into another dérivativerepresented by formula (I), and/or into a sait thereof.
27. A compound represented by formula (V): R
(V) wherein R is a C3-C6 cycloalkyl group optionally substituted with a straight or branched C,-C6alkyl group. SUBSTITUTE SHEET (RULE 26)DUPLICATA 1 2046 PCT/US00/06699 WO 01/12189 120
28. A pharmaceutical composition, comprising the 3-amino-pyrazole dérivative ofClaim 14 and at ieast one pharmaceutically acceptable carrier and/or diluent.
29. A pharmaceutical composition according to claim 28 further comprising one ormore chemotherapeutic agents.
30. A product comprising a compound of Claim 14 or a pharmaceutical compositionthereof as defined in Claim 28 and one or more chemotherapeutic agents, as a combinedpréparation for simultaneous, separate or sequential use in anticancer therapy.
31. A compound as defined in Claim 14 for use as a médicament.
32. Use of a compound as defined in Claim 14 in the manufacture of a médicamentwith antitumor activity. ÎSUBSTITÜTE SHEET (RULE 26) DmiOAÏÀ
OA1200200051A 1999-08-12 2000-05-05 3(5)-Amino-pyrazole derivatives, process for theirpreparation and their use as antitumor agents. OA12046A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37283199A 1999-08-12 1999-08-12

Publications (1)

Publication Number Publication Date
OA12046A true OA12046A (en) 2006-05-02

Family

ID=23469802

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200200051A OA12046A (en) 1999-08-12 2000-05-05 3(5)-Amino-pyrazole derivatives, process for theirpreparation and their use as antitumor agents.

Country Status (35)

Country Link
US (2) US7034049B1 (en)
EP (1) EP1202733B1 (en)
JP (1) JP2003507329A (en)
KR (1) KR20020060160A (en)
CN (1) CN1373662A (en)
AP (1) AP2002002442A0 (en)
AR (1) AR026122A1 (en)
AT (1) ATE305782T1 (en)
AU (1) AU4971400A (en)
BG (1) BG106480A (en)
BR (1) BR0013143A (en)
CA (1) CA2383555C (en)
CZ (1) CZ2002422A3 (en)
DE (1) DE60023012T2 (en)
DK (1) DK1202733T3 (en)
EA (1) EA005373B1 (en)
EE (1) EE200200065A (en)
ES (1) ES2249270T3 (en)
GE (1) GEP20053476B (en)
HK (1) HK1046866A1 (en)
HR (1) HRP20020128A2 (en)
HU (1) HUP0203542A3 (en)
IL (1) IL147923A0 (en)
IS (1) IS6265A (en)
MA (1) MA25493A1 (en)
MX (1) MXPA02001498A (en)
NO (1) NO20020684L (en)
NZ (1) NZ517237A (en)
OA (1) OA12046A (en)
PE (1) PE20010130A1 (en)
PL (1) PL353455A1 (en)
SK (1) SK1812002A3 (en)
WO (1) WO2001012189A1 (en)
YU (1) YU9602A (en)
ZA (1) ZA200201511B (en)

Families Citing this family (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9901691D0 (en) 1999-01-26 1999-03-17 Cerebrus Ltd Chemical compounds
GEP20053476B (en) * 1999-08-12 2005-03-25 Upjohn Co 3(5)-Amino-Pyrazole Derivatives, Process for Their Preparation and Their Use as Antitumor Agents
AU2001229727B2 (en) 2000-02-07 2004-10-14 Bristol-Myers Squibb Co. 3-aminopyrazole inhibitors of cyclin dependent kinases
JP2004507455A (en) 2000-04-25 2004-03-11 ブリストル−マイヤーズ　スクイブ　カンパニー Use of 5-thio-, sulfinyl- and sulfonylpyrazolo [3,4-b] -pyridine as cyclin dependent kinase inhibitors
DE10037310A1 (en) 2000-07-28 2002-02-07 Asta Medica Ag New indole derivatives and their use as medicines
US20020103185A1 (en) * 2000-08-31 2002-08-01 Sanner Mark A. Pyrazole derivatives
CZ2003468A3 (en) * 2000-08-31 2004-05-12 Pfizeráproductsáinc Pyrazole derivatives and their use as protein kinase inhibitors
US6455559B1 (en) * 2001-07-19 2002-09-24 Pharmacia Italia S.P.A. Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents
US20040019046A1 (en) * 2000-11-27 2004-01-29 Paolo Pevarello Phenylacetamido-pyrazole derivatives and their use as antitumor agents
JP2004519486A (en) * 2001-01-26 2004-07-02 フアルマシア・イタリア・エツセ・ピー・アー CHROMAN DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE AS ANTI-TUMOR AGENT
WO2002070514A1 (en) * 2001-03-02 2002-09-12 F. Hoffmann-La Roche Ag Alkoxycarbonylamino heteroaryl carboxylic acid derivatives as ip antagonists
SE0100903D0 (en) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100902D0 (en) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
US6727364B2 (en) 2001-04-30 2004-04-27 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
US6787555B2 (en) * 2001-04-30 2004-09-07 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
US6890915B2 (en) 2001-05-25 2005-05-10 Bristol-Myers Squibb Pharma Company Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
DE10148618B4 (en) * 2001-09-25 2007-05-03 Schering Ag Substituted N- (1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl) derivatives, their preparation and use as medicaments
DE10148617A1 (en) * 2001-09-25 2003-04-24 Schering Ag New 3-acylamino-cyclopentanopyrazole derivatives, useful for treating e.g. cancer and viral infections, inhibit cyclin-dependent kinase
WO2003027104A1 (en) * 2001-09-27 2003-04-03 Idrtech Inc. Fumagillol derivatives and preparing method thereof
SE0103710D0 (en) 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
AU2002362030A1 (en) * 2001-11-27 2003-06-10 Fred Hutchinson Cancer Research Center Methods for inhibiting deacetylase activity
SE0202539D0 (en) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
US6593477B1 (en) 2002-10-29 2003-07-15 Eastman Kodak Company Synthesis of 3-acylaminopyrazoles
CA2508990C (en) * 2002-12-10 2013-05-28 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of flavivirus infections
UA81790C2 (en) 2002-12-19 2008-02-11 Фармация Италия С.П.А. Substituted derivatives of pyrolopyrazol as kinaze inhibitors
WO2004063194A1 (en) * 2003-01-06 2004-07-29 Eli Lilly And Company Heteroaryl compounds
PL378117A1 (en) 2003-02-11 2006-03-06 Prosidion Limited Tri(cyclo) substituted amide compounds
EP1610776A4 (en) * 2003-03-27 2007-03-28 Merck & Co Inc Ophthalmic compositions for treating ocular hypertension
SE0301446D0 (en) 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
JP5043432B2 (en) 2003-05-22 2012-10-10 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
JP4220548B2 (en) 2003-06-05 2009-02-04 エラン ファーマシューティカルズ，インコーポレイテッド Acylated amino acids, amidylpyrazole, and related compounds
US7141568B2 (en) 2003-07-09 2006-11-28 Pfizer Italia S.R.L. Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US7749999B2 (en) 2003-09-11 2010-07-06 Itherx Pharmaceuticals, Inc. Alpha-ketoamides and derivatives thereof
WO2005073198A1 (en) * 2004-01-16 2005-08-11 Wyeth Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole
WO2005072731A1 (en) * 2004-01-29 2005-08-11 X-Ceptor Therapeutics, Inc. 3-phenyl-n- ((1, 3, 4) thiadiazol-2-yl) -acrylamide derivatives and related compounds as modulators of estrogen-related receptors for the treatment of e.g. cancer, rheumatoid arthritis or neurological disorders
ES2791303T3 (en) 2004-01-30 2020-11-03 Vertex Pharma ATP-binding cassette transporter modulators intermediate
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
TW200526204A (en) 2004-02-03 2005-08-16 Pharmacia Italia Spa 1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors
WO2005118543A1 (en) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. Kinase inhibitor and use thereof
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0401762D0 (en) * 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
AU2005311269B2 (en) * 2004-12-03 2011-11-10 Transtech Pharma, Inc. Heteroaromatic glucokinase activators
SE0403086D0 (en) 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
SE0403085D0 (en) 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
US7361672B2 (en) 2004-12-23 2008-04-22 Hoffmann-La Roche Inc. Heteroarylacetamide inhibitors of factor Xa
FR2880540B1 (en) * 2005-01-13 2008-07-11 Aventis Pharma Sa USE OF PURINE DERIVATIVES AS INHIBITORS OF HSP90 PROTEIN
AU2006267387B2 (en) 2005-07-11 2010-11-18 Mitsubishi Tanabe Pharma Corporation An oxime derivative and preparations thereof
JP5303271B2 (en) 2005-07-19 2013-10-02 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 1H-thieno [2,3-c] pyrazole compounds useful as kinase inhibitors
US20100016298A1 (en) * 2005-08-29 2010-01-21 Housey Gerad M Theramutein modulators
UY30048A1 (en) 2005-12-23 2007-07-31 Astrazeneca Ab SUBSTITUTED DERIVATIVES OF THE N, 2- (1H-BENZIMIDAZOL-1-IL) ACETAMIDE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCESSES AND APPLICATIONS
WO2007081966A2 (en) * 2006-01-09 2007-07-19 University Of Southern California Small molecules for treating cancer and abnormal cell proliferation disorders
WO2007095383A2 (en) * 2006-02-15 2007-08-23 Myriad Genetics, Inc. Prodrugs
UY30183A1 (en) * 2006-03-02 2007-10-31 Astrazeneca Ab QUINOLINE DERIVATIVES
US8211925B2 (en) 2006-04-28 2012-07-03 Transtech Pharma, Inc. Benzamide glucokinase activators
CN101484438A (en) * 2006-05-03 2009-07-15 阿斯利康(瑞典)有限公司 Pyrazole derivatives and their use as PI3k inhibitors
US20090263398A1 (en) * 2006-07-14 2009-10-22 Astex Therapeutics Limited Pharmaceutical combinations
TWI433839B (en) 2006-08-11 2014-04-11 Neomed Inst New benzimidazole derivatives 290
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
EP2105435A4 (en) 2007-01-10 2011-06-15 Mitsubishi Tanabe Pharma Corp Hydrazone derivative
WO2008084873A1 (en) * 2007-01-10 2008-07-17 Mitsubishi Tanabe Pharma Corporation Oxime derivative
JP5491871B2 (en) * 2007-02-28 2014-05-14 アドビナス セラピュティックス プライベート リミテッド 2,2,2-Trisubstituted acetamide derivatives as glucokinase activators, methods and pharmaceutical applications thereof
KR100923540B1 (en) * 2007-11-23 2009-10-27 한국과학기술연구원 5-Acylhydrazinecarbonyl-3,4-disubstituted pyrazole derivatives and preparation thereof
WO2009153592A1 (en) * 2008-06-19 2009-12-23 Astrazeneca Ab Pyrazole compounds 436
CA2729988C (en) * 2008-07-10 2016-09-13 Pharma Ip General Incorporated Association Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient
JP5683462B2 (en) 2008-07-24 2015-03-11 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Therapeutic combination comprising an aurora kinase inhibitor and an antiproliferative agent
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
EP3666758A1 (en) * 2008-12-05 2020-06-17 AbbVie Inc. Process for the preparation of a sulfonamide derivative
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
CA2750565C (en) * 2009-01-30 2015-10-20 Glaxosmithkline Llc Crystalline n-{(1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
WO2010129681A1 (en) * 2009-05-05 2010-11-11 Van Andel Research Institute Methods for treating autophagy-related disorders
CN102470127A (en) * 2009-08-19 2012-05-23 埃姆比特生物科学公司 Biaryl compounds and methods of use thereof
US9062076B2 (en) * 2009-10-22 2015-06-23 Fibrotech Therapeutics Pty Ltd Fused ring analogues of anti-fibrotic agents
WO2011056916A1 (en) * 2009-11-05 2011-05-12 Lexicon Pharmaceuticals, Inc. Tryptophan hydroxylase inhibitors for the treatment of cancer
RU2017144535A (en) 2010-03-30 2019-02-18 Версеон Корпорейшн MULTI-DISPLACED AROMATIC COMPOUNDS AS THROMBINE INHIBITORS
SG186229A1 (en) 2010-06-07 2013-01-30 Novomedix Llc Furanyl compounds and the use thereof
EP2582666B1 (en) 2010-06-16 2014-08-13 Purdue Pharma L.P. Aryl substituted indoles and their use as blockers of sodium channels
AP3821A (en) * 2010-11-03 2016-09-30 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
US9073895B2 (en) * 2010-12-16 2015-07-07 Boehringer Ingelheim International Gmbh Biarylamide inhibitors of leukotriene production
EP2614065B1 (en) 2010-12-17 2017-04-19 Nerviano Medical Sciences S.r.l. Substituted pyrazolo-quinazoline derivatives as kinase inhibitors
US20140249105A1 (en) * 2011-07-25 2014-09-04 Diverchim Novel ceramide analogues, processes for preparing same and uses thereof
AR087701A1 (en) * 2011-08-31 2014-04-09 Japan Tobacco Inc PIRAZOL DERIVATIVES WITH SGLT1 INHIBITING ACTIVITY
JP6165733B2 (en) * 2011-09-16 2017-07-19 ノバルティス アーゲー N-substituted heterocyclylcarboxamides
JP6027128B2 (en) 2011-10-26 2016-11-16 ダウ アグロサイエンシィズ エルエルシー Pest control compositions and related methods
US9282739B2 (en) 2012-04-27 2016-03-15 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
AP2014008072A0 (en) 2012-04-27 2014-11-30 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
US9708288B2 (en) 2012-04-27 2017-07-18 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
CN103936637B (en) * 2013-01-18 2016-04-06 北京大学 The preparation method of E-3,4-dihydroxyphenyl vinyl sulfoxide compounds and the application as nerve protection medicine thereof
CN108354933A (en) 2013-03-15 2018-08-03 维颂公司 The pharmaceutical applications of polysubstituted aromatic compounds as serpin
BR112015023618A2 (en) 2013-03-15 2017-07-18 Glaxosmithkline Ip Dev Ltd pyridine derivatives as reorganized kinase inhibitors during transfection (ret)
MA38394B1 (en) 2013-03-15 2018-04-30 Glaxosmithkline Ip Dev Ltd Pyridine derivatives used as inhibitors of rearranged kinase during transfection (ret)
EP2970141B1 (en) 2013-03-15 2020-02-26 Verseon Corporation Halogenopyrazoles as inhibitors of thrombin
WO2014170350A1 (en) * 2013-04-17 2014-10-23 Albert Ludwigs Universität Freiburg Compounds for use as bromodomain inhibitors
CN103265535B (en) * 2013-05-14 2015-06-17 浙江医药高等专科学校 Antitumor compounds, preparation method and application thereof
CA2922230A1 (en) * 2013-08-30 2015-03-05 Ambit Biosciences Corporation Biaryl acetamide compounds and methods of use thereof
MX2016004945A (en) 2013-10-17 2016-06-28 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds.
CA2925954A1 (en) 2013-10-17 2015-04-23 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
EP3057426A4 (en) 2013-10-17 2017-03-29 Dow AgroSciences LLC Processes for the preparation of pesticidal compounds
MX2016004946A (en) 2013-10-17 2016-06-28 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds.
KR20160072154A (en) 2013-10-17 2016-06-22 다우 아그로사이언시즈 엘엘씨 Processes for the preparation of pesticidal compounds
US9044017B2 (en) 2013-10-17 2015-06-02 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
CA2925873A1 (en) 2013-10-17 2015-04-23 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
RU2016119569A (en) 2013-10-22 2017-11-28 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи SYNERGETIC PESTICIDE COMPOSITIONS AND WAYS RELATED TO THEM
JP2016535739A (en) 2013-10-22 2016-11-17 ダウ アグロサイエンシィズ エルエルシー Agrochemical compositions and related methods
JP6490681B2 (en) 2013-10-22 2019-03-27 ダウ アグロサイエンシィズ エルエルシー Pesticide composition and related methods
MX2016005316A (en) 2013-10-22 2017-03-01 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods.
JP2016536307A (en) 2013-10-22 2016-11-24 ダウ アグロサイエンシィズ エルエルシー Agrochemical compositions and related methods
TW201519774A (en) 2013-10-22 2015-06-01 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
WO2015061149A1 (en) 2013-10-22 2015-04-30 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
WO2015061145A1 (en) 2013-10-22 2015-04-30 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
WO2015061151A1 (en) 2013-10-22 2015-04-30 Dow Agrosciences Llc Pesticidal compositions and related methods
NZ719952A (en) 2013-10-22 2017-05-26 Dow Agrosciences Llc Pesticidal compositions and related methods
EP3060055A4 (en) 2013-10-22 2017-03-29 Dow AgroSciences LLC Synergistic pesticidal compositions and related methods
EP3060050A4 (en) 2013-10-22 2017-04-05 Dow AgroSciences LLC Synergistic pesticidal compositions and related methods
WO2015061142A1 (en) 2013-10-22 2015-04-30 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
TW201519779A (en) 2013-10-22 2015-06-01 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
CN105792652A (en) 2013-10-22 2016-07-20 美国陶氏益农公司 Synergistic pesticidal compositions and related methods
CA2927214A1 (en) 2013-10-22 2015-04-30 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
KR20160074637A (en) 2013-10-22 2016-06-28 다우 아그로사이언시즈 엘엘씨 Pesticidal compositions and related methods
WO2015143653A1 (en) * 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
KR20170039121A (en) 2014-07-31 2017-04-10 다우 아그로사이언시즈 엘엘씨 Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
WO2016018443A1 (en) 2014-07-31 2016-02-04 Dow Agrosciences Llc Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
CA2954345A1 (en) 2014-07-31 2016-02-04 Dow Agrosciences Llc Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
EP3183238A4 (en) 2014-08-19 2018-01-10 Dow AgroSciences LLC Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
US9879021B2 (en) 2014-09-10 2018-01-30 Glaxosmithkline Intellectual Property Development Limited Compounds as rearranged during transfection (RET) inhibitors
PE20170705A1 (en) 2014-09-10 2017-05-21 Glaxosmithkline Ip Dev Ltd NEW COMPOUNDS AS RET INHIBITORS (REORGANIZED DURING TRANSFECTION)
WO2016039781A1 (en) 2014-09-12 2016-03-17 Dow Agrosciences Llc Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
AU2015317522A1 (en) 2014-09-17 2017-03-23 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
GB201416513D0 (en) * 2014-09-18 2014-11-05 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
AU2016224974B2 (en) 2015-02-27 2019-09-26 Verseon Corporation Substituted pyrazole compounds as serine protease inhibitors
US11186576B2 (en) 2015-03-09 2021-11-30 Aurigene Discovery Technologies Limited Pyrazolo[1,5-A][1,3,5]triazine and pyrazolo[1,5-A]pyrimidine derivatives as CDK inhibitors
KR20180017013A (en) 2015-05-06 2018-02-20 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 K-Ras modulator
CA2987552A1 (en) 2015-06-04 2016-12-08 Aurigene Discovery Technologies Limited Substituted heterocyclyl derivatives as cdk inhibitors
CA3032586A1 (en) * 2016-08-12 2018-02-15 Athenex, Inc. Biaryl compounds and use thereof for modulating a kinase cascade
CN110139853B (en) 2016-12-29 2023-06-16 美国陶氏益农公司 Process for the preparation of pesticidal compounds
US10233155B2 (en) 2016-12-29 2019-03-19 Dow Agrosciences Llc Processes for the preparation of pesticide compounds
EP3562818B1 (en) 2016-12-29 2022-05-18 ENYO Pharma Thiophene derivatives as antiviral agents
MX2019009235A (en) 2017-02-03 2019-12-11 Certa Therapeutics Pty Ltd Anti-fibrotic compounds.
CA3056886A1 (en) 2017-03-21 2018-09-27 Arbutus Biopharma Corporation Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
US11358940B2 (en) * 2017-04-20 2022-06-14 The Regents Of The University Of California K-Ras modulators
JP7319977B2 (en) 2017-12-06 2023-08-02 リン バイオサイエンス，インコーポレイテッド tubulin inhibitor
EP3746422A4 (en) * 2018-02-01 2021-06-09 The University Of Sydney Anti-cancer compounds
WO2019193509A1 (en) * 2018-04-04 2019-10-10 Aurigene Discovery Technologies Limited Substituted pyrazole derivatives as selective cdk12/13 inhibitors
WO2020142559A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Inhibitors of menin-mll interaction
MX2021007925A (en) 2018-12-31 2021-10-26 Biomea Fusion Llc Irreversible inhibitors of menin-mll interaction.
US20230149414A1 (en) * 2020-01-29 2023-05-18 Foghorn Therapeutics Inc. Compounds and uses thereof
CN111793034B (en) * 2020-07-24 2021-11-19 华中科技大学 Benzimidazole salt derivative and application thereof in preparing antitumor drugs
US20240132485A1 (en) * 2020-10-16 2024-04-25 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
WO2022135442A1 (en) * 2020-12-22 2022-06-30 上海拓界生物医药科技有限公司 Cdk2 inhibitor and preparation method therefor
US12018032B2 (en) 2021-08-20 2024-06-25 Biomea Fusion, Inc. Crystalline forms of N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide as an irreversible inhibitor of menin-MLL interaction
IL313539A (en) * 2021-12-10 2024-08-01 Prothena Biosciences Ltd Methods for treating neurological disorders
WO2023203174A1 (en) * 2022-04-20 2023-10-26 Proxygen Gmbh Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
CN116496151B (en) * 2023-04-26 2024-08-23 长沙医学院 Method for preparing fluorenone derivative by utilizing CATELLANI strategy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162360A (en) 1991-06-24 1992-11-10 Warner-Lambert Company 2-heteroatom containing urea and thiourea ACAT inhibitors
JPH10509708A (en) 1994-11-10 1998-09-22 コア セラピューティクス，インコーポレイティド Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases
EP0955293B1 (en) 1996-12-03 2003-03-19 Banyu Pharmaceutical Co., Ltd. Urea derivatives
WO1998052941A1 (en) 1997-05-22 1998-11-26 G.D. Searle And Co. PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS
TR200100918T2 (en) * 1997-12-22 2001-06-21 Bayer Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted ureas
DE1041982T1 (en) 1997-12-22 2001-06-07 Bayer Corp., Pittsburgh INHIBITION OF p38 KINASE ACTIVITY BY SUBSTITUTED HETEROCYCLIC UREAS
GEP20053476B (en) * 1999-08-12 2005-03-25 Upjohn Co 3(5)-Amino-Pyrazole Derivatives, Process for Their Preparation and Their Use as Antitumor Agents
US6455559B1 (en) * 2001-07-19 2002-09-24 Pharmacia Italia S.P.A. Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents

Also Published As

Publication number Publication date
IL147923A0 (en) 2002-08-14
ZA200201511B (en) 2003-05-28
PE20010130A1 (en) 2001-02-01
MA25493A1 (en) 2002-07-01
EE200200065A (en) 2003-04-15
MXPA02001498A (en) 2003-07-21
AU4971400A (en) 2001-03-13
YU9602A (en) 2004-11-25
DE60023012T2 (en) 2006-07-20
NZ517237A (en) 2004-02-27
BG106480A (en) 2002-09-30
EP1202733A1 (en) 2002-05-08
HRP20020128A2 (en) 2003-04-30
EA200200248A1 (en) 2002-08-29
CA2383555C (en) 2009-02-17
ATE305782T1 (en) 2005-10-15
WO2001012189A1 (en) 2001-02-22
ES2249270T3 (en) 2006-04-01
AR026122A1 (en) 2003-01-29
EA005373B1 (en) 2005-02-24
PL353455A1 (en) 2003-11-17
HUP0203542A2 (en) 2003-05-28
JP2003507329A (en) 2003-02-25
AP2002002442A0 (en) 2002-03-31
HK1046866A1 (en) 2003-01-30
EP1202733B1 (en) 2005-10-05
NO20020684D0 (en) 2002-02-11
DE60023012D1 (en) 2006-02-16
EP1202733A4 (en) 2003-05-14
IS6265A (en) 2002-02-11
CZ2002422A3 (en) 2002-11-13
NO20020684L (en) 2002-04-03
DK1202733T3 (en) 2005-10-31
CN1373662A (en) 2002-10-09
GEP20053476B (en) 2005-03-25
US7034049B1 (en) 2006-04-25
SK1812002A3 (en) 2003-02-04
KR20020060160A (en) 2002-07-16
BR0013143A (en) 2002-06-11
CA2383555A1 (en) 2001-02-22
US6218418B1 (en) 2001-04-17
WO2001012189A8 (en) 2001-08-02
HUP0203542A3 (en) 2003-07-28

Similar Documents

Publication Publication Date Title
EP1202733B1 (en) 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
AU2007284562B2 (en) Using PI3K and MEK modulators in treatments of cancer
EP1124810B1 (en) 2-amino-thiazole derivatives, process for their preparation, and their use as antitumor agents
EP2313399B1 (en) Thiophene or thiazole derivatives and their use as pi3k inhibitors
NZ525892A (en) Phenylacetamido- pyrazole derivatives their use as antitumor agents and preparation process thereof
NZ517238A (en) 3(5)-ureido-pyrazole derivatives, process for their preparation and their use as antitumor agents
ZA200606530B (en) (3-Oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compound as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity
WO2013161919A1 (en) Trk-INHIBITING COMPOUND
NZ526624A (en) Substituted triazole diamine derivatives as kinase inhibitors
KR20150041164A (en) Cyclopenta〔d〕pyrimidines as akt protein kinase inhibitors
JPWO2007063868A1 (en) Arylmethylene urea derivatives and uses thereof
CA3029278A1 (en) Pyrazole compounds and compositions for the treatment of cancer
US20040116497A1 (en) Chromane derivatives, process for their preparation and their use as antitumor agents
WO2022237780A1 (en) Amide derivative and use thereof
AU2002250840A1 (en) Chromane derivatives, process for their preparation and their use as antitumor agents